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Abstract
Cytochromes P450 (P450) are a ubiquitous class of monooxygenases located in the
endoplasmic reticulum of mammalian cells. These enzymes catalyse the Phase I
oxidative metabolism of a wide range of structurally diverse chemicals resulting in
increased hydrophilicity and excretion. Certain chemicals are, however,
metabolically activated by cytochrome P450, leading to the formation of cytotoxic
and/or carcinogenic metabolites. This has been exploited in the design of many
prodrugs, including anti-tumour agents, which are inactive as administered but
become active in vivo following metabolism by one or more of the P450 isozymes.
The regulation of P450 gene expression has been well documented in experimental
animals, but at present there is very little information available about the
regulation of human P450 genes, particularly in extra-hepatic tissues.
Regulation of P450 expression by a range of xenobiotics, known to have
profound effects on the expression of rodent P450 genes, has been studied in a mouse
model and in cultured cells. Of particular interest were the potent and pleiotropic
effects on murine P450 expression of TCPOBOP (1,4 bis [2,(3,5-
dichloropyridyloxy)] benzene), which showed marked tissue and species specificity
in its inductive effects in rodents. A model was developed, using human tumours
grown as xenografts in immune deficient mice, in which the in vivo regulation of
human P450 genes could be examined. TCPOBOP was shown to be equally effective at
influencing human P450 gene expression and, in most cases, the patterns of gene
regulation observed in experimental animals were also seen in the human tumours.
These studies suggest that modulation of intra-tumour P450 levels by agents such as
TCPOBOP may lead to enhanced metabolism of anticancer drugs such as
cyclophosphamide, which require P450-mediated activation in order to exert their
anti-tumour effects. Preliminary results with cyclophosphamide and TCPOBOP
indicated that this was indeed the case. The cell line Hepa 1, which did not respond to
P450 inducing agents j_n vitro, became responsive to the same inducing agents when
grown j_n vivo as a solid tumour xenograft. This therefore provides an extremely
powerful model for studying the i n vivo regulation of human P450 genes, not only by





In 1775, a British surgeon, Sir Percival Pott, proposed that a link existed
between the incidence of scrotum cancer in chimney sweeps and their exposure to
soot. It was not until the 1930s, however, that polycyclic aromatic hydrocarbons
such as dibenz[a,h]anthracene and benzo[a]pyrene were identified as the
carcinogenic agents in coal tar. Subsequent epidemiological studies have shown that
many ubiquitous environmental pollutants are potent carcinogens. Indeed,
environmental chemicals have been strongly implicated as the causative agent in
many types of cancer, and is has been proposed that up to 80% of all cancer incidence
is related to carcinogen exposure (Doll & Peto, 1980).
Although many of these compounds are inherently cytotoxic and/or
carcinogenic, others require metabolic activation before exerting their carcinogenic
effects. A superfamily of inducible microsomal monooxygenases, the cytochromes
P450 (P450) have been shown to play a central role in this metabolic activation.
Both inter-individual variation and genetic polymorphism in the expression of
certain of these P450 enzymes has been linked to cancer incidence. Cytochromes
P450 metabolise a wide variety of structurally diverse chemicals, several of which
have an important endogenous role. In many cases, P450 metabolism results in the
introduction of a hydrophilic moiety into an otherwise hydrophobic molecule, thus
facilitating its excretion from the body. Other substrates, however, are
metabolically activated by P450 enzymes leading to increased cytotoxicity or
carcinogenicity. This property is exploited in the metabolism of many anticancer
drugs which are inactive as administered, but become active as anti-tumour agents
following activation by one or more of the P450 isozymes.
Understanding the factors which regulate the expression of cytochrome P450
genes is therefore of central importance. A number of model systems have been
established which have provided valuable information about how P450 genes are
regulated in experimental animals, but very little information is currently
available about the regulation of cytochrome P450 genes in man, particularly in
extra-hepatic tissues. The experiments described within this thesis are designed to
address this question and, additionally, to determine to what extent the mechanisms
of regulation observed in rodent and cell culture models are applicable to the
regulation of human P450 genes.
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1.2 Introduction to Drug Metabolism
Almost any foreign chemical entering the body, whether it be a clinical drug
or environmental toxin, is metabolised by one or more of the drug metabolising
enzymes. These enzyme systems, which also have an important endogenous role in
maintaining cellular homeostasis, generally have wide substrate specificities, such
that each can metabolise a variety of structurally diverse chemicals. The enzymes
which are involved in drug metabolism, the drug metabolising enzymes, are sub¬
divided into two classes - Phase I and Phase II.
Phase I enzymes catalyse functionalisation reactions where, in most cases, a
reactive centre is created in the substrate such that it is can participate in
subsequent Phase II metabolism. Phase II reactions, in contrast, are conjugative,
involving the addition of a hydrophilic moiety to the molecule to facilitate its
excretion from the body.
Phase I reactions: Oxidation, reduction, hydrolysis and hydration are all examples of
Phase I reactions, mediated by a number of enzyme systems including alcohol
dehydrogenase and xanthine oxidase. One, if not the most important of this class of
enzymes, however, is the microsomal mixed function oxidase, cytochrome P450
(P450). This ubiquitous class of enzymes plays a central role in the oxidative
metabolism of structurally diverse xenobiotics and also has an important endogenous
role in the synthesis and/or degradation of many important biosynthetic
intermediates. P450 structure and function will be discussed in Section 1.3.1, while
the regulation of cytochrome P450 expression in a number of model systems will
form the basis of Chapters 3, 4 and 5. In most cases, the products of these Phase I
reactions contain a chemically reactive functional group e.g. -OH, -NH2, -SH, -
COOH, which forms the reactive centre for interaction with Phase II enzymes.
Phase II reactions: Again, several distinct enzyme systems are responsible for the
Phase II metabolism of a structurally diverse range of chemicals, resulting in the
generation of water soluble products which are excreted in bile or urine. Examples
of common Phase II reactions are glucuronidation, catalysed by the UDP-
glucuronosyltransferases and glutathione conjugation, catalysed by the glutathione
S-transferases. Although xenobiotic regulation of Phase II metabolism will not be
discussed in detail in this thesis, it is important to realise that many of the
compounds e.g. phenobarbital and 3-methylcholanthrene, which are powerful
modulators of cytochrome P450 expression can also influence the expression of
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Phase II enzymes such as the glutathione S-transferases. Thus, the effect of a
particular xenobiotic can not be considered simply in terms of its Phase I
metabolism. The ultimate disposition and action of a particular compound within the
cell is therefore a balance between its affinity for several distinct enzyme systems
which are active in its metabolism. Similarly, xenobiotic-mediated induction of a
specific isozyme e.g. a hepatic P450, will alter the overall enzyme profile of the
cell, and may thus affect cellular homeostasis.
1.3 The Cytochrome P450 mono-oxygenase superfamily
1.3.1 Introduction to cytochrome P450 - structure and catalytic function
Cytochrome P450 is the generic name for a superfamily of haem-containing
monooxygenases located, like many other Phase I enzymes, in the endoplasmic
reticulum of mammalian cells. P450s are monomeric enzymes, with molecular
weights in the range 45-55 kD, which function as the terminal oxidases (electron
acceptors) in an electron transport chain, supported by the flavoprotein NADPH-
cytochrome P450 reductase. The name cytochrome P450 arises from the spectral
absorbance maximum obtained at 450nm when the protein is reduced and complexed
with carbon monoxide (CO). P450 structure, function and regulation has recently
been extensively reviewed (Gonzalez, 1990; Gonzalez & Nebert, 1990; Okey,
1990).
NADPH-cytochrome P450 reductase is a 78kD monomeric flavoprotein
which contains one mole of flavin adenine dinucleotide (FAD) and one mole of flavin
mononucleotide (FMN) per mole of apoprotein. The role of NADPH-cytochrome P450
reductase is to transfer reducing equivalents (electrons) from NADPH to cytochrome
P450 according to the following equation:
NADPH Cytochrome
NADPH + H+ —> (FAD > FMN) > Cyt. P450 + NADP+
P450 Reductase
From the stoichiometry of the above equation, it can be seen that the left hand
side (NADPH + H+) is a 2 electron donor, while the right hand side (Cytochrome
P450) is a one electron acceptor. Although it has not been formally proven, it is
hypothesised that NADPH-P450 reductase accepts both electrons and then transfers
them sequentially to cytochrome P450. By measuring the relative redox potentials,
it appears to be more energetically favourable (AE° is more positive) for FAD to act
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as the electron acceptor from (NADPH + H+), and FMN to transfer electrons to
cytochrome P450.
Cytochrome P450 is present in a large (10-25 fold) molar excess over
reductase (Estabrook et al. 1971; Peterson et al. 1976). The functional interaction
between P450 and reductase, however, appears to exist as a 1 :1 ratio (Miwa et al.
1979; Miwa & Lu, 1984). Therefore, only a fraction of the total microsomal P450
can exist as a functional complex at any one time. Accessibility to reductase is
therefore rate-limiting, particularly in cases where the levels of P450 apoprotein
are significantly increased by exposure to a drug or environmental pollutant.
Although, in certain cases, the level of reductase is also increased on exposure to
these agents, the fold increase is usually significantly lower than for the
corresponding P450 apoprotein.
The nature of the interaction between P450 and reductase is not yet fully
understood. Two possible mechanisms have, however, been proposed (Miwa & Lu,
1984; Wagner et al. 1984):
(a) P450 and reductase form a stable, catalytically active complex
(b) Transient complexes are formed as a result of random collisions occurring from
lateral diffusion within the microsomal membrane
Although the exact mechanism of interaction has not yet been elucidated, and
it has therefore not been demonstrated to what extent the mechanism of interaction is
conserved between different P450 isozymes, recent evidence suggests that there is
an electrostatic interaction between P450 and reductase which mediates electron
transfer (Bernhardt et al. 1984, 1988). Based on the crystal structure of
P450cam, the soluble camphor hydroxylase, isolated from Pseudomonas putida, it
has been suggested that specific ionic amino acids such as lysine and arginine interact
with putidaredoxin, the bacterial equivalent of NADPH-cytochrome P450 reductase.
Similarly, Shimizu et al (1991) demonstrated that specific lysine and arginine
residues were involved in forming an electron transfer complex in the interaction of
rat CYP1A1 with reductase. Shen & Strobel (1992) showed that modification of
these lysine residues with acetic anhydride lead to a 95% decrease in 7-
ethoxycoumarin hydroxylation in a reconstituted CYP1 A1/reductase complex.
Spectrophotochemical analysis indicated that this did not occur as a result of major
conformational change.
P450 heme is present as a prosthetic group, ferric photoporphyrin IX,
which is non-covalently bound to the apoprotein. Cyclic oxidation/reduction of the
16
heme iron is central to the activity of the enzyme. Although the catalytic cycle is not
yet fully understood, a simplified reaction scheme is illustrated in Figure 1.3.1.
Figure 1.3.1 Catalytic cycle for P450 oxidation
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The overall stoichiometry of the reactions catalysed by cytochrome P450 can be
represented by:
P450
NADPH + H++02+ RH > NADP+ + H20 + R0H
where RH is substrate and ROH is oxidised substrate.
Step (1) in Figure 1.3.1 illustrates substrate binding to ferric iron. Substrate
binding occurs at the opposite side of the porphyrin ring to the cysteine sulphur.
Step (2): First electron reduction of ferric to ferrous iron.
i.e. Fe3 + + e > Fe2 +
The electron is derived from [NADPH + H + ], and is transferred to cytochrome P450
by NADPH-cytochrome P450 reductase. This electron transport system is modified
in mitochondrial P450s, such as those found in the adrenal gland - in this system a
non-heme protein, adrenodoxin and a flavoprotein, NADPH-adrenodoxin reductase
mediate the transfer of electrons from NADPH to reductase (Lambeth et al. 1980)
Step (3): Binding of molecular oxygen. This has not been well characterised to date
in mammalian systems, but the intermediates shown have been identified
spectrophotometrically in the adrenal mitochondria and bacterial P450cam.
Steps (4) and (5) are hypothetical electron re-arrangement reactions. The
intermediates in this proposed pathway are highly reactive and have not yet been
isolated and characterised. A second electron is transferred to the cycle from NADPH
cytochrome P450 reductase at this stage.
Step (6): In this step, one atom of molecular oxygen is inserted into the carbon chain
of the substrate to produce the oxidised reaction product. The precise reaction
mechanism for this step is unknown, but is thought to proceed via an unstable
hydroxylated intermediate.
The derivation of the catalytic cycle for cytochrome P450 is based on studies
of P450cam (CYP101A), the soluble camphor hydroxylase isolated from
Pseudomonasputida (Poulos et al. 1985). Although there is less than 30% amino
acid sequence identity between P450cam and the mammalian P450s, there is
considerable evidence that the structure of P450cam can be used as a model for the
mammalian enzymes (Nelson & Strobel, 1989). At present, P450cam is the only
P450 for which a crystal structure has been determined (Poulos et al. 1985,
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1987). There is, however, a high degree of homology in the active site region
between P450cam and many of the eucaryotic isozymes, which suggests that the
mechanisms of oxygen and substrate binding and oxygen activation will be conserved.
Site-directed mutagenesis of individual mammalian isozymes has revealed
several "key residues" which are important for catalytic function or the control of
substrate specificity (reviewed by Johnson et al. 1992). The position of these
residues has been related to the crystal structure of P450cam, and, more
relevantly, will be compared to structures of the mammalian enzymes as they
become available. Several amino acid residues have been thus identified (Aoyama et
al. 1989; Lindberg & Negishi, 1989; Kronbach et al. 1991). These studies suggest
that P450 structures can selectively accommodate genetic change such that substrate
metabolism is altered but the fundamental capacity of the enzyme to reduce
molecular oxygen is unaffected. Johnson (1992) proposed the following model to
account for this: Many of the "key residues" identified to date are found in loop
regions in the structure of P450cam (Poulos, 1989) and are likely to be similarly
placed in the mammalian enzymes. These regions bind and orientate the substrate
with respect to the heme plane. Thus, alteration in the amino acid composition of this
region can dramatically influence the substrate specificity and thus the catalytic
function of the enzyme. The overall membrane topology of the enzyme and oxygen
binding to the heme iron are unaffected by changes in these loop regions. In
agreement with this, Gotoh (1992) aligned the sequences of several CYP2 proteins
with P450cam and concluded that sequence diversification occurred primarily in
substrate recognition regions.
The membrane topology of mammalian P450s has been studied by a number of
techniques including computer modelling and site-directed mutagenesis (Figure
1.3.1.2). The findings of several groups have been recently reviewed (Black,
1992), and suggest that all mammalian P450s may be similarly constructed.
Microsomal P450s are bound to the endoplasmic reticulum (ER) by one or two
transmembrane peptides at the NH2-terminal end. The active site, which is located
in the cytoplasmic domain of the protein may have further peripheral membrane
contacts. The heme-porphyrin plane lies between perpendicular and parallel to the
plane of the endoplasmic reticulum. Purified P450s are amphipathic and exist as
micellular aggregates of approximately six monomers. Signal peptides control the
insertion of membrane proteins into the ER (Wickner & Lodish, 1985). P450s are
inserted into the ER by an NH2-terminal signal peptide which is not cleaved on
insertion, but acts as anchor in the membrane. Modification of the NH2-terminal
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amino acids has been show to lead to the complete translocation of the P450 across
the ER membrane.
Figure 1.3.1.2 Orientation of P450 and NADPH-cytochrome P450 reductase in the
endoplasmic reticulum
Redrawn from Waxman & Azaroff, 1992
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1.3.2 Spectrophotometric analysis of P450 - substrate interaction
The heme iron in cytochrome P450 is bound by four equatorial ligands, the
pyrrole nitrogens of photoporphyrin IX, and an additional one or two axial ligands
which lie normal to the porphyrin plane. These axial ligand(s) are amino acids in the
heme binding pocket of the apoprotein, one of which is the thiol of a cysteine residue
in the -COOH terminus of the apocytochrome which has been shown to be highly
conserved in all P450 sequences (Poulos et al. 1987). Thus, the incorporation of
heme to form a catalytically active P450 can result in two different co-ordination
spheres around the central iron - (a) where the iron is bound to only one axial
ligand, the conserved cysteine residue, and the sixth d-orbital is occupied by a lone
pair of electrons; or (b) where the iron is bound by two axial ligands, the conserved
cysteine and another amino acid. The particular co-ordination adopted can be
rationalised by ligand field theory.
Free (uncomplexed) ferric iron has 5 degenerate d orbitals which each
contain a single unpaired electron. When the iron is surrounded by a ligand co¬
ordination sphere, however, the energy levels of the d orbitals are influenced by
differences in the electronic environment and lose their degeneracy, resulting in the
creation of two distinct energy levels, designated t2g and eg. Two unique
distributions of the 5 d-electrons are therefore possible (Figure 1.3.2):
Figure 1.3.2 High and low spin complexes of ferric iron
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In (a), the low-spin state, maximum electron pairing occurs, the repulsion
between electrons in an electron pair is less than the ligand field energy (AE) and it
is therefore more energetically favourable for the electrons to exist as pairs
wherever possible. In (b), the high spin state, however, the ligand field splitting
energy is lower and less than the electron-electron repulsion energy. The electrons
are therefore found unpaired, each occupying a unique orbital. AE, the ligand
(crystal) field splitting energy, is a function of the nature of the ligands as each
ligand interacts differently with the d orbital electrons of the heme iron. Whether
the complex adopts a high or a low spin configuration is therefore a function of AE
and is determined by the nature of the ligands. As the four equatorial nitrogens are
invariant, the overall stereochemistry of the complex is dependent on the nature of
the axial ligand(s).
No quantitative assessment has yet been made of the relationship between the
spin state and geometric configuration of metal-porphyrin complexes such as
cytochrome P450. In most cases, however, 5 co-ordinate models have been observed
to be high spin, with an out of plane heme iron with a lone pair of electrons in place
of the sixth axial ligand. Six co-ordinate complexes are generally low spin, with the
heme iron lying in the equatorial plane. Most free P450s i.e. not bound by substrate,
exist in a low spin 6 co-ordinate stereochemistry, with a characteristic absorption
band at around 420nm. Substrate binding can occur in one of two ways:
(a) Type I substrates e.g. benzphetamine, caffeine, testosterone
These bind to the apoprotein, thus altering the conformation of the heme binding site.
This results in conversion from low to high spin configuration, accompanied by a
Type 1 spectral change with a minimum at 420nm and maximum at 390nm. Any
change in the intensity of the absorbance is directly proportional to AE, the ligand
field splitting energy.
(b) Type II substrates e.g. the nitrogenous bases aniline and pyridine, ligate directly
to the heme iron, replacing one of the axial ligands and resulting in a 6 co-ordinate
low spin complex (Absorbance maximum at 420nm).
Thus, an estimate of the extent of ligand binding and the nature of the bound
ligand can be made spectrophotometrically. A further spectrophotochemical
technique, Surface Enhanced Resonance Raman Spectroscopy (SERRS) has also been
used to determine the spin state of the heme iron in a series of P450s, stabilised by
absorption onto a silver colloid (Kelly et al. 1987; Rospendowski et al. 1991). This
sensitive technique requires only a small amount of sample and can be used to
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determine the specific oxidation and spin state of the heme iron. In addition, it can be
used to differentiate between P450 and P420, the biologically inactive form of the
enzyme. Wolf et al (1988), using this technique, demonstrated that the differences
in catalytic activity between rat CYP2B1 and CYP2B2 were related to differences in
the heme environment of the proteins. In addition, these workers found that changes
in the ionic strength of the solvent affected P450/reductase coupling, suggesting that
an electrostatic interaction between the proteins occurs (see Section 1.3.1).
Substrate binding can also affect the redox biochemistry of the electron
transport chain. It has been demonstrated that the ligand induced transition from low
to high spin in both bacterial and mammalian P450s is accompanied by an increase
in the mid-point redox potential of the haemoprotein (E°) (Fischer & Sligar,
1983). This in turn leads to an increasingly negative value of Ad-'for the reaction,
facilitating the transfer of the first electron from NADPH-cytochrome P450
reductase to cytochrome P450. Therefore, the reduction of ferric to ferrous iron is
more thermodynamically favourable in the presence of substrate. Fischer & Sligar
also demonstrated that a linear free energy relationship exists between redox
potential and spin state, and proposed that both redox potential and spin state are
correlated with the extent of hydration at the active site. In the absence of substrate,
the substrate binding pocket is filled with solvent molecules, with an additional
molecule of solvent co-ordinated to the heme iron. This highly symmetrical co¬
ordination complex is low spin. The presence of solvent also acts to stabilise Fe3 +
rather than Fe2 +, as the more highly charged iron has a better electrostatic
interaction with the porphyrin core. In addition, Eyer & Backes (1992) showed that
the rate of transfer of the first electron was directly proportional to the rate of
functional reductase/P450 complex formation and that this was generally applicable
to P450 catalysis i.e. the mechanism is not isozyme specific.
1.3.3 Nomenclature and evolution of P450 genes
1.3.3.1 Nomenclature
More than 150 different P450 genes had been characterised by the end of
1990 - these had been isolated from a total of 23 different eukaryotic and 6
prokaryotic species. It therefore became necessary to devise a systematic
nomenclature system which could identify each gene uniquely. Until the advent of this
nomenclature system, individual genes had been given trivial names by the labs in
which they had been characterised, leading to a great deal of confusion in the
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literature, as the same gene product often had several trivial names. Nebert et al
(1987, 1989, 1991) proposed a nomenclature system based on the evolution of the
P450 superfamily, the main proposals of which are outlined below:
1. All P450 genes have the root symbol CYP ( Cyp for mouse genes) to represent
Cytochrome £450.
2. The root symbol is followed by an arabic number to denote the gene family and a
letter to denote the subfamily. Protein sequences within the same gene family have
>40% amino acid homology. Twenty seven distinct gene families have been described
to date, ten of which are mammalian. There are 18 distinct mammalian subfamilies
which exhibit >60% sequence identity.
3. An Arabic number is used to denote an individual gene within a particular
subfamily. A hyphen precedes this final number in mouse genes. The number of a
particular gene within a subfamily is assigned according to the order in which the
genes were isolated e.g. CYP2A1 is a rat gene, while CYP2A6 is human.
4. The human nomenclature is to be used for all species except mouse.
5. Genes andcDNAs are to be written in italic script - mRNAs and proteins in non-
italics.
Examples : Cyp2a-4 Family 2A, gene 4, cDNA, mouse
Cyp2a-5 Family 2A, gene 5, protein, mouse
CYP2B1 Family 2B, gene 1, mRNA, rat
CYP2B6 Family 2B, gene 6, gene, human
This nomenclature system is based on the assumption that each P450 protein is the
product of a separate gene. To date, two exceptions to this have been reported, where
alternative splicing of the mRNA coding for these genes lead to the production of
functional proteins with different catalytic activities to the parent genes (Lacroix et
a], 1990; Lephart et al. 1990).
1.3.3.2 Evolution
Cytochrome P450 genes are thought to have been present in the earliest
organisms. The large number of P450s which have been characterised to date are
thought to have evolved from a single gene and attempts have been made to correlate
the divergence of P450 sequence with species diversification, based on
paleontological evidence. From these studies and alignments of known P450
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sequences, a phylogenetic tree has been constructed for P450 evolution (Figure
1.3.3.2). Although this is a useful model, it is not a quantitative representation of
the evolutionary pathway. Such a model assumes that the rate of gene divergence is
linear, which has been shown to be inaccurate for P450 gene divergence (Nebert &
Gonzalez, 1987), and it does not allow for gene conversion events. Genes from within
the same subfamily have all been found to lie within the same gene cluster
(Matsunaaa et al. 1990). In addition, the intron-exon organisation is unique to each
gene family, with the intron-exon boundaries at the same position for members
within the same family (Gonzalez et al. 1985; Zaphiropoulos et al. 1990).
Following the first divergence between microsomal and mitochondrial species
(approximately 1.5 x 10® years ago), the number of microsomal proteins has
increased greatly. This is thought to have occurred in response to environmental
challenge and may have coincided with vertebrate adaptation to terrestrial life.
Mitochondrial P450s are primarily involved in endogenous metabolism, catalysing
reactions such as steroid oxidations, and thus have diversified to a lesser extent. In
general, P450s which are involved in xenobiotic metabolism, the "drug
metabolising P450s", are found within families CYP1, CYP2 and CYP3. The greatest
structural diversity is seen in the CYP2 subfamily, which plays a central role in
xenobiotic metabolism.
25
Figure 1.3.3.2 Evolution of cytochrome P450 genes
CYPGENE
SUPERFAMILY
1 i 1 I i i » 1 1 ' ■ 1 ■ » j 1
4.0 3.0 2.0 1.0 0
EVOLUTIONARY DISTANCE
Redrawn from Nebert et al. 1991
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1.3.4 Regulation of P450 expression
The expression of P450 genes can be regulated at a number of levels. The
expression of many isozymes is dramatically influenced by the administration of
foreign compounds - these chemicals often increase the expression of the particular
isozyme(s) which are active in their metabolism. Xenobiotic regulation of P450
expression will be discussed in Section 1.3.4.2. Constitutive expression is often
under endocrine control, while the expression of several P450 genes is sexually
differentiated and tissue and species specific.
1.3.4.1 Constitutive expression
Most constitutively expressed P450s become transcriptionally active after
birth. Unlike most experimental animals, however, human fetuses have detectable
levels of P450 protein (Kitamura et al. 1992). Four proteins have been purified
from human fetal liver - P450 HFLa, P450HFLb, P450HFLc and P450HFLd. N-
terminal sequencing of the purified proteins suggested that they were members of the
CYP3A subfamily. P450 HFLa has subsequently been classified CYP3A7 and the
CYP3A7 cDNA has been shown to be highly homologous to the cDNA for CYP3A4,
isolated from a cDNA library prepared from adult human liver. As trans-placental
induction of P450 activity has been demonstrated in mice and rats (Vodicnik et al.
1980; Tagaki et al. 1976), it seems likely that these human fetal P450s will be
regulated in a similar manner, and will therefore be capable of activating
carcinogens i n situ, thus initiating genetic damage. In support of this, it has been
demonstrated that CYP3A7 is active in the metabolism of Aflatoxin B1 in an i n vitro
system (Kitamura et al. 1992). Similarly, in a recent study, Murray et al. (1992)
identified a CYP1A protein in both adult and fetal human liver. Immunohistochemical
analysis demonstrated that expression of this protein was localised predominantly to
hepatocytes, and while expression in human liver was very heterogeneous, the
distribution in fetal liver was more uniform.
Most studies on the ontogenic development of P450 expression have been
carried out in rodent models, and have shown that many P450 genes are
differentially regulated, both in the time of their transcriptional activation and the
tissue specificity of their expression. The expression of CYP2E1 in the rat is
transcriptionally activated immediately after birth (Song et al. 1986), while other
genes, such as CYP2C6 and CYP2C7, are not activated until puberty (Zaphiropoulos
et al. 1989). Developmental regulation of rat CYP2E1 expression has been
correlated with the demethylation of specific cytosine residues in the 5' region of the
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gene (Umeno et al. 1988). The expression of CYP2A1 is lost in male rats at puberty
(Matsunaga et al. 1988), while females lose the expression of CYP3A2 (Gonzalez et
a], 1986). This has been related to differences in serum growth hormone
concentrations (Zaphiropoulos et al. 1989). In addition, it has been shown that the
expression of several P450 genes is regulated by binding to a series of transcription
factors (Johnson, 1990). Yano et al (1992) proposed that the transcriptional
activation of P450 gene expression is directly related to the expression of these
transcription factors, some of which are expressed at different stages of
development.
Hormonal regulation of P450 gene expression has recently been
comprehensively reviewed (Lund et al. 1991). P450 expression in liver, lung,
kidney, adrenals, gonads, prostate and kidney is under endocrine control. Although
P450 expression in these extra-hepatic tissues is significantly lower than in the
liver, j_n situ formation of reactive metabolites may lead to tissue specific
sensitivity to a particular drug or toxin, leading to enhanced cytotoxicity or adverse
side effects. The influence of particular hormones is tissue specific. For example, the
peptide hormones adrenocorticotropic hormone (ACTH), luteinising hormone (LH),
follicle-stimulating hormone (FSH) and parathyroid hormone (PTH) influence
P450 expression in the adrenal gonads and kidney, while P450 expression in the
prostate is androgen dependent. In the liver, the major steroid hormone-
metabolising P450s are regulated by growth hormone (Gustafsson, 1978; Colby,
1980). Many of the P450s which are regulated by hormones have an important
endogenous function - these are summarised in Table 1.4.
Most of the studies on the influence of hormones on P450 expression have
been carried out in the rat, where pronounced a pronounced sexual differentiation in
the hepatic metabolism of both endogenous compounds and xenobiotics has been
observed. For example, CYP2C7 and CYP2C12 are female specific, while CYP2C11
and CYP2C13 are expressed only in male rats (Zaphiropoulos et al. 1988; Gonzalez
et al. 1986). This has been attributed to differences between the sexes in androgen
exposure, both neonatally and at later stages of development. These androgen-
mediated effects on hepatic P450 expression have been shown to be mediated by
growth hormone, via the hypothalamic-pituitary axis (Gustafsson et al. 1980). The
pattern of growth hormone secretion has been shown to vary dramatically between
males and females (Eden, 1979). Hypophysectomy was found to eliminate the sexual
differentiation in the expression of these hepatic P450s. The administration of
physiologically relevant doses of exogenous growth hormone to hypophysectomised
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rats resulted in the re-establishment of sexually differentiated P450 expression and
hence steroid metabolism (Morgan et al. 1985). The effects of growth hormone are
thought to be exerted at the level of transcription.
Hepatic gene expression can also be influenced by thyroid and glucocorticoid
hormones (Waxman, 1990) and insulin (Yamazoe et al. 1989). Insulin is thought to
affect P450 gene expression indirectly - growth hormone secretion in the pituitary
is suppressed in the absence of insulin (Tannenbaum, 1981). Growth hormone is
thought to exert its growth-promoting effects via insulin-like growth factor I (IGF-
I) (Daughaday, 1989). In a recent study (Ram & Waxman, 1992), thyroid hormone
has also been shown to regulate the expression of NADPH-cytochrome P450
reductase.
Similar mechanisms of gene regulation have been shown to exist in the mouse
(Macleod & Shapiro, 1989). Henderson et al (1990) demonstrated that P450
expression in mouse kidney is sexually differentiated, mediated by testosterone and
regulated at the level of transcription. A companion study (Henderson & Wolf,
1991) showed that the effects of testosterone are exerted through the androgen
receptor.
Although the effects of hormonal regulation on human P450 gene expression
have not yet been fully characterised, it seems likely that the effects will be as
complex, if not more complex than those observed in experimental animals. This is
likely to have profound toxicological consequences and may alter the susceptibility of
tissues which are sensitive to the effects of hormones to environmental insult or
drug treatment.
P450 gene expression can also be regulated post-transcriptionally. Freeman
et al (1992) demonstrated that induction of Cyp2e-1 protein expression by acetone
treatment was not accompanied by an increase in the expression of the corresponding
mRNA. Indeed, the levels of mRNA were significantly decreased. This phenomenon has
also been observed in ethanol (Song et_a|, 1986) and pyridine (Kim & Novak, 1990)
treated rats and ethanol treated rabbits (Porter et al. 1989). The increase in
Cyp2e-1 protein must therefore arise as a consequence of increased mRNA
translation or, more likely, by post-translational protein stabilisation. Similarly,
the regulation of CYP1A2 expression by TCDD and CYP2B1/2 by dexamethasone have
been shown to occur by mRNA stabilisation (Kimura et al. 1986; Simmons et al.
1987). Hormonal regulation of CYP2E1 expression in the rat has also been reported
(Johansson et al. 1989), evidenced by alterations in the phosphorylation status of
the protein.
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Post-translational modification by phosphorylation has been shown to be an
additional mechanism by which several P450 genes are regulated. J_n vivo studies
have shown that many hepatic P450 genes can be phosphorylated by purified protein
kinases (Pyerin et a I. 1987) and the phosphorylation status of several P450 genes
has also been studied in isolated hepatocytes and in vivo (Koch & Waxman,1989;
Bartlomowicz et al. 1989). Phosphorylation i n vitro can be increased by raising the
intracellular levels of cAMP by the addition of hormones such as glucagon which
control the regulation of intracellular adenylate cyclase. Phosphorylation status has
been implicated in the regulation of P450 activity and may also be important in
controlling P450 degradation (Eliasson et al. 1990). In all cases studied to date,
phosphorylation of P450 genes lead to a decrease in activity. This was reflected in
the studies of Oesch et al. who reported that the rate of generation of cytotoxic
metabolites from compounds such as cyclophosphamide was significantly reduced
when the phosphorylation status of CYP2B1 was increased. Similarly, CYP1A2,
which is involved in the metabolic activation of aromatic amines e.g. 2-
aminofluorene. was phosphorvlated in vitro bv purified protein kinases. Inhibition
of dephosphorylation by okadaic acid lead to decreased mutagenicity of all the
aromatic amines tested. Polyacrylamide gels showing native and phosphorylated
P450s revealed the presence of a higher molecular weight band in the
phosphorylated samples, which may represent a complex with ubiquitin, thus
targetting the proteins for degradation.
The mechanism for P450 degradation has not been fully elucidated, but it is
known that P450 turnover obeys first order kinetics (Parkinson et al. 1983;
Watkins et al. 1986). The half life (t-j/2) °f individual isozymes can therefore be
obtained from calculating the first order rate constant for the reaction. Individual
P450 half lives vary widely e.g rat CYP1A2 = 10 hours, while CYP2C6 and
CYP2C11 = 20 hours (Shiraki & Guengerich, 1984), and are, in general,
significantly shorter than the t-j/2 for reductase and cytochrome b5 (Correia,
1991). Induced P450s often have markedly longer half lives due to substrate-
induced protein stabilisation, but these values do not necessarily reflect the true half
life of the proteins.
P450 heme has a shorter t-j / 2 than the corresponding apocytochromes
(Correia, 1991). Dynamic exchange of heme between apoproteins has been shown to
occur and this greater lability has been proposed to account for the shorter half life
(Sadano & Omura, 1983).
Although individual P450s have different half lives, it is likely that there is
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a degradation pathway or pathways which is common to all isozymes. The variation in
t-j / 2 between isozymes may well represent different binding affinities for the
enzymes within this degradative pathway. Although the mechanism of degradation of
the apoprotein has not yet been elucidated, heme catabolism is relatively well
characterised. Labelling studies in rats given 5 - ["* ^C] amino-laevulinic acid
(ALA) showed that microsomal heme is converted to bilirubin and carbon monoxide
(CO) by heme oxygenase (Landaw et al. 1970). This microsomal enzyme ligates
heme and catalyses the breakdown of the tetrapyrrole ring to yield CO, biliverdin IX
and iron (Tenhunen, 1969). Biliverdin is then converted to bilirubin by the
cytoplasmic biliverdin reductase, followed by bilirubin conjugation with glucuronic
acid and elimination. Maines & Kappas (1977) proposed that heme oxygenase
activity is rate limiting in the degradation of hepatic P450 heme. Bissell & Guzelian
(1980), however, demonstrated that heme oxidase mediated degradation of heme to
biliverdin accounted for only 60-70% of P450 heme in rat liver homogenates,
implying that an alternative pathway(s) exists. This has not, as yet, been
characterised, and is not clear whether heme catabolism is regulated in humans in a
similar manner to rodents.
A recent study (Celier & Cresteil, 1991) demonstrated that administration of
3-MC to congenitally jaundiced Gunn rats did not lead to an increase in hepatic P450
protein, due to decreased heme availability as determined by tryptophan pyrrolase
activity. Heme oxygenase activity was also significantly lower in these rats,
suggesting that it was not responsible for the decrease in available heme. In order for
new catalytically active P450 to be synthesised following xenobiotic administration,
an endogenous heme pool must exist. The rate limiting enzyme for heme biosynthesis,
5-aminolevulinate synthase (ALVS) is inducible by both phenobarbital and TCDD
(Poland & Glover, 1973), which are also powerful regulators of P450 expression
(Guengerich, 1987). It has been proposed, however, that these agents act indirectly
to decrease the amount of available heme by increasing the levels of P450 apoprotein
to a greater extent than they induce ALVS activity. Heme from the intracellular heme
pool is therefore taken up at a rate which exceeds its synthesis.
1.3.4.2 Xenobiotic regulation of P450 gene expression
Regulation of P450 gene expression by foreign compounds has been studied
extensively in a number of model systems. Xenobiotic regulation of P450 expression
in mouse and human tissues and in a cell culture model will form the basis of
Chapters 3, 4 and 5.
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Exposure to a wide variety of structurally diverse xenobiotics results in
increased expression of the P450 isozymes which are active in their metabolism
(Conney, 1982; Okey, 1990). Although there is some overlap in substrate
specificity between isozymes, in general, different classes of chemical are
metabolised by distinct P450s. Certain chemicals which contain a variety of
functional groups e.g. Aflatoxin B-| can be metabolised by several distinct P450
isozymes, often resulting in the formation of regio- and stereospecific reaction
products.
Regulation of the expression of CYP1A genes has been most fully
characterised to date. CYP1A genes are regulated at the level of transcription on
exposure to polycyclic aromatic hydrocarbons (PAHs) (Whitlock, 1990). Recent
work in a cell culture model has considerably advanced our knowledge of the
mechanism of this transcriptional regulation (Reyes et al. 1992). It has been
known for some time that PAHs such as TCDD and aromatic amines interact with and
bind to a cytosolic protein, the Ah receptor. The Ah receptor has recently been
purified from mouse liver (Poland et al. 1991) and the corresponding cDNA cloned
and characterised. The ligand-receptor complex is then translocated to the nucleus
where it binds DNA at an enhancer sequence upstream of the transcription start site
leading to transcriptional activation of the CYP1A gene(s) (Fujisawa-Sehara et al.
1987, 1988). The mouse hepatoma cell line, Hepa-1 has been shown to contain a
functional Ah receptor. In a recent study, Hankinson et al (19911 isolated a series of
mutant clones from this cell line which were defective in some aspect of the ligand
activated transcription process. Mutants were selected on the basis of their
resistance to benzo(a)pyrene. Four unique mutant cell lines were thus isolated:
(A) contained an inactivating mutation in the Cyp1a1 structural gene;
(B) mutants had greatly reduced levels of the Ah receptor;
In (C) mutants the receptor could not translocate to the nucleus and
(D) combined the mutations in (B) and (C).
Further studies of the (C) mutant lead to the identification of the cDNA encoding a
gene responsible for translocation of the receptor to the nucleus, the Ah receptor
nuclear translocator or Arnt gene (Hoffmann et al. 1991). The deduced amino acid
sequence of the protein encoded by this cDNA contains a basic helix-loop-helix
domain, a common motif in proteins which bind DNA. It has been proposed that the Ah
receptor and the Arnt gene bind DNA as a heterodimeric complex, almost certainly in
the 5' upstream region of Cypla genes, termed the xenobiotic regulatory element or
XRE (Reves et al. 1992).
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A similar regulatory mechanism is thought to exist for hormone responsive
P450s, such as those in the CYP3A family. In this case, the hormone e.g. the
synthetic glucocorticoid dexamethasone, interacts with a glucocorticoid responsive
element (GRE) in the upstream region of the gene which initiates or leads to
enhanced transcription. CYP4A genes are also thought to be regulated by binding to an
intracellular receptor. CYP4A gene expression is inducible by a range of
structurally dissimilar compounds termed peroxisome proliferators. These
compounds, which include drugs such as nafenopin and clofibric acid, cause marked
peroxisome proliferation in several species. The cDNA for a receptor which is
responsive to these compounds, the peroxisome proliferator activated receptor
(PPAR), has recently been cloned (Issemann & Green, 1990). This receptor is a
member of a superfamily which also contains receptors for steroids, thyroid
hormones and retinoic acid. Fatty acids, which are also metabolised by CYP4A genes,
are likely to be endogenous ligands for the PPAR (Gottlicher et al. 1992).
Although CYP2 genes are centrally involved in the metabolism of many
structurally dissimilar chemicals, little is known about their mechanism of
regulation. The regulation of CYP2B gene expression has been studied in the most
detail. CYP2B gene expression is regulated by barbiturates such as phenobarbital
(Guengerich, 1987). A 17 base pair sequence has been identified in the 5' flanking
regions of CYP2B genes which is thought to be responsible for transcriptional
activation by phenobarbital and which is conserved between rat CYP2B1, CYP2B2
and the barbiturate-inducible genes in the bacteria Bacillus megaterium. In the
absence of bound barbiturate, a repressor is bound to a 24 base pair sequence which
overlaps the phenobarbital binding sequence. This repressor is thought to be
displaced on barbiturate binding, leading to transcriptional activation of the gene (He
& Fulco, 1991).
Many of these xenobiotic-responsive genes also have important endogenous
functions e.g. CYP4A proteins are involved in the co- and co-1 hydroxylation of
fatty acids. It is therefore important to realise that exposure to many xenobiotic
regulators can lead to altered expression of the genes which are involved in the
regulation of many important biosynthetic processes within the cell. The P450-
mediated metabolism of a particular drug or environmental pollutant can therefore
lead, in addition to increased inherent cytotoxicity, to altered cellular homeostasis.
1.4 Endogenous role of cytochrome P450
In addition to their role in xenobiotic metabolism, P450 enzymes are also
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active in the metabolism and biosynthesis of many endogenous compounds such as
steroid hormones, fatty acids, prostaglandins and vitamins. Individual P450
isozymes exhibit a high degree of regio- and stereoselectivity in the metabolism of
many of these endogenous compounds. This is illustrated by the P450-mediated
metabolism of testosterone and cholesterol, the metabolism of which leads to the
production of sex hormones, glucocorticoids and mineralocorticoids. Indeed, analysis
of the regio- and stereospecific hydroxylation products of the steroid nucleus has
been shown to be a convenient method of determining the relative concentrations of
individual P450 isozymes present in a complex mixture such as rat liver
microsomes (Wood et al. 1983; Waxman, 1988). The major biosynthetic reactions
catalysed by P450 are summarised in Table 1.4.
Vitamin D3 (cholecalciferol) is responsible for regulating cellular calcium
and phosphorus homeostasis. The vitamin is inactive as administered, however, and
undergoes oxidative metabolism to the active 1,25-dihydroxyvitamin D3, catalysed
by an initial P450-mediated hydroxylation in the liver to a product which is further
hydroxylated by a P450 in the kidney mitochondria. In addition, further P450
mediated reactions can metabolise the pro-vitamin to different hydroxylation
products which are catalytically inactive (DeLuca, 1982; Henry & Norman, 1984).
Vitamin A (retinol) is also metabolised by a P450 mediated oxidation to retinoic acid
which itself undergoes further oxidative metabolism. Rat liver microsomes have
been shown to be capable of oxidising both retinol and retinoic acid, and it is been
demonstrated that these reactions can also be performed by purified CYP2B1 and
CYP2C7 in a reconstituted system (Leo et al. 1984, 1985). Vitamins E (a-
tocopherol) and B2 (riboflavin) are also thought to be metabolised by P450
enzymes, although the individual isozymes responsible for their metabolism have not
yet been determined.
Arachadonic acid is metabolised by cytochrome P450 to a number of products
(Karara et al. 1989), including epoxyeicosatetrienoic acids which regulate insulin
and glucagon release from the pancreas (Karara et al. 1989; Capdevila et al. 1990),
and hydroxyeicosatetranoic acids which can act as templates for prostaglandin and
leukotriene biosynthesis. CYP4A isozymes are responsible for the metabolism of
arachadonic acid to various oo- and co-1 hydroxylated products (Capdevila et al.
1981). Many individual prostaglandins, including PGA1, PGA2, PGE-j andPGE2 are
further metabolised by P450s in the liver, kidney and lung to yield a>- and co- 1
hydroxylated products, co-oxidation of prostaglandins is the major metabolic route
leading to excretion in the urine (Pace-Asciak & Edwards, 1980). Arachadonic acid
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can also be metabolised to prostacyclin and thromboxane, which function as cellular
mediators of platelet aggregation and thrombosis, respectively. Although the enzymes
involved in these biosynthetic pathways have not been formally characterised,
partial purification and spectrochemical studies have shown that they are catalysed
by P450.
Table 1.4 Biosynthetic processes catalysed by cytochrome P450
REACTION P450
STEROL SYNTHESIS CYP51





Cholesterol -> Pregnenolone CYP11A1 (P450scc)
Pregnenolone -> 17a-Hydroxypregnenolone CYP17
Progesterone -> 17a-Hydroxyprogesterone (P45017a.C17 20)
17a-Hydroxy-20-dihydropregnenolone -> DHEA
17a-Hydroxy-20-dihydroprogesterone -> Androstenedione
Androstenedione -> Estrone CYP19 (P450AROM)
Testosterone -> Estradiol
11-Deoxycortisol -> Cortisol CYP11B1 (P45011p)
PROSTAGLANDIN METABOLISM
PGr2 "> Prostacyclin (PGI2) P450PGI2




Retinoic acid -> 4-Hydroxyretinoic acid P4504.ra
Abbreviations: 14DM: 14a-demethylase; see: side chain cleavage; 17a: 17a-hydroxylase;
C17,20: 17,20-lyase; DHEA: dehydroepiandrosterone; AROM: aromatase; 11 ~p: 11(3-
hydroxylase; PGH2: prostaglandin endoperoxide; LTB4: 5(S),12(R)-dihydroxy-6-c/s-8,10-
trans-14-c/s-eicosatetraenoic acid; RA: retinoic acid
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1.5 Xenobiotic metabolism by cytochrome P450
A wide variety of foreign compounds (xenobiotics) are metabolised by the
P450 system. For ease of discussion these will divided into two sections:
1) Environmental pollutants, chemical toxins and carcinogens
2) Drugs in common clinical use, including anticancer drugs
1.5.1 Xenobiotic metabolism
The diversity of P450 has been proposed to have occurred as an adaptive
response to environmental challenge. The so called "drug metabolising" P450s i.e.
those within the CYP1, CYP2 and CYP3 families, are thought to have appeared at
more advanced stages of evolution to protect against toxins in the environment
(Nebert, 1979). This adaptive response is analogous to the response of the immune
system when challenged by a foreign compound. It has been proposed that an organism
encountering an environmental toxin can activate or induce the synthesis of a P450
which is active in its metabolism. This is illustrated by the P450-mediated
production of phytoalexins by plants. These compounds are not toxic to the plants and
are not necessary for their survival, but are sufficiently toxic to animals and birds
that the plant is considered inedible. This selective toxicity has been successfully
exploited in the design of many common therapeutic agents which are structural
and/or functional analogues of natural products. TCPOBOP, a potent and pleiotropic
inducer of P450 activity, the effects of which will be described in later chapters,
was isolated as a contaminant in the preparation of a commercially available
herbicide.
Thus, a variety of P450 enzymes exist which are active in the metabolism of
a wide range of structurally diverse chemicals. Significant inter-species variation
in the metabolism of many chemicals exists, however. This is illustrated by the
metabolism of Aflatoxin B1.
Aflatoxin B-j (AFB1) is a mycotoxin produced by various species of the mould
Aspergillus. Metabolism of AFB1 by cytochrome P450 results in the generation of a
highly carcinogenic metabolite, Aflatoxin 8,9-oxide (Swenson et al. 1975, 1977).
Exposure to AFB-j has been linked with the aetiology of liver cancer, particularly in
regions of Asia and Africa where exposure to the toxin is common (Harris & Sun,
1984). A recent study (Forrester et al. 1990) demonstrated that several distinct
P450 isozymes were capable of metabolically activating this compound. While
CYP3A proteins were the most active in the conversion of AFB-| to mutagenic
products in human liver microsomes, CYP2C, CYP1A2 and CYP2A1 proteins were
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also capable of metabolic activation. Significant inter-individual variation in the
metabolism of AFB-j was found to correlate with variation in the expression of CYP3A
protein(s). The metabolism of AFB-j in rodent models was significantly different,
however. In the rat, metabolism by CYP3A was not as dominant as in the human, and
CYP2B and CYP4B proteins were also catalytically active (Robertson et al. 1981;
Kawajiri et al. 1980).
Further examples of compounds which are metabolised by P450 isozymes in
a species specific manner are given in are given in Chapters 3 and 5.
1.5.2 Clinical applications
P450 enzymes have been shown to be involved in the metabolism of
some of the earliest drugs, many of which were administered before their metabolic
pathways had been determined. Liu (1991) described a range of Chinese medicinal
herbs including the Fructus Shizindrae derivatives, dibenzo(a,c)cyclooctenes
isolated from the fruit kernels of the plant Schizandra Bail. Isoquinoline alkaloids
extracted from the herb Corydalis bungeane Diets and the amide alkaloids Clausena
lansium, found in fruit tree leaves, have also been shown to undergo P450-mediated
metabolism. These have been and still are used to treat a variety of disorders
including viral and idiopathic hepatitis. Moreover, P450 enzymes catalyse the
metabolism of a variety of drugs which are currently used in clinical practise. For
some of these drugs, the P450 isozyme responsible for their metabolism and the
metabolic process(es) involved have been characterised - examples of these are
given in Figure 1.5.2. Other drugs, such as cimetidine, can inhibit P450 function.
Confident identification of the enzymes involved in the metabolism of a
particular drug in man is often difficult, due to factors such as drug/drug
interactions, effects of diet and ingestion of environmental toxins, all of which can
influence P450 expression. An additional complication is that the previous
medication history for a particular individual is not always known.
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Table 1.5.2 Human P450 isozymes involved in the metabolism of clinically
important drugs
P450 Drug Reaction type


















Adapted from Watkins, 1990
Acetaminophen, a widely used analgesic and antipyretic is known to cause
centrilobular hepatic necrosis, both in experimental animals and man (Prescott et
al, 1971). The parent compound is metabolised by CYP1A2 and CYP2E1 (Morgan et
a], 1983; Raucy et al. 1989) to the hepatotoxin NAPQI (N-acetyl-p-benzoquino-
imine) which binds to and depletes cellular glutathione and covalently binds to
cellular macromolecules (Hinson et ai, 1981). Paracetamol (4-hydroxy
acetanilide) is similarly metabolised. Acetaminophen can be metabolised by both
adult and fetal livers. Chronic alcoholics who have greatly induced levels of CYP2E1
show toxicity to acetaminophen at much lower doses, although this may also be due in
part to reduced glutathione availability. Acetaminophen overdose is treated by the
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administration of N-acetyl cysteine to raise the level of circulating glutathione and
aid elimination.
Cimetidine (Tagamet) administration leads to the inhibition of P450 activity
and, as such, can affect the metabolism of other co-administered drugs (Knodell et
ai, 1991). This is exemplified in the reduced clearance of theophylline, diazepam
and alcohol in patients on cimetidine therapy (Reitberg et al. 1981; Klotz &
Reimann, 1980; Nelson et al. 1985). There is considerable inter-individual
variability in the extent to which the clearance of these drugs is affected - whether
this is simply a function of individuality in the expression of the particular P450
isozymes responsible for their metabolism has not been established. Inhibition is
thought to occur by the imidazole ring of cimetidine interacting with P450 heme
(Knodell et al. 1982), with steric interactions with the amino acids in the heme
binding site determining binding affinity. The extent of inhibition is therefore
different for individual P450 isozymes. CYP2C gene expression is largely unaffected
and there is correspondingly only a very slight inhibition of tolbutamide and
hexobarbital hydroxylation. CYP1A2 and CYP2E1 activities show moderate inhibition
but, in contrast, cimetidine binds with high affinity to the heme in CYP3A4 and
CYP2D6 resulting in almost complete inhibition of the oxidation of nifedipine. The
concentration of drug needed to inhibit P450 in isolated microsomes (mM) is,
however, usually much higher than circulating blood levels in patients on cimetidine
therapy. In a similar manner to cimetidine, 8-methylpsoralen, used in the
treatment of psoriasis, binds to CYP1A2 resulting in its activation. Patients
receiving this medication therefore have an increased ability to metabolise and
eliminate caffeine (Mays et al. 1987; Tinel et al. 1987).
In many cases, two or more drugs are in competition for metabolism by the
same P450 isozyme. The extent of metabolism of a particular drug is therefore
dependent on its lipophilicity and the binding affinity of the drug for the P450
isozyme active in its metabolism. In addition, certain drugs can be metabolised to
different products by different P450s, and the overall metabolic outcome is
therefore dependent on the relative binding affinities for each isozyme. Such
interactions often leads to the impaired metabolism of one drug, while the
metabolism of another is increased.This is exemplified in the co-administration of
cyclosporin and erythromycin (Ptachcinski et al. 1985), both of which are
metabolised by hepatic CYP3A enzyme(s). Cyclosporin metabolism is inhibited by
the erythromycin administration, leading to cyclosporin toxicity. Similarly,
rifampicin administration can lead to failure of oestrogen based contraceptives
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(Guengerich, 1989). The situation is further complicated by the demonstration that
that certain compounds which are potent inhibitors of one P450 isozyme can
significantly increase the metabolism of another. For example, quinidine inactivates
CYP2D6 (Leeman et al, 1986), but is itself metabolised by CYP3A (Guengerich et
a], 1986).
1.5.3 Anticancer drug metabolism
Many of the anticancer drugs in current use are subject to metabolism by one
or more of the P450 isozymes (Le Blanc & Waxman, 1989). These include CCNU
(1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea), which acts by inducing DNA
strand breakage (May et al. 1974) and procarbazine (N-isopropyl-oc- (2 -
methylhydrazino)-p-toluamide) (Lee & Lucier, 1976) which inhibits
transcription by DNA methylation. The epipodophyllotoxin etoposide (VP-16) is
also activated by a P450 mediated process (Relling et al. 1992). Etoposide is
thought to stabilise complex formation between DNA and topoisomerase II (Topo II),
inhibiting the process of DNA repair and resulting in the formation of strand breaks.
The chemical structures of these drugs and of cyclophosphamide, tamoxifen and the
morpholinodoxorubicins, the metabolism of which is described below, are given in
Figure 1.5.3.
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Figure 1.5.3 Anti-cancer drugs which undergo P450-mediated metabolism
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More recent studies have identified the P450 isozymes which catalyse the
activation and/or detoxification of cyclophosphamide, tamoxifen and the
morpholinodoxorubicins. This raises the possibility that increasing the expression
of these P450s could lead to increased drug metabolism and hence greater efficacy.
Synthesis of the immunosuppressive bifunctional alkylating agent
cyclophosphamide was first reported by Arnold & Bourseaux in 1958.
Cyclophosphamide toxicity is thought to be mediated by the formation of reactive
carbonium ions which alkylate guanine residues, leading to the formation of DNA
cross links (Calabresi & Parks, 1985). The parent compound is inactive as
administered and has been shown to undergo P450 mediated metabolism to generate
two reactive products, phosphoramide mustard and acrolein. In support of this, it
was demonstrated that activation was NADPH and 02 dependent, was inhibited by the
non-specific P450 inhibitor SKF525A and induced by phenobarbital (Brock &
Hohorst, 1963,1967; Brock, 1967). A simplified reaction scheme for
cyclophosphamide metabolism is shown in Figure 1.5.4. Several further metabolites
are also formed which are not described in this reaction scheme - these do not have
cytotoxic properties.
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Step (1): The first step is a P450-mediated hydroxylation, catalysed by CYP2B
proteins. Several independent lines of evidence support the identification of a
protein(s) from the CYP2B family in catalysing this reaction. Pretreatment of rats
with phenobarbital resulted in an increased rate of cyclophosphamide metabolism
(Sladek, 1972), while CYP2B1 mRNA was detected in HepG2 cells which
metabolically activated the drug (Dearfield et al. 1986). Additional evidence was
provided by Black et al (19891 who demonstrated that expression of a full-length
rat CYP2B1 cDNA in Saccharomyces cerevisiae resulted in an increased mutation
frequency on exposure to cyclophosphamide.
Step (2): 4-hydroxycyclophosphamide exists in tautomeric equilibrium with
aldophosphamide, neither of which have any cytotoxic activity. Aldophosphamide can
then be further metabolised in one of two ways:
Step (3): Hydrolysis to phosphoramide mustard and acrolein, both of which
metabolites are cytotoxic or;
Step (4): Oxidation to carboxyphosphamide, a non-toxic metabolite, catalysed by
either aldehyde oxidase or NAD-dependent aldehyde dehydrogenase.
The major cytotoxic metabolites, phosphoramide mustard and acrolein exert
their cytotoxic effects in different ways: the major cytotoxic effects arise from DNA
cross-linking, initiated by the aziridinium ion of the phosphoramide mustard.
Acrolein, in contrast, produces single DNA strand breaks rather than inter-strand
cross links (Erickson et al. 1980; Cairney et al. 1984). The clinical use of
cyclophosphamide is often compromised by its toxicity to the bladder, which usually
manifests as haemorrhagic cystitis. Acrolein has been identified as the primary
causative urotoxic agent (Brock et al. 1981; Sladek et al. 1982).
In 1896, Beatson demonstrated that an "ovarian product" promoted tumour
growth in the breast, providing early evidence for the involvement of oestrogens in
the aetiology of breast cancer. More recent studies have shown that approximately
one third of breast tumours are oestrogen dependent (Lippmann & Dickson, 1989),
and there is evidence linking oestrogen-based contraceptives to the initiation of both
benign and malignant tumours (Fornander et al. 1989). Tamoxifen, (Z-1-[4-[2-
(dimethylamino)ethoxy]phenyl]-1,2-diphenyl-1-butene), which has become the
most widely used drug in the clinical management of breast cancer, has been shown to
act by binding to the oestrogen receptor (ER) where it can mimic the effects of
endogenous oestrogen. The compound has different effects in different species,
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however. In the mouse, it acts as a full oestrogen agonist, while in the rat in can act
as a partial agonist or partial antagonist. In humans, tamoxifen is a full oestrogen
antagonist (Jordan & Robinson, 1987) and as such has become a powerful drug in
the treatment of hormone-dependent breast cancer. Binding of oestradiol and
tamoxifen to the ER is competitive. This was confirmed by the studies of lino et al
(1991) which showed that tamoxifen inhibited the oestrogen dependent tumour
growth of MCF7 cells grown as a solid tumour xenograft in athymic nude mice while
the addition of exogenous oestradiol reversed tamoxifen induced growth inhibition.
Tamoxifen bound to the ER blocks cell division and the cell cycle is
interrupted at the G-j/S interface (Osborne et al. 1983; Sutherland et al. 1983).
The effects of the drug are cytostatic rather than cytocidal (Jordan, 1983) and it is
therefore necessary to administer the drug continuously to maintain therapeutic
serum concentrations. For therapy to succeed, it is also a prerequisite that the
tumour remains hormone dependent (Jordan, 1990). The drug is currently
undergoing trials for prophylaxis in women who are considered to be at high risk of
developing breast cancer (Powles et al. 1990).
Although five tamoxifen metabolites have been detected in human serum
(Jordan, 1982; Kemp et al. 1983), the two major forms are N-desmethyl
tamoxifen and 4-hydroxy tamoxifen (Figure 1.5.5).
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Figure 1.5.5 Tamoxifen metabolism
Demethyltamoxifen Tamoxifen N-oxide
Demethyl - 4 - hydroxytamoxif en
N-desmethyl tamoxifen is the major metabolite in plasma, while 4-hydroxy
tamoxifen is the most potent anti-oestrogen and binds the ER with the greatest
affinity. The involvement of cytochrome P450 in the metabolism of tamoxifen was
first demonstrated by Mani & Kupfer (1991), who showed that tamoxifen was
metabolised to a reactive intermediate in human liver microsomes which bound
irreversibly to microsomal proteins. This process was NADPH and 02 dependent and
was inhibited by CO and antibodies to NADPH-cytochrome P450 reductase. In
addition, binding was increased by pretreatment of the microsomes with
phenobarbital. Similar results were obtained for the compound chlorotrianisene
(TACE) which can also act as both an oestrogen agonist and antagonist. Previous
studies had shown that TACE is metabolised by P450 (Jeudes et al. 1987; Jeudes &
Kupfer, 1990). Jacolot et al (1991) demonstrated that a protein(s) from the
CYP3A family was responsible for the metabolism of tamoxifen to N-
desmethyltamoxifen in human liver microsomes. Whether the drug can also be
metabolised within breast tissue and which P450 is involved in the in situ
metabolism has not yet been determined. It is also not known which P450 is
responsible for metabolism to 4-hydroxy tamoxifen, the most active form. Plasma
concentrations of tamoxifen metabolites were shown to vary widely between
individual patients. This may be due to inter-individual variation in the expression
of the drug metabolising enzymes which are active in its metabolism.
Both tamoxifen and N-desmethyl tamoxifen are potent inhibitors of protein
kinase C (O'Brian et al. 1985,1986, 1988), which may be one mechanism by
which these compounds inhibit tumour cell proliferation. Tamoxifen has also been
shown to bind calmodulin which is involved in DNA synthesis. Inhibition of
calmodulin activity may therefore inhibit DNA synthesis, leading in turn to tumour
growth inhibition (Lam, 1984). Turner et al (1991) proposed that tamoxifen
cytotoxicity was mediated by a reactive free radical intermediate(s). Attempts were
made to isolate this intermediate by spin trapping, using nitrones to trap the radical
as the corresponding nitroxide, detected by electron spin resonance (ESR).
Intracellular production of superoxide radicals was indeed detected, but there was no
evidence for the production of hydroxyl radicals.
As with many other anticancer drugs, prolonged tamoxifen therapy can lead to
the development of resistance. A number of mechanisms have been proposed to
account for this: Loss of oestrogen receptors or selection of hormone independent
clones may be responsible, as may alteration in the steady state serum levels of
drug, leading to decreased cytostatic action; A correlation has also been found between
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the isomerisation of frans-4-hydroxy tamoxifen to the cis -4-hydroxy form and
decreased antitumour effects (Osborne et al. 1992). The trans isomer, although a
minor metabolite, has been shown to bind to the ER with a greater affinity than
tamoxifen itself and acts as an oestrogen antagonist. As such, it has been proposed to
be the major active form of the drug. In contrast, the cis isomer has reduced affinity
for the ER and acts as a full oestrogen agonist. A high concentration of c/s-4-hydroxy
tamoxifen has been observed in patients who have developed resistance to tamoxifen
therapy.
The morpholino and cyanomorpholino-doxorubicin analogues (MRAs) are
intensely potent anthracyclines which do not have the same cardiotoxic side effects as
their parent compound, adriamycin (Acton et al. 1984). The clinical effectiveness of
adriamycin is often significantly impaired by the development of drug resistance
(Batist et al. 1986). Neither MRA or MRA-CN show cross-resistance in cell lines
which are resistant to adriamycin (Streeter et al. 1985). While adriamycin
participates in redox cycling, the morpholino derivatives exert their anti-tumour
effects by different mechanisms - MRA initiates DNA strand breakage, while MRA-
CN causes DNA cross-linking (Scudder et al. 1988; Jesson et al. 1987). Lau et al
(1989) demonstrated that MRA cytotoxicity could be potentiated up to 100-fold in
the presence of human liver microsomes and NADPH and inhibited by carbon
monoxide and SKF-525A, thus implying P450 involvement in the metabolic
activation of these compounds. A recent in vitro study (Lewis et al. 1992)
demonstrated that CYP3A isozymes (CYP3A3 and/or CYP3A4) were capable of
metabolically activating these drugs.
NADPH-cytochrome P450 reductase also plays a role in the activation of
anti-tumour agents. This is of particular importance in the metabolism of
anthracycline antibodies such as adriamycin. The anti-neoplastic properties of this
agent have been shown to depend on the one electron reduction of the parent
compound to the corresponding semiquinone free radical (Sinha, 1980; Basra et al.
1985). This reactive species can either bind DNA (Sinha, 1980) or protein (Ghezzi
et al. 1981) directly or undergo redox cycling, leading to the production of
superoxide radicals (Sinha, 1989). A recent study (Bartoszek & Wolf, 1992) using
the breast carcinoma cell line MCF-7, demonstrated that the cytotoxicity of
adriamycin was significantly increased by the addition of exogenous NADPH and
NADPH-cytochrome P450 reductase. Neither of these agents was toxic in its own
right.
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1.5.4 The role of P450 in autoimmune disease
The inflammatory liver disease autoimmune chronic active hepatitis is
thought to be caused by loss of immunological tolerance against liver tissue and, as
such, responds well to immunosuppressive therapy. Administration of the diuretic
tienilic acid lead to the onset of hepatitis, accompanied by a high serum concentration
of antibodies which react with liver and kidney microsomes (LKM-2). The antigen
recognised by these antibodies was found to be a CYP2C protein which is involved in
the metabolism of tienilic acid (TA). It has been proposed that CYP2C9 metabolism of
TA leads to the formation of an active metabolite which binds to the P450 resulting
in altered antigenicity. This modified protein is no longer recognised by the immune
system which causes autoantibodies to be raised against it (Homberg et al. 1984;
Beaune et al. 1987).
Two further P450 proteins have been similarly identified as human
autoantigens. These are recognised by the so-called liver-kidney-microsomal
antibodies (LKMs) in sera from patients with drug-induced or idiopathic chronic
immune hepatitis. These are summarised in Table 1.5.4.
Table 1.5.4 Microsomal autoantigens in liver disease
Mol. wt. Nomenclature Associated P450 Disease
50 LKM-1 CYP2D6 autoimmune CAH
50 LKM-2 CYP2C9 drug-induced hepatitis (tienilic acid)
? LKM-3 ? chronic hepatitis D
50 - CYP1A2 autoimmune CAH, dihydralazine
hepatitis
55 - ? autoimmune CAH
64 ? autoimmune CAH
CAH: idiopathic autoimmune chronic active hepatitis
Adapted from Manns, 1991
LKM-1 autoantibodies characterise autoimmune hepatitis type II and
recognise CYP2D6 protein. Not all patients expressing these antibodies have received
drugs which are known CYP2D6 substrates, however, it has been proposed that the
autoimmune response is initiated by compounds in the diet or environment (Zanger
et al. 1988; Manns et al. 1989).
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Oxidative metabolism of the anaesthetic halothane can also lead to an adverse
immunological response. Halothane (1-bromo-1-chloro-2,2,2-trifluoroethane) is
metabolised by cytochrome P450 to an unstable halohydrin intermediate which goes
on to form trifluoroacetyl chloride or bromide (Gandolfi et al. 1980). This is then
hydrolysed to yield trifluoroacetic acid which acetylates hepatic proteins. These
acetylated proteins are not recognised by the immune system, which mounts an
immunological response leading to liver damage, manifested as halothane hepatitis
(Poul & Gillette, 1982). The P450 isozyme responsible for halothane metabolism
has not yet been identified, but a trifluoroacetyl adduct of halothane bound to a 54kD
P450 protein has been detected in rat hepatocytes (Satoh et al. 1985).
1.6 Aims of thesis
Cytochrome P450 enzymes are therefore, in addition to their endogenous
role, centrally involved in the metabolism of many environmental toxins and
commonly prescribed drugs. At present, however, there is very little information
available about the regulation and expression of these genes in human tissues. P450
expression has been extensively studied in experimental animals, but significant
inter-species variation has been observed in the metabolism of many chemicals, and
it is therefore not clear which species best represents P450 regulation in man.
Cultured cells have also been used in the study of cytochrome P450 expression, but
there are often inherent limitations imposed by the j_n vitro culture environment
which are not observed i n vivo.
The aims of this thesis were therefore three-fold:
1) To study the xenobiotic regulation of cytochrome P450 gene expression in a
number of model systems - in particular, to characterise the effects of TCPOBOP
(1,4-bis 2-(3,5-dichloropyridyloxy)benzene)), an extremely potent modulator of
P450 expression, which had previously been shown to be both tissue and species
specific in its inductive effects.
2) To develop a model in which the expression and regulation of human P450 genes
could be investigated, and to determine if this could be exploited to therapeutic
benefit.
3) To determine the response of human tumour cells to a range of xenobiotic
modulators and to determine to what extent the response of the human tumours was
representative of the response obtained in experimental animals and cultured cells.
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Chapter 2: Materials and Methods
2.1 Chemicals
Unless otherwise indicated, all chemicals were purchased from either Sigma
Chemical Co. Ltd., Poole, Dorset, or BDH Ltd., Burnfield Avenue, Thornliebank,
Glasgow, and were of analytical grade or better. Cell culture reagents were obtained
from Gibco, Ltd., PO Box 35, 3 Washington Road, Paisley. A complete list of the
chemical reagents used and their respective suppliers is given in Appendix 1.
TCPOBOP was synthesised according to a modified version of the method of Poland et
a] (1980). Two molar equivalents of 2,3,5-trichloropyridine were added to 1 molar
equivalent of hydroquinone in DMSO. The solution was heated to 65°C under reflux
for 30 minutes before the addition of 30mM NaOH to make a 50% aqueous solution.
After a further 2 hours at 110°C, the solution was cooled to room temperature and
the solid product collected by the addition of 10% NaOH and subsequent filtration. The
product was washed with dH20 to remove any aqueous impurities and re-crystallised
from carbon tetrachloride before analysis by nuclear magnetic resonance




All the experiments described within this section, with the exception of part
(c) below, were carried out in the Faculty of Medicine Animal Area, Department of
Biochemistry, Edinburgh University.
Male and female C57/BL6 and DBA/2 mice (average weight 20g) and Wistar
rats (average weight 250g) were obtained from Banton & Kingman, Hull, UK. The
animals were allowed to acclimatise for at least 7 days before treatment in a
controlled environment with a 12hr light/dark cycle, and were fed at libitum on
standard rodent laboratory chow. These animals were then treated according to the
following experimental protocols:
(a) Administration of dexamethasone, phenobarbital and TCPOBOP to DBA/2 mice:
Characterisation of the extent of P450 induction
Male and female DBA/2 mice (10 of each sex per treatment group) were
treated intra-peritoneally as described below:
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Control, corn oil, 3 injections
Dexamethasone, 100mg/kg in corn oil, 4 injections
Phenobarbital, 80mg/kg in PBS, 3 injections
TCPOBOP, 3mg/kg in corn oil, SINGLE INJECTION
Injections were administered at intervals of 24 hours, in 0.2mls vehicle per
mouse. 24 hours following the final injection, or on Day 4 for the TCPOBOP-treated
group, the animals were sacrificed by cervical dislocation and their livers removed,
rinsed in phosphate buffered saline (PBS) and snap-frozen on cardice. Organs from
within the same treatment group were pooled. Tissue was stored at -70°C prior to
processing.
(b) Duration of the inductive effect
Male and female DBA/2 mice (6 of each sex per treatment group) were given
a single intra-peritoneal injection of TCPOBOP (3mg/kg) on Day 1 and were
sacrificed by cervical dislocation on Day 4 and at 2, 4, 8 and 12 weeks respectively.
Livers were removed and snap-frozen as previously described. Control animals
received injection vehicle (corn oil) only, and were sacrificed on Day 4.
(c) Long term effects of TCPOBOP
This experiment was carried out at the Imperial Cancer Research Fund Clare
Hall Laboratories, Blanche Lane, South Mimms, Potters Bar, Herts. EN6 3LR. DBA/2
mice (3 of each sex per treatment group) were treated as described in part (c)
above, except that mice were sacrificed by cervical dislocation on Day 4 and at 3, 4,
6, 8, 10 and 12 months following a single intra-peritoneal injection of TCPOBOP
(3mg/kg).
(d) Induction in hypophysectomised animals
C57BL/6 mice were obtained from Charles Rivers Laboratories,
Willmington, Massachusetts, USA, where para-pharyngeal hypophysectomy and
sham-operations were carried out. The extent of hypophysectomy was assessed by
monitoring weight gain of the hypophysectomised animals relative to the sham-
operated controls. Both groups were then treated with a range of P450 inducing
agents as described in part (a) above.
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(e) TCPOBOP administration to Wistar rats
Male and female Wistar rats (average weight 250g, 3 of each sex per
treatment group) were administered a single IP injection of TCPOBOP (3mg/kg).
Control animals received injection vehicle (corn oil) only. Three days following
injection, the rats were sacrificed and their livers removed, rinsed in PBS and
snap-frozen on cardice. Tissue was stored at -70°C prior to processing.
2.2.2 Induction experiments in mice bearing human tumours as
xenografts
These experiments were conducted in the ICRF Clare Hall Laboratories. Animal
maintenance and treatment was carried out by Nick East and Hazel Holdsworth, under
the direction of Mr. D. Watling.
2.2.2.1 Mice and Tumours
The tumours NCH (infiltrating ductal carcinoma of the breast) and
GFH (adenocarcinoma of colon) were maintained as xenografts growing sub-
cutaneously in the flanks of 6-12 week old specific pathogen free Nu-Nu mice of
mixed genetic background and were passaged as required. These animals were
maintained as previously described (Malik et al. 1989). The tumours were
established from primary untreated human tumours without prior tissue culture.
These animals were then treated according to the following experimental protocols:
(a) Assessment of tumour P450 levels
Human breast and colon tumours were established bilaterally as xenografts
by sub-cutaneous injection of tumour mash in each flank of a panel of immune-
deficient mice and allowed to grow until they had reached 1cm in diameter. The
tumour-bearing mice were then assigned at random into groups (3 mice per
treatment group) and treated intra-peritoneally with a range of P450 inducing
agents as follows:
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Control , corn oil, 3 injections
p-naphthoflavone, 80mg/kg, 3 injections in corn oil
3-methylcholanthrene, 100mg/kg, 3 injections in corn oil
Clofibric acid, 200mg/kg, 4 injections in corn oil
TCPOBOP, 3mg/kg, SINGLE INJECTION in corn oil
Dexamethasone, 100mg/kg, 4 injections in corn oil
Phenobarbital, 80mg/kg, 3 injections in PBS
Araclor 1254, 500mg/kg, SINGLE INJECTION in corn oil
All injections were made in 0.2mls vehicle, and at intervals of 24 hours. Animals
were sacrificed 24 hours following the final injection, with the exception of the
TCPOBOP and Araclor 1254 treated groups, which were sacrificed on Day 4 and Day
8 respectively. Livers and tumours were removed, rinsed in PBS, snap-frozen and
stored at -70°C prior to processing. Tissue from animals within the same treatment
group was pooled, although left and right flank tumours were kept separate for
protein and RNA analysis respectively.
(b) Increased dose of TCPOBOP
Mice bearing human breast and colon tumours as xenografts were established
as described in (a) above, and treated intra-peritoneally as follows:
Stock control, NO TUMOUR, corn oil, 3 injections
Control, corn oil, 3 injections
3-methylcholanthrene, 100mg/kg, 3 injections in corn oil
TCPOBOP 1, 3mg/kg, SINGLE INJECTION in corn oil
TCPOBOP 2, 15 mg/kg, SINGLE INJECTION in corn oil
Following treatment, livers and tumours were removed and processed as
previously described. An untreated, unxenografted group of mice (stock control)
were included in this study to determine whether the xenografting process itself had
any effect on cytochrome P450 levels.
(c) Colon dose-response
Mice bearing human colon tumour xenografts, as described in (a) above,
were treated intra-peritoneally with TCPOBOP in a range of concentrations as
detailed below :
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Control , corn oil, single injection
TCPOBOP 1, 1mg/kg, SINGLE INJECTION in corn oil
TCPOBOP 2, 3mg/kg, SINGLE INJECTION in corn oil
TCPOBOP 3, 10mg/kg, SINGLE INJECTION in corn oil
TCPOBOP 4, 15mg/kg, SINGLE INJECTION in corn oil
Livers and tumours were removed on Day 4 following treatment and processed as
previously described.
(d) TCPOBOP and cyclophosphamide administration
This experiment was designed to determine whether prior administration of
TCPOBOP to mice bearing human breast or colon tumours as xenografts would alter
their response to subsequent cyclophosphamide administration. Mice were implanted
with human breast and colon xenografts as described previously. The tumours were
allowed to grow until an average diameter of 0.2cm was achieved, when the mice
were assigned at random into groups and treated intra-peritoneally as follows :
Group 1: Control, corn oil, single injection
Group 2: TCPOBOP, 3mg/kg in corn oil, SINGLE INJECTION on Day 1
Group 3: Cyclophosphamide, 0.25mg/mouse in corn oil, 3 injections
on Day 6, 13 and 20
Group 4: TCPOBOP, 3mg/kg in corn oil, SINGLE INJECTION on Day 1,
followed by Cyclophosphamide, 0.25mg/mouse in corn oil, 3
injections on Day 6, 13 and 20
Tumour surface area was measured (the product of the two largest tumour
diameters, measured at right angles using callipers) on TCPOBOP administration,
and at 7 day intervals thereafter. At the end of the experiment, animals were
sacrificed, livers and tumours removed and processed as previously described.
(e) The effect of TCPOBOP on tumour regression
Human colon tumours were established as xenografts as described in (d)
above and allowed to grow to approximately 0.2cm in diameter. Mice were then
treated intra-peritoneally with TCPOBOP at a range of concentrations as described
below to assess the effect of this compound on tumour growth.
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Control , corn oil, single injection
TCPOBOP 1, 1mg/kg, SINGLE INJECTION in corn oil
TCPOBOP 2, 3mg/kg, SINGLE INJECTION in corn oil
TCPOBOP 3, 15mg/kg, SINGLE INJECTION in corn oil
TCPOBOP 4, 30mg/kg, SINGLE INJECTION in corn oil
TCPOBOP 5, 60mg/kg, SINGLE INJECTION in corn oil
Tumour growth was monitored on a daily basis, as long as any tumour persisted.
Tissue was collected at the end of the experiment as previously described.
(f) Generation of xenograft tumours from the cell line Hepa-1
1 08 cells were implanted into each flank of Nu-Nu mice and the resulting solid
tumours were allowed to grow until they had reached 1cm in diameter. The tumour
bearing mice were then treated intra-peritoneally as follows:
Control, corn oil, 3 injections
3-methylcholanthrene, 100mg/kg, 3 injections in corn oil
Phenobarbital, 80mg/kg, 3 injections in PBS
TCPOBOP, 3mg/kg, single injection in corn oil
Livers and tumours were removed on Day 4 following treatment and
processed as previously described.
2.3 Human tissue samples
2.3.1 Sources of material
Samples of normal colonic mucosa and colon tumours were obtained from
patients undergoing surgery at the Royal Infirmary or Western General Hospital,
Edinburgh. Identification of normal and tumour tissues was made histopathologically.
Samples were snap-frozen as soon as was practical following resection and were
stored at -70°C prior to processing. The available clinical data on these samples is
summarised in Table 2.3.
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Table 2.3 Clinical data on human colon tumour samples
Sample Patient Location Size Duke's status'
1 91/4328 hepatic flexive colon 11 x 7 cm B
2 91/4818 rectum 4 x 3.5 cm B
3 91/7239 ascending colon 13 x 6 cm B
4 91/7283 sigmoid colon 3 x 3 cm C
5 91/7952 sigmoid colon 4 x 3.5 cm C
* The most commonly used system for classifying colon tumours and assessing their
prognosis is that of Duke, summarised in Monfardini et al. (1987).
2.4 Analysis of rodent and human tissue samples
2.4.1 Subcellular fractionation
Microsomal and cytosolic fractions were prepared from tissue samples as
described by Meehan et al (1988a). Tissue samples (_1g) were thawed rapidly at
3 7°C, scissor minced and homogenised (Silverson Laboratory Mixer Emulsifier) at
4°C in 3 volumes of 10mM KHPO4, pH 7.4, containing 1.15% (w/v) KCI and
0.1 mM EDTA. The homogenate was centrifuged at 11000rpm for 20 minutes (Du
Pont Sorvall RC5B Refrigerated Superspeed Centrifuge, SS-34 rotor) to remove cell
debris, the pellet discarded and the resulting supernatant transferred to ultra-
centrifuge tubes and spun at 45000rpm (Du Pont Sorvall OTD65B Ultracentrifuge,
TFT 45.6 rotor) for 80 minutes to separate the microsomal and cytosolic fractions.
The supernatant (cytosolic fraction) was removed and stored at -40°C for future
analysis. The microsomal pellet was washed by resuspension in phosphate buffer
using a glass-teflon hand homogeniser and re-centrifuged at 45000rpm for 1 hour.
The final pellet was resuspended in 0.25M sucrose/1 OmM phosphate, pH 7.4 to a
protein concentration of 10-20mg/ml and stored at -40°C until required. Whenever
possible, several aliquots of each microsomal suspension was prepared, to minimise
the number of freeze-thaw cycles to which each was subjected.
2.4.2 Preparation of RNA
All tips, eppendorfs and tubes used in the preparation of RNA were soaked
overnight in dH20 containing 0.1% diethylpyrocarbonate (depc-dH20) and
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autoclaved before use to ensure sterility and to eliminate any contaminating RNAases.
All glassware was rinsed in depc-dH20 before use.
RNA was isolated from tissue samples according to the method of Cox (1986).
1g of frozen tissue was placed directly in 20mls of ice-cold 8M guanidinium
hydrochloride in a 30ml depc-treated polypropylene tube, scissor minced and
homogenised. The resulting homogenate was centrifuged (RC5B, SS-34 rotor,
9000rpm, 5 minutes, 4°C) to remove cell debris and the supernatant transferred to
a fresh tube, mixed with 0.5 volumes (10mls) of cold absolute alcohol and placed at
- 2 0°C for 45 minutes to precipitate nucleic acids. Following centrifugation
(9000rpm, 10minutes, 4°C), the pellet was resuspended using a glass-teflon
homogeniser in 20mls of 6M guanidinium hydrochloride and ethanol-precipitated as
before. This 6M precipitation step was repeated once more and the resulting pellet
dissolved in 1ml of depc-dH20. 0.5 volumes of 7.5M ammonium acetate and 2.5
volumes of cold absolute alcohol were added and the tubes placed at -20°C for > 2
hours to selectively precipitate RNA (DNA remains in solution under these
conditions), which was collected by centrifugation (9000rpm, 10 minutes, 4°C).
The purity of the RNA was further increased by 2-3 re-precipitation steps with 0.1
volumes 2M sodium acetate, pH5.2 and 2.5 volumes cold absolute alcohol. The final
pellet was resuspended in a minimum volume of depc-dH20 and stored at -70^0 until




Protein concentration was determined spectrophotometrically according to
Lowry et al (1951), using serial dilutions of bovine serum albumin (BSA) to
generate a standard curve each time the assay was performed. The absorbances
obtained at 600nm were effectively linear over the range 0-200pg/ml, and all
samples were therefore diluted (0.1 M NaOH) to lie within this range.
2.5.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was carried out
according to the method of Laemmli (1970). All protein samples were analysed by
SDS-PAGE prior to immunoblotting to demonstrate equivalence of loading and to
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ensure that the samples were not degraded. Samples were prepared for
electrophoresis by dilution in distilled deionised water (dH20) to a concentration of
3mg/ml of total protein, before the addition of an equal volume of "boiling mix"
(0.05M Tris-HCI pH8, 2% (w/v) SDS, 5% (v/v) p-mercaptoethanol, 10% (v/v)
glycerol, 0.005% (w/v) bromophenol blue) to give a final protein concentration of
1.5mg/ml. Proteins were denatured by heating to 100QC for 5 minutes. For
Coomassie Brilliant Blue stained gels, 15pg of total cellular protein (or microsomal
or cytosolic fractions as appropriate) was loaded per track. Molecular weight
markers containing alpha-lactalbumin (Mr=14,200), soybean trypsin inhibitor
(Mr=20,100), trypsinogen (Mr=24,000), bovine erythrocyte carbonic anhydrase
(Mr=29,000), rabbit muscle glyceraldehyde-3-phosphate dehydrogenase
(Mr=36,000), chicken egg albumin (Mr=45,000) and bovine serum albumin
(Mr=66,000) were prepared according to the manufacturer's instructions and were
loaded at 10pl per track. SDS-PAGE gels (0.15cm) were cast using Biorad Protean II
electrophoresis apparatus. Separating gel composition was dependent on the
particular proteins of interest - P450 proteins were analysed using 9% separating
gels. The composition of the separating gel is given below :
9%: 8.0mls 40% (w/v) acrylamide, 5.5mls 2% (w/v) bis-acrylamide, 9.25mls
separating gel buffer, 12.3mls ddH20, 2mls 1% (w/v) APS, 20pl TEMED; where
TEMED (N,N,N',N'-tetra-methyl ethylenediamine) and APS (ammonium
persulphate) function as cross-linking agents; separating gel buffer (1.5M Tris-
HCI, 0.5%w/v SDS, pH8.8)
Gels were poured to a height of 12cm and immediately overlaid with a 1:1 mixture of
isobutanol and water. The rapid separation of this mixture into organic and aqueous
phases resulted in an even boundary forming at the interface with the gel. The
presence of this overlay also served to prevent evaporation of the gel components
during polymerisation. Once set, the butanol overlay was removed and the gel rinsed
several times with dH20, before a stacking gel (4.5% (w/v) acrylamide: 1.1ml
(w/v) 40% acrylamide, 0.7ml (w/v) 2% bisacrylamide, 2.5mls stacking gel
buffer (0.5M Tris-HCI, 0.5% (w/v) SDS, pH 8.8), 5.4mls dH20, 0.3mls 1%
(w/v) APS, 10)0.1 TEMED) was poured to the top of the plates and a well-forming
comb (15 tracks) inserted. The same percentage stacking gel was poured in every
case, irrespective of the composition of the separating gel. When the stacking gel had
set, the plate assemblies were securely attached to the central cooling reservoir of
the Protean II apparatus and the positions of the wells clearly marked. The top buffer
chamber was filled with freshly prepared electrode buffer (0.05M Tris-HCI pH
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8.3, 0.05M glycine & 0.1% SDS), and the combs carefully removed. Samples were
loaded using a Hamilton syringe, before the entire apparatus was placed in a gel tank
containing 3 litres of electrode buffer. Gels were run (50mA/gel stacking,
20mA/gel separating) with cold water cooling and with continuous mixing of the
electrode buffer to minimise any build-up of buffer gradients. When the dye front
was approximately 1cm from the bottom of the plates, electrophoresis was stopped,
the gels removed from the glass plates, stained for 1 hour in Coomassie Brilliant
Blue (0.25% (w/v) Coomassie Brilliant Blue, 45.5% (v/v) methanol, 9% (v/v)
acetic acid) and destained (10% (v/v) methanol, 9% (v/v) acetic acid) to visualise
the protein bands.
2.5.3 Immunoblotting
Immunoblotting (Western blotting) was performed essentially as
described by Towbin et al (1979), with modifications according to Lewis et al
(1988). Proteins were separated on SDS-PAGE, with the amount of protein loaded
dependent on the tissue or cell type being studied. Following electrophoresis, gels
were removed from the glass plates, the stacking gel removed and discarded and the
remaining gel portion marked uniquely for orientation. A gel/membrane "sandwich"
was then assembled as follows: A large basin was filled with transfer buffer (20mM
sodium orthophosphate.12H20, 20% (v/v) methanol), into which was placed a
plastic cassette containing a nylon "Scotchbrite" pad, a sheet of 3mm filter paper
cut to a size slightly larger than the gel and a sheet of nitrocellulose (pore size 0.45
pm) cut to a similar size. The gel was placed on top of the nitrocellulose filter,
covered with another sheet of filter paper, a further nylon pad and the cassette
closed, thus clamping the gel sandwich firmly together. Each gel was assembled in a
similar manner, and the cassette(s) placed into a Biorad transblot apparatus
containing freshly prepared transfer buffer. Proteins were then transferred
electrophoretically (250mA, 16 hours) from the gel to the nitrocellulose sheet.
Following transfer, the gel sandwiches were disassembled and the nitrocellulose
filter cut to an exact replica of the gel. Any excess gel and nitrocellulose were
discarded at this stage. The nitrocellulose filter was washed several times in TBST
(50mM Tris-HCI, pH7.9, 0.15M NaCI, 0.05% (v/v) Tween 20) to eliminate any
trace of transfer buffer and non-specific antigen binding blocked by incubation in a
solution of low-fat dried milk powder (3% (w/v) Marvel in TBST, 1 hour). The
filter was then washed thoroughly and incubated with the specific antisera of interest
(diluted 1:500 in TBST, 1 hour). Excess unbound antigen was removed by washing
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the filter several times in TBST before incubation with an HRP-labelled secondary
antibody (donkey anti-rabbit IgG-HRP for polyclonal primary antisera or donkey
anti-mouse IgG-HRP for monoclonal primaries, diluted 1:1000 in TBST, 1 hour).
After visualisation of the immunoreactive polypeptides using freshly prepared 4-
chloro 1-naphthol as substrate (0.6g/l 4-chloro-1-naphthol, 20% (v/v)
methanol in TBS, 0.04% (v/v) hydrogen peroxide) the signal was enhanced with
125l-protein A (50pl or 0.19MBq in 50mls TBST) (Amersham International, pic)
and subsequent autoradiography (Kodak X-Omat AR5 X-ray film) with intensifying
screens at -70°C. Differing exposure times were used in order to optimise the
autoradiographic signal from each blot. When the level of expression of the proteins
of interest was particularly low, enhanced chemiluminescent detection (ECL) was
used (Amersham International, pic). This technique relies on the generation of an
unstable photodynamic complex on reaction of H20>, HRP-labelled secondary
antibody and the cyclic diacylhydrazine luminol. Dissociation of this complex results
in luminol returning to its ground state with associated light emission. The amount of
light emitted is directly proportional to the amount of immobilised protein bound to
the HRP-labelled secondary antibody.
In order to determine the relative levels of protein expression, an
appropriate exposure of each autoradiograph was scanned using a Joyce-Loebl
scanning densitometer. Linearity of the method was established by generating a
standard curve from a series of microsomal standards loaded in serial dilutions.
2.5.4 Mini-kits
When a limited number of samples was to be analysed, or a number of
different antibodies screened, the Biorad Mini-Protean kit and Transblot cell were
used. These kits, which allow SDS-PAGE to be run in 45 minutes and transfer to
nitrocellulose in 1 hour, operate on the same principle as the larger kits, with the
following modifications:
(a) Gels were run at 200V, constant voltage, with no alteration in the running
conditions between the stacking and separating gels or allowance made for the
number of gels being run
(b) Transfer was achieved at 100V for 1 hour in a Tris/glycine/methanol buffer
(25mM Tris-HCI, 112mM glycine, 20% (v/v) methanol, pH8.3). To prevent
excessive heat building up during transfer, a Bio-ice cooling unit was placed next to
the gel cassettes to absorb the heat generated during transfer.
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2.5.5 Antibodies
Cytochrome P450 antisera and purified rat P450 proteins which were run
as standards on SDS-PAGE were provided by Dr. C.R. Wolf, and have been extensively
characterised in this laboratory and others (Wolf et al. 1983, 1984). Antibodies to
purified rat cytochrome P450 proteins were isolated as described previously (Wolf
& Oesch, 1983; Adams et al. 1985; Wolf et al. 1988). These antibodies have been
extensively used in immunoblotting studies with both mouse and human microsomal
samples (Meehan et al. 1988a; Henderson et al. 1990). In addition, the isozyme
specificity of the antisera have been demonstrated by immunoblot analysis with
expressed human recombinant P450 proteins (Forrester et al. 1992). Cytochrome
P450 CYP4A1 was isolated according to the method of Tamburini et al (1984), and
was of high purity, running as a single band on SDS-PAGE. Antibodies used in
Western blot analysis were raised against rat CYP1A1, CYP2A1, CYP2B1, CYP2C6,
CYP2E1, CYP3A1 and CYP4A1 proteins. CYP2E1 antisera was a generous gift from
Dr. C.S. Yang, Department of Chemical Biology, College of Pharmacy, Piscataway,
N.J., USA).
2.6 RNA analysis
2.6.1 Quantitation of RNA
(a) Spectrophotometric quantitation
RNA concentration was determined by measuring the UV absorbance at
260nm. The RNA sample of interest was diluted (usually 1:100) in depc-dH2Oto
1ml, mixed thoroughly and placed in a quartz cuvette. An identical reference cuvette
contained depc-dH20 only. The absorbance of the sample was read at 260nm and the
RNA concentration calculated according to the following equation:
[RNA] = OD260x D.F.
24
where D.F. = dilution factor (usually 100); OD2gQ is the absorbance at 260nm. The
above equation is based on the assumption that OD260 = 24.0 for a 1mg/ml solution
of RNA.
To assess the purity of the sample, the absorbance at 280nm was also
obtained and the ratio OD26q/OD28q calculated. A pure RNA sample has an
CD2e o/2 8 0 rat'° 2-°- rat'° samP'e was below 1.8, the sample was
extracted with phenol/chloroform and sodium acetate/ethanol precipitated to
eliminate any traces of contaminating DNA and protein.
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(b) Ethidium bromide fluorescence quantitation
The RNA concentration measurements obtained spectrophotometrically were
confirmed by running each sample on a horizontal 1% denaturing agarose gel (1%
(w/v) agarose, 2 x GRB (0.1 M 4-morpholinepropanesulphonic acid (MOPS),
pH7.0, 40mM sodium acetate, 5mM EDTA, pH8.0), 18% (v/v) formaldehyde)
before proceeding to Northern blot analysis. This method (Lehrach et al. 1 9771
involves the electrophoretic size fractionation of RNA samples on a denaturing
formaldehyde/agarose gel which is then stained with the fluorescent interchelator
ethidium bromide. RNA samples were prepared for electrophoresis as follows:
samples were diluted in depc-dh^O to 5pg, based on the concentration values
obtained from the spectrophotometric analysis. 3 volumes of sample buffer (66%
(v/v) formamide, 8% (v/v) formaldehyde, IxMOPS) were then added to each
sample, and the resulting mixture incubated at 55°C for 15 minutes. Loading dye
(1/10 total volume) was added to each sample, which was mixed thoroughly before
loading. Conditions for electrophoresis were dependent on the size of gel used: Mini-
kits were run for 2-3 hours at 60V, midi-kits at 20V overnight. All gels were run
in TBE buffer, which was freshly prepared from a 10 X stock (10 x TBE: 0.09M
Tris base, 0.09M Boric Acid, 0.002M EDTA, pH 8.0) on each occasion to prevent
contamination with formaldehyde. Following electrophoresis, the gel was removed
from the apparatus, stained for 15 minutes in ethidium bromide (1.5mg/ml) and
destained in dH20. UV-induced fluorescence of the RNA samples was visualised by
placing the gel on a short wavelength transilluminator. The amount of fluorescence
obtained was directly proportional to the [RNA] of the sample. Thus, an estimation of
loading equality between a series of samples could be obtained when the gel was
examined under UV light. Two sharp bands corresponding to the 18S (2366bp) and
28S (6333bp) ribosomal RNA species were present in all samples, indicating that
the RNA was intact.
2.6.2 Northern blot analysis
Northern blot analysis was performed essentially as described by Meehan et
a] (1984). RNA was size-fractionated by denaturing gel electrophoresis as described
in Section 2.6.1 (b). 10pg of each RNA sample was loaded onto a 1% formaldehyde-
agarose midi-gel which was run at 20V overnight (_16 hours) in 1 x TBE buffer. A
3pl aliquot of RNA ladder was loaded in the final lane of the gel - this consisted of a
mixture of DNA species (bacteriophage T7, yeast 2p circle and bacteriophage lambda
DNA) with molecular weights ranging from 0.24 - 9.5kb. Following
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electrophoresis, the gel was removed from the apparatus and washed in an excess of
10 x SSC (1.5M NaCI, 0.15M tri-sodium citrate, pH 7-9) for 20 minutes to
remove excess formaldehyde. Transfer to Hybond-N was achieved by capillary action
in 10 x SSC (overnight, _20 hours). The edges of the gel were sealed with Parafilm
during transfer to ensure that all buffer flow was directed through the gel. The
Hybond membrane was overlaid with several sheets of filter paper which had been
soaked in 2 x SSC to create a buffer gradient and initiate transfer. Following
transfer, the positions of the tracks were transferred from the gel to the Hybond
filter, the transfer apparatus disassembled and the RNA permanently attached to the
filter by "Stratalinking" i.e. exposure of the membrane to ultra-violet irradiation
(254nm). To ensure that transfer was complete, the gel was stained with ethidium
bromide as previously described and examined under UV-illumination. No RNA bands
were visible, indicating that transfer to the Hybond membrane was complete. The
portion of the membrane containing the RNA ladder was removed and stained (15
minutes) in methylene blue (0.04% (w/v) methylene blue, 0.5M sodium acetate).
The RNA standards were clearly visible as a series of blue bands when the filter was
destained in d^O. These were used to quantitate the size of the RNA transcript
obtained on hybridising the filter with a cDNA probe. Hybridisation was performed at
6 5°C in a rotating glass tube in a Techne rotisserie oven. The filter was incubated in
hybridisation mix (5 x SSC, 4 x Denhardt's solution (50 x Denhardt's: 1% Ficoll,
1% polyvinylpyrrolidone (PVP), 1% BSA ), 10% (w/v) dextran sulphate, 0.1%
(w/v) SDS, 0.1% (w/v) sodium pyrophosphate (NaPPj)) for at least 3 hours
before the addition of a 3 2P-labelled cDNA probe. This "pre-hybridisation" allowed
equilibration of the filter in the hybridisation solution and the blocking of non¬
specific binding sites. A 3 2P-labelled cDNA probe, prepared and labelled as
described in Sections 2.6.4 and 2.6.6, was denatured by heating to lOO^C for 5
minutes and added directly to the tube containing the filter. Hybridisation with the
probe was continued at 65°C for a further 16-18 hours. Excess probe was then
removed and the filter washed several times (2 x SSC, 0.1% (w/v) SDS, 0.1%
(w/v) NaPPj). All washes were carried out at 65° C to minimise any non-specific
binding of the probe to the filter. Once the radioactive counts in the wash solution
had returned to background, the filter was removed from the tube, air dried,
wrapped in Saran-wrap and exposed to Kodak X-Omat AR-5 film at -70°C in a
cassette with intensifying screens. If re-probing of the filter with a second cDNA
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probe was required, the filter was stripped by incubation at 65°C in stripping
solution (5mM Tris-HCI, pH 8.0, 2mM EDTA, 0.1 x Denhardt's solution ) for 2 x 1
hour periods, according to the manufacturer's instructions.
2.6.3 cDNA probes
Details of the cDNA probes used are given in Table 2.6
The bacterial host for all clones was JMIOI, with the exception of pMP1,
which was JM83; All clones were contained within pUC expression vectors - pUC9
for pMP1, 16, 26, 63 and 112; pUC19 for pMP17, 23, 81 and 90 and pUC12 for
pMP193; All plasmids conferred Ampicillin resistance. The human cDNA probes
have been shown to be specific for their respective gene families in mouse by
mapping in recombinant inbred lines (Meehan et al. 1984; Miles et al. 1990).
Equivalence of RNA loading was monitored by probing with a mouse (3-actin cDNA
probe, a generous gift from Dr. Joan McNab, Institute of Virology, Glasgow. The rat
CYP2B1 probe was kindly provided by Dr. M. Adesnik, Department of Cell Biology,
New York University School of Medicine, New York, USA and the rat CYP4A1 probe
by Dr. G.G. Gibson, Department of Biochemistry, University of Surrey, Guildford,
Surrey. The mouse metallothionein MT-lla cDNA probe was kindly provided by Dr.
Peter Searle, CRC Laboratories, Medical School, Birmingham and the mouse MUPS
cDNA probe by Dr. Reya Al-Shawi, Department of Genetics, Edinburgh University.
All other cDNA probes were produced and characterised in this laboratory.
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Table 2.6 cDNA probes used in Northern blot analysis
Lab name Clone Species Insert size R.E. Reference
pMP1 CYP1A1 human 1088bp Eco Rl Spurr et al. 1987
pMP16 CYP2E1 human 1.6kb Eco Rl Sona et al. 1986
pMP17 CYP2B6 human 700bp Eco Rl Miles et al. 1989
pMP23 CYP2B1 rat 1.7kb Eco Rl Friedberq et al. 1986
pMP26 CYP3A4 human 727bp Eco Rl Spurr et al. 1989
pMP63 Cyp2c mouse 1.4kb Pst 1 Meehan et al. 1 988
pMP81 CYP2A6 human 1.75kb Eco Rl Miles et al. 1 99 0
pMP90 Actin mouse 1.2kb Xba 1 Leader et al. 1 985
pMP112 CYP4A1 rat 2.1 kb Eco Rl Earnshaw et al, 1 9 8 8
pMP193 MTII mouse 220bp EcoRI/Hind III Searle et al. 1 984
pMP240 MUPS mouse 714bp Sma I Clark et al. 1 985
R.E. = Restriction enzyme required to release the cDNA from the plasmid
2.6.4 Preparation of cDNA probes
cDNA probes were prepared according to the small-scale alkaline lysis
procedure of Birnboim & Doly (1979). An overnight culture of transformed
bacteria was prepared as follows: 10mls of L-broth (10g/I bactotryptone, 5g/l
yeast extract, 5g/l NaCI) was equilibrated to 37°C in a shaking incubator, before the
addition of 10pl of selectable marker (ampicillin or tetracycline as appropriate).
Transformed bacteria were added in one of two ways:
(a) 10pl of the glycerol stock of the cDNA containing the plasmid of interest (see
Section 2.6.5)
(b) An aliquot (single colony) of the bacterial culture growing on an L-amp plate
taken using a sterile hot loop (Section 2.6.5)
After overnight incubation, 1.5ml aliquots of the bacterial culture were
transferred to eppendorf tubes and spun (13000rpm, 10 minutes) in a microfuge to
pellet the bacteria. The supernatant was discarded and the pellet re-suspended in
0.15mls of Solution A (2mg/ml lysozyme, 50mM glucose, 25mM Tris-HCI pH8.0,
10mM EDTA ) and left on ice for 30minutes to lyse the bacterial cell wall before the
addition of 0.3mls Solution B (1% (w/v) SDS, 0.2M NaOH) to disrupt the bacterial
cell membrane. After a further 5 minutes at 4°C, 0.25mls of Solution C (3M sodium
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acetate, pH 4.8) was added and the resulting suspension left to precipitate for 1 hour
at 4°C. Cell debris was removed by centrifugation (13000rpm, 5 minutes) and the
nucleic acids precipitated from the plasmid-containing supernatant with 0.7
volumes of isopropanol for 30 minutes at -20°C. After further centrifugation
(13000rpm, 10 minutes), the nucleic acids were re-suspended in 0.1ml TE buffer
(10mM Tris-HCI, pH8.0, 0.1 mM EDTA) and any contaminating proteins removed by
phenol/chloroform extraction. The resulting extract was re-precipitated (10pl 2M
sodium acetate, pH5.2, 0.25mls cold absolute alcohol) and the final pellet collected
by centrifugation (13000rpm, 10 minutes), washed with cold ethanol, dried under
vacuum and re-suspended in 25pl TE. The concentration of this final solution was
usually between 25 and 50pg of plasmid DNA.
cDNAs were released from their carrier plasmids by digestion with an
appropriate restriction enzyme. Plasmid DNA (20pl) was mixed in a sterile
eppendorf tube with dH20 (10pl), RNAaseA (3pl of a 10mg/ml stock), 10xRB
( 4pl) and 3pl of the appropriate restriction enzyme. RB is a commercially supplied
reaction buffer specific for the particular restriction enzyme used. Digestion of the
DNA was carried out at 37°C for 2 hours, before loading dye (1/10 total volume)
was added to each tube and the contents loaded on a 0.8% low-melting point agarose
midi-gel (0.8% LMA, 1 x TBE, 5pl EtBr). An aliquot (3pl) of 1kb DNA ladder was
run to estimate the insert size(s) obtained and some uncut plasmid run as a control
to assess the success of the digestion. The gel was run overnight (_18 hrs ) at 20V
in 1xTBE buffer and visualised on a transilluminator. The portions of gel which
contained the insert cDNA of interest were excised and placed into a pre-weighed
eppendorf tube. Sterile dH20 was added (1.5mls per 1g of gel) and the DNA denatured
by heating to 100°C for 5 minutes. The probe was then aliquoted and stored at -20°C
prior to use.
2.6.5 Storage of plasmid DNA
(a) Permanent storage was achieved by making a glycerol stock of each plasmid as
follows: transformed bacteria (JM101) were grown overnight in L-broth with
appropriate antibiotic selection. Glycerol was added to a final concentration of 40%
(v/v) and 1ml aliquots stored at -70°C.
(b) A working stock of commonly used plasmids was maintained on L-agar plates
(L-broth plus 15g/l Difco agar) containing ampicillin (100pg/ml). L-agar plates
were re-streaked with bacterial colonies every four weeks and were stored at
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4°C.
2.6.6 Labelling of cDNA probes
cDNA probes were labelled according to the random priming method of
Feinburg & Vogelstein (1983,1984). Purified double stranded DNA was mixed with
an excess of nucleotide primers, denatured and synthesis of 32P-labelled
transcripts carried out by the Klenow fragment of DNA polymerase I. This fragment
lacks 5'-3' exonuclease activity and the product is therefore synthesised exclusively
by primer extension. The DNA was denatured (100°C, 5 minutes), added to dH20,





3 2P -adCTP 3pl
Klenow 2pl
Notes:
1. The reaction is initiated by the addition of the Klenow fragment of E.Coli DNA
polymerase I.
2. 3pl of 3 2P -adCTP has a specific activity of 30p.Ci.
3. OLB is a 2 : 5 : 1 mixture of the following solutions A, B, and C.
Solution A: 2M Tris-HCI, pH 8.0 (625pl); dH20 (82pl); (3-mercaptoethanol
(1 8)0.1); 1M MgCI2 (1 2 5pl); 10mM dATP, dGTP, cTTP (50p.l of each)
Solution B: 2M Hepes titrated to pH 6.6 with NaOH
Solution C: Hexadeoxyribonucleotides suspended in 3mM Tris-HCI, 0.2mM EDTA, pH
7.0, at a concentration of 90 O.D. units/ml.
The extent of incorporation of 32P into the DNA was determined
chromatographically. A 1pl aliquot of each probe to be tested was spotted at the origin
of a piece of DE81 chromatography paper and allowed to air-dry. The filter was then
placed into a chromatography tank containing a small volume of 0.4M ammonium
formate, pH8.0. Chromatographic separation was carried out until the solvent front
was 1cm from the top of the filter paper (~15minutes), which was then removed
from the tank, air dried, wrapped in Saran-wrap and exposed to X-ray film.
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Incorporated radioactivity appeared as a spot at the origin of the chromatogram,
while any unincorporated nucleotides eluted up the paper with the solvent front.
Incorporation was routinely found to be >80%.
2.7 Cell culture
2.7.1 Cell line information
Five cell lines were used during this project. These lines were chosen as they
have previously been shown to have constitutive monooxygenase activity (HepG2,
C3H10T1/2, Hepa-1), or because they are derived from human breast (MCF7) or
colon (HT29) tissues and thus provide an i n vitro model for comparison with the j_n
vivo studies. All cell lines were grown as monolayers and were maintained in a
humidified atmosphere of 5% CC>2 / 37% air at 37°C. A brief description of each cell
line is given below :
(a) C3H10T1/2 (Reznikoff et al. 1973a,b) Culture conditions : BME (Basal Eagle's
Medium) with 15% foetal calf serum (FCS). L-glutamine (0.2mM), penicillin
(15U/ml) and streptomycin (5mg/ml) (P/S) were added to all media to prevent
bacterial contamination : Doubling time 15.5 hours : C3H10T1/2 fibroblasts were
established from C3H mouse embryos in order to study malignant transformation
with polycyclic hydrocarbons. Recent reports (Jefcoate et al. 1990, 1991) suggest
that this cell line has constitutive mono-oxygenase activity and we and other
workers have attributed this to an as yet uncharacterised cytochrome P450 protein
from the Cyp2a family.
(b) Hepa-1 (Bernhard et al. 1973) Culture conditions : RPMI + Hepes, 10% FCS,
L-glutamine & P/S : Doubling time 28 hours : This cell line, isolated from the mouse
hepatoma BW7756, retains many liver specific functions including albumin
production, a function which is dramatically reduced in many immortalised cell
lines. Hepa-1 cells have constitutive cytochrome P-450 dependent aryl hydrocarbon
hydroxylase activity, illustrated by their ability to hydroxylate benzo(a)pyrene.
(c) HepG2 (Knowles et al. 1980) Culture conditions : DMEM, 10%FCS, L-glutamine
& P/S : Doubling time 60 hours: The Hep G2 cell line was derived from a childhood
hepatoblastoma and has been shown to retain many of the differentiated features of
human liver including detectable levels of cytochrome P450-dependent mono¬
oxygenase activity.
(d) MCF7 (Soule et al. 1973) Culture conditions : RPMI, 10% FCS, L-glutamine &
P/S : Doubling time 24 hours : This cell line, which is oestrogen-receptor positive,
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was derived from a pleural effusion from a 69 year old female Caucasian patient with
metastatic mammary carcinoma.
(e) HT29 (Fogh & Trempe, 1975) Culture conditions : RPMI, 10% FCS, L-
glutamine & P/S: HT29 is derived from the primary colonic adenocarcinoma of a 44
year old female Caucasian patient.
2.7.2 Routine cell culture techniques
Routine cell culture was performed as described by Freshney (1987,1992).
(a) Cryopreservation of cells
Cell lines were prepared for storage in liquid nitrogen as follows: Confluent
cell monolayers were washed 3 times in phosphate buffered saline (PBS) and
harvested with trypsin-versene (0.1% trypsin, 0.01% EDTA). Once the cell
monolayer had detached, fresh medium was added to inhibit the trypsin and the cells
were collected by centrifugation (2500rpm, 5 minutes). The cell pellet was washed
with PBS, spun down again and the resulting cell pellet re-suspended (10^
cells/ml) in freezing-mix (90% newborn calf serum, 10% DMSO). 1ml aliquots of
this cell suspension were frozen at -70°C for 24 hours before transfer to long term
storage in liquid nitrogen (-196°C). When required, a vial of cells was removed
from storage and thawed rapidly at 37°C, washed several times with pre-warmed
media to eliminate any traces of DMSO, transferred to a 25cm^ flask and allowed to
adhere for 24 hours before re-feeding.
(b) Refeeding
Cells were refed by pouring off the spent medium and replacing it with fresh
medium which had been pre-warmed to 37QC. If the cell density was low and there
were viable cells present in the supernatant which had not yet adhered to the flask,
these were recovered by centrifugation, washed in fresh medium and added back to
the original flask. Refeeding was carried out as often as was required to maintain
stable pH and optimal cell growth - frequency of refeeding was determined by the
growth rate of the cells, but in most cases was required only 2-3 times per week. All




Cells were subcultured when confluent by washing 3 times in PBS and
treating with trypsin-versene to detach the cell monolayer. Once the cells had
detached, fresh medium was applied to inhibit the trypsin and the cells were
dispersed using a Pasteur pipette until a single cell suspension was achieved. If an
accurate cell count was required, the cells were spun down, resuspended in a known
volume of medium and counted using a Neubauer haemocytometer. The cells were then
seeded at an appropriate density into new flasks.
2.7.3 Sterility testing of cell lines
Sterility was maintained as far as was practicable in the cell culture suite
and all cell culture techniques were carried out aseptically in a Class 2 Biological
Safety Cabinet which was maintained under UV light when not in use. Routine tests
for mycoplasma contamination were regularly performed on all cell lines by Mr. W.
Christie, MRC Clinical and Population Cytogenetics Unit, Western General Hospital,
Crewe Road, Edinburgh. The tests used involved staining cells with Hoescht 33258
fluorescent dye (Chen,1977) and growth of the cell supernatant on selective broth
(Taylor-Robinson,1978). All media and other cell culture reagents were autoclaved
or filter sterilised (0.22pm filter) as appropriate on preparation and tested for
bacterial contamination by incubation of an aliquot of each solution in L-broth (2%
bactotryptone, 1% bactoyeast, 2% NaCI) at 37^C for at least one week prior to use.
If any turbidity was observed, the solution was assumed to be contaminated and
discarded.
2.7.4 Cell line induction experiments
TCPOBOP (dissolved in DMSO) was administered to all cell lines at a
concentration of 10" 5M. The compound, at this dose, was not toxic to any of the cell
lines tested. Higher doses resulted in decreased solubility in the culture media and
crystals of TCPOBOP forming on the cell monolayer.
2.7.5 Preparation of protein from cultured cells
Cells were harvested when confluent by washing 3 times in PBS and treating
with trypsin-versene to detach the cell monolayer. Fresh medium was added to
inhibit the trypsin and the cells collected by centrifugation (2000rpm, 5 minutes).
The resulting cell pellet was resuspended (0.4mls per 75cm2 flask) in Buffer H
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(10mM Na2HP04, 2mM MgCI2, 2mM DTT, 1mM EDTA, pH7.4) and homogenised
with a glass-teflon homogeniser (30-40 strokes). The extent of cell disruption was
assessed microscopically. When complete, the disrupted cells were transferred to an
eppendorf tube and crude pellet/cytosol fractionation achieved by spinning (6500
rpm) in a microcentrifuge. This was carried out at 4°C to minimise protein
degradation. The resulting supernatant (cytosolic fraction) was removed and stored
at -40°C for future analysis. The pellet was washed several times with PBS and
finally resuspended in a minimum volume of Buffer H and stored at -40°^.
2.7.6 Preparation of RNA from cultured cells
RNA was prepared from cultured cells according to the single-step acid
guanidinium thiocyanate-phenol-chloroform method of Chomczynski & Sacchi
(1987). A 75cm^ flask of cells was grown to confluency, washed several times with
ice-cold phenol-red free PBS and 1.72mls of denaturing solution (DNS) (4M
guanidinium isothiocyanate, 25mM sodium citrate, pH7.0, 0.5% (v/v) sarcosyl,
0.1 M (3-mercaptoethanol) added to detach the cell monolayer. The resulting cell
suspension was immediately transferred to a depc-treated 15ml polypropylene tube
and the following reagents added (in this order) : 0.401 mis 2M sodium acetate, pH
4.0; 4.01 mis dH20-saturated phenol; 0.802mls chloroform/isoamyl alcohol (49 :
1); with thorough mixing after the addition of each component. The final suspension
was shaken vigorously for 10 seconds and cooled on ice for 15 minutes before
centrifugation (15000 rpm, 20 minutes, 4°C). The lower (organic) layer and the
interface contained DNA and protein and were discarded, while the upper (aqueous)
phase contained RNA and was carefully removed and transferred to a fresh tube.
Isopropanol (1.72mls) was added to precipitate the RNA (-20°C, 1 hour), which
was collected by centrifugation (15000rpm, 20 minutes, 4°C). The resulting pellet
was dissolved in 0.5mls DNS, transferred to a depc-treated eppendorf and re-
precipitated with 1 volume of isopropanol (-20^0, 1 hour). After centrifugation in
an Eppendorf centrifuge at 4°C, the RNA pellet was washed in 75% ethanol, vacuum
dried and dissolved in depc-dH20. The purity and concentration of the product were
determined as described in section 2.6.1.
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2.7.7 The MTT cytotoxicity assay
This assay (Mossman, 1983) is based on the principle that only live
metabolically active cells have the functional mitochondrial dehydrogenases required
to reduce the water-soluble yellow dye MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide) to an insoluble blue formazan product which can be
quantitated spectrophotometrically. The amount of formazan product generated
(measured at 540nm) is proportional to cell number, and is therefore used as an
estimate of cell survival following exposure to a cytotoxic drug. Although it is not
possible to distinguish between cytotoxic and cytostatic effects, the assay provides a
useful screening method to determine the maximum tolerated doses of a range of test
compounds (Carmichael et al. 1987). Cells were plated in 96-well microtitre
plates so that several samples and a wide range of drug dilutions could be assayed
simultaneously and were plated at a density such that the control (untreated) cells
were in exponential growth at the time of harvest. Cell growth was found to be
affected by evaporation of media from the outermost wells of the plate and these were
therefore excluded from the assay. To minimise further evaporation, these wells
were filled with PBS and the plates incubated in a sandwich box lined with damp
tissues to maintain high humidity. The first column (6 wells) was filled with media
only and was used to zero the spectrophotometer. Cells were plated at an appropriate
density (e.g. 5x103 cells/well for the C3H10T1/2 cell line) in a volume of
1 8 Opil/well and allowed to adhere overnight before the addition of serial dilutions of
a 10x concentrated stock of the drug of interest (added in 20pl aliquots in serum-
free media). When it was necessary to prepare the stock drug in an organic solvent
(e.g. DMSO), an additional control was included, where cells were treated with
solvent only. Incubation with drug was carried out for 3 days - this was long enough
for drug-induced cell death to occur but sufficiently short that re-feeding of the
cells did not become necessary. The extent of cell kill was assessed by the addition of
5 Opil of MTT (2mg/ml in dH20) to each well. The plates were then incubated for a
further 4 hours, the media removed by aspiration with a Pasteur pipette and 50pl of
DMSO added to each well to dissolve the formazan crystals. The OD540 °f the wells
was measured in a Biorad Model 2550 EIA plate reader and the % survival of the
drug treated cells calculated relative to the controls. The results presented were the
average of the OD540 results obtained for 6 independent wells for each drug
concentration. Each assay was carried out in triplicate and the results combined.
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2.7.8 Transfections
Transfection of ZR-75 cells and the non-chromatographic assessment
of CAT activity (Section 2.7.9 (b)) was carried out by Roger White, under the
direction of Dr.M.G. Parker. ZR-75 cells were routinely maintained in Dulbecco's
modified Eagle's medium (DMEM) containing phenol red with 10% FCS and 10" 8M
estradiol. For transfection, cells were plated at 5x10" 5 per 6cm dish in phenol-red
free DMEM containing 5% FCS from which endogenous steroids had been removed by
treatment with dextran coated charcoal. Transient transfections were performed
using the calcium phosphate precipitation technique (Wigler et al. 1979),
essentially as described by Ham et al (19881. The cells were then maintained for 48
hours in the appropriate hormones. Dexamethasone and R5020 were added to 10" ^M
and phenobarbital and TCPOBOP in a range of concentrations from 10" 8 to 10" 8M.
CAT activity was assayed non-chromatographically (Sleigh, 1986) and normalised
for transfection efficiency with luciferase activity as described in Section 2.7.9 (b).
The construction of the reporter plasmid pLTR-CAT has been described previously
(Parker et al. 1987). The control vector pJ3 Luciferase consists of the luciferase
gene (De Wet et al. 1987) cloned into the eucaryotic expression vector pJ3W
(Morgenstern & Land, 1990). C3H10T1/2 cells were transfected as described above
with one of two constructs: (a) The GRE cloned into pLTR-CAT; (b) Two GRE
sequences linked in series and cloned into pLTR-CAT. These cells were maintained in
1 0" 8M dexamethasone and TCPOBOP for 48 hours following transfection. CAT
activity was determined chromatographically as described in section 2.7.9 (a).
2.7.9 CAT assays
The CAT assay provides a simple and sensitive measure of the effects of a
range of compounds on a specific regulatory sequence. Compounds which interact
with the sequence of interest cause activation of the CAT reporter gene, which is
under the control of the SV40 early promoter. Chloramphenicol acetyltransferase
(CAT) activity can be measured in a number of ways :
(a) Chromatographic determination of CAT activity
This was performed as described by Gorman et al (1982). Cells (25cm2
flask) were harvested by washing 5 times in Ca2 + and Mg2 + free PBS before the
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addition of 1 ml/flask of TEN solution (40mM Tris-HCI, pH 7.5, 10mM EDTA,
150mM NaCI). When the monolayer had detached (_5 minutes), cells were removed
from the flask by scraping, pelleted in an Eppendorf table-top centrifuge and
resuspended in 150pl Tris-HCI (250mM, pH 8.0). The cells were lysed by 3
successive freeze-thaw cycles and incubated at 60°C for 10 minutes to inactivate
endogenous acetylases. Denatured cell debris was removed by centrifugation and the
resulting cell extract (supernatant) transferred to a fresh tube and stored at -20°C
if analysis was to be carried out at a later date. CAT activity was determined by
combining the following reagents in a sterile eppendorf tube - 50pl cell extract,
2 0pl acetyl CoA (3.5mg/ml, freshly prepared), 3pl [1 4C]- chloramphenicol &
250mM Tris-HCI, pH8.0 to a total volume of 180pl. The acetyl CoA was added last to
initiate the reaction, which was incubated at 37^ for 60 minutes. The [14C]-
labelled reaction products were extracted with two successive aliquots of ethyl
acetate and evaporated to dryness under vacuum (the lower aqueous phase was
discarded in each case), redissolved in 30pl ethyl acetate and applied (3x1 Opl
aliquots) to the origin of a 25cm silica TLC plate. Chromatography was carried out in
chloroform-methanol (95 : 5) in a closed tank, until the solvent front was _1 inch
from the top. The plate was dried, sprayed with enhancing reagent (En^Hance spray,
Du Pont), and exposed to autoradiography film at -70°C. Unacetylated reaction
products remained at the origin, while acetylated forms migrated with the solvent
front. In cases of very high CAT activity, spots with a greater Rf value corresponding
to doubly acetylated products could be detected. Although it was not necessary in this
case, CAT activity can be quantitated by removing the radioactive spots from the TLC
plate and determining their relative activities by liquid scintillation counting.
(b) A modified, non-chromatographic method of determining CAT activity was
reported by Sleigh (1986). Cell transfections and extract preparation were as
previously described. CAT activity was determined by combining the following
reagents in a sterile eppendorf tube: 20pl chloramphenicol (8mM), 30pl cell
extract, 20pl [1 4C]-acetyl CoA (1mCi/ml), 0.25M Tris-HCI, pH7.8 to a total
volume of 1ml. The reactants were incubated at 37°C for 1 hour, extracted with
ethyl acetate and the product mixed with 1ml of Packard Instagel. The amount of
incorporated radioactivity in each sample was determined by liquid scintillation
counting. Determination of luciferase activity in each sample (De Wet et al. 1987)
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acted as a control for transfection efficiency.
2.7.10 Hepatocyte isolation and culture
This experiment was carried out by Dr. R.G. Bars, ICI Central Toxicology
Laboratories, Alderley Park, Macclesfield. Hepatocytes were isolated from adult male
Alderley Park Swiss mice (20-25g) by j_n situ perfusion of the liver with
collagenase, essentially as described by Mitchell etal (1984), with the following
modifications: the superior vena cava was cut and the perfusate was not recirculated;
flow rate was 12ml/min and collagenase digestion was 50mg collagenase/250ml
perfusate for 10 mins. The viability of isolated hepatocytes was determined by
trypan blue dye exclusion and was greater than 80%. Hepatocytes isolated from the
two animals were pooled and primary monolayer cultures were prepared by seeding
2x1 06 viable cells in 4ml CL15 medium in 25cm2 tissue culture flasks. Four hours
after seeding, the spent medium was aspirated and fresh medium applied.
Phenobarbital (PB) dissolved in 0.9% NaCI and TCPOBOP dissolved in
dimethylformamide (DMF) were added to the medium when it was changed each day
(at 24, 48 and 72h after seeding). Hepatocytes were therefore exposed for 3 days to
2mM PB; 2, 10, or 50pm TCPOBOP or vehicle alone (0.9% NaCI or 0.25% DMF).
Observation under phase contrast microscope showed the presence of few or
numerous crystal needles in the culture medium containing 10 and 50pM TCPOBOP
respectively, indicating the limit of solubility of this compound in CL15 medium.. At
96h after seeding, the cells from individual flasks were harvested in 1ml of SET
buffer (0.25M sucrose/5mM EDTA/20mM Tris-HCI (pH7.4)) and disrupted by
sonication.
2.8 Cytochrome P450 activity measurements
2.8.1 Spectrophotometric determination of P450 content
This was performed according to Omura & Sato (1964). Microsomal samples
were diluted to an approximate concentration of 2mg/ml. Each sample was divided
equally between two identical glass cuvettes, and the base line absorbance between
550 and 400nm measured on a Schimadzu spectrophotometer. Carbon monoxide was
then bubbled through one cuvette only (_2 bubbles / sec) for 1 minute, before the
contents of both cuvettes were reduced by the addition of 3mgs of sodium dithionite
and the absorbances re-measured over the same absorbance range as before. The
concentration of P450 in the samples was then calculated according to the following
equations:
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S = 91cm" 1mM" 1
nmol/ml = x / 0.091, where x = A450 - A490 / full scale deflection
nmol/mg protein = x / 0.091 x dilution factor / [sample](mg/ml)
2.8.2 Cytochrome P450 reductase assay
P450 reductase activity was measured spectrophotometrically in microsomal
samples as described by Yasukochi & Masters (1976). The assay was carried out in
0.3M KHPO4, pH 7.4, 0.1mM EDTA at 37°C. Two identical glass cuvettes were set up
as follows: 970pl of cytochrome C standard (1.5mgs/ml in phosphate buffer) were
mixed with 20pl of microsomes (diluted to 1mg/ml) and the spectrophotometer
zeroed to generate a baseline. 1 OjliI of NADPH (16mg/ml in phosphate buffer) was
added to each cuvette to initiate the reaction and the absorbance at 550nm recorded
for several minutes. P450 reductase activity was calculated according to the
following equation :
a/b x [E x 50 / 0.0187 x t ]
where a = deflection (mm),
b = total height of scale (mm), t = time (minutes), E = (upper-lower) scan limits
2.8.3 Resorufin assay
The O-dealkylation of a series of substituted phenoxazones (Resorufins) has
been shown to be a sensitive and specific method to quantify cytochrome P450
activity in microsomal samples (Burke & Mayer, 1974). The nature of the alkoxy
group determines the substrate specificity e.g. 7-ethoxyresorufin is a substrate for
the CYP1A family and is therefore suitable for measuring induction by compounds
which act through the Ah locus such as 3-MC (Burke & Mayer, 1974). Similarly,
7-pentoxyresorufin is a substrate for CYP2B proteins and its metabolism is
increased on phenobarbital pretreatment and inhibited by CYP2B antisera (Lubet et
a], 1985). Another substrate which is relatively specific for CYP2B proteins is 7-
benzyloxyresorufin, although this substrate is also metabolised by other P450
isozymes (Burke et al. 1985). P450 activity was assayed fluorimetrically - the
assay was carried out directly in a Perkin-Elmer LS3 Fluorescence Spectrometer
with a built-in temperature regulator set to 37°C. The reaction mixture consisted of
substrate (1ml of 1mM R-Resorufin in 100mM Tris-HCI, pH7.4), which was
equilibrated to 37°C before use and sample (e.g. 10pg of mouse liver microsomal
protein). These were thoroughly mixed in a 1ml glass fluorimeter cuvette and the
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background fluorescence (excitation 530nm, emission 585nm) of the mixture
obtained. When the baseline was linear (_30seconds), the reaction was initiated by
the addition of 10(0.1 NADPH (10mM in Tris-HCI, pH 7.4) and the resulting
fluorescence monitored continuously on a Perkin-Elmer 561 Chart Recorder. The
reaction was allowed to proceed until a measurable gradient had been produced (_3
minutes). It was important to make all measurements during the period when the
reaction was linear i.e. before the substrate concentration became rate limiting. A
known amount of resorufin (10pl of a 10mM stock in ethanol) was then added as a
standard to calibrate the reaction. Each assay was performed in triplicate and each
result is the mean of at least 3 separate experiments.
2.9 Immunohistochemical analysis
All the experiments within this section were carried out under the direction of Dr.
D.J. Harrison. Immunohistochemical staining was performed by Mrs. Helga Wolf and
i n situ hybridisation by Mrs. Frances Rae.
2.9.1 Tissue fixation
Tissue for immunohistochemical analysis was treated in one of two ways :
(a) cut into small fragments and placed directly into cold buffered formalin on
sacrifice
(b) coated in OCT (Tissue-Tek OCT compound, Miles, USA ) and snap-frozen. OCT is a
sugar-based embedding medium which prevents the tissue from drying out.
All the analysis which is described in this section was performed on formalin-fixed
tissue.
2.9.2 Haematoxylin and Eosin staining of tissue sections
This was performed as described by Lillie (1965). Nuclei were stained blue
with haematoxylin, while cytoplasm and other structures stained pink with eosin.
H&E staining of the breast and colon tumours used in these experiments is shown in
Figure 2.9.2.
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Figure 2.9.2 H & E staining of xenograft colon and breast tumours
B
The breast xenograft tumour NCH (A) was a ductal carcinoma (no special
type). Cords and clumps of malignant cells are present. Nuclei show considerable
variation in size (pleomorphism) and nucleoli are prominent. Necrosis in the centre
of the tumour was marked.
The colon xenograft tumour GFH (B) was was a moderately differentiated
adenocarcinoma. Cytologically, the tumour cells are obviously malignant. There was
moderate focal mucin production.
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2.9.3 Immunocytochemical detection of proteins
Sections for immunohistochemistry were cut at 3(i.m, dewaxed in xylene and
rehydrated through graded alcohols. Slides were washed several times in buffer
(100mM Tris, 0.1% (v/v) Tween 20, 5% (v/v) normal goat serum) before
incubation overnight at 4°C with rabbit polyclonal P450 antisera, diluted 1:50 in
buffer. Slides were then washed (3x10mins) and incubated (30 min) with
biotinylated goat anti-rabbit IgG (1:500 in buffer), exposed to strepavidin-
peroxidase conjugate (Dako, Ltd., UK) for 30 minutes and developed with 3,3'
diaminobenzidene before light counterstaining with haematoxylin.
2.9.4 Antibodies
Antibodies to P450 proteins were as previously described (Section 2.5.5).
2 .1 0 I n s i t u hybridisation for mRNA
2.10.1 Experimental procedure
In situ hybridisation was performed essentially according to Herrington et al
(1991), with the following modifications:
Formalin fixed sections were dewaxed and then permeabilised in 0.2M HCI
followed by 0.3% Triton-X100 in phosphate-buffered saline. Proteinase K was used
at 10-20pg/ml and reactions were postfixed in 0.4% paraformaldehyde. After 1h at
3 7°C in prehybridisation buffer (0.6M NaCI, 10% dextran sulphate, 30% deionised
formamide, 0.1% sodium pyrophosphate, 0.2% polyvinylpyrrolidone, 0.2% Ficoll),
20-40ng of biotinylated probe was incubated overnight at 37°C. Detection of
oligonucleotide binding was achieved using a mouse anti-biotin antibody, followed by
alkaline phosphatase labelling using nitroblue tetrazolium (NBT)/ 5-bromo-4-
chloroindolyl phosphate (BCIP), overnight at 4°C for visualisation.
2.10.2 Oligonucleotide probes
The oligonucleotides used were an 18mer from Exon 2 (bp 112-130) of the
cDNA sequence of the human CYP2B6 gene, (5' CCCATATTTCTCTCGGAA 3' antisense);
(5' TTCCGAGAGAAATATGGG 3' sense). These oligonucleotides had 6 mismatches
relative to the mouse Cyp2b9 sequence (Figure 2.10). Three biotin molecules were
added at the 5' end of each oligonucleotide using a monomer developed by Link
Technologies, Cumbernauld, Scotland.
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Figure 2.10 Comparison of human CYP2B and mouse Cyp2b nucleotide sequences
CYP2B6: 5' TTC CGA GAG AAA AT GGG 3'
Cyp2b-9: 5' CTT CAA GAA AAA CAT GGC 5'
Cyp2b-10: 5' CTT CGA GAA AAA TAT GGC 3'
= mismatch
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Chapter 3 : Xenobiotic regulation of murine hepatic P450
expression
3.1 Introduction
In this chapter, the regulation of murine hepatic P450 expression by three
compounds is discussed. Phenobarbital is a potent inducer of CYP2B1 expression in
the rat where it has been shown to act by transcriptional gene activation. It appears
to be equally potent, but more pleiotropic, in inducing hepatic P450 expression in
the mouse. Dexamethasone, a synthetic glucocorticoid, also has marked effects on
hepatic P450 expression, mediated in part at least, by binding to a glucocorticoid
responsive promoter element in the upstream regions of certain P450 genes. The
most profound effects on murine P450 expression were, however, observed with
TCPOBOP. This compound, the effects of which are long-lasting and both tissue and
species specific, shows similarity to both dexamethasone and phenobarbital in its
patterns of induction. Regulation of cytochrome P450 expression by TCPOBOP has
been characterised in mouse liver and attempts made to elucidate its mechanism of
action. In Chapter 5, the regulation of murine hepatic P450 expression by these
compounds will be compared to the effects observed in human tumour tissues.
3.2 Cytochrome P450 expression in mouse liver
Much of the work to date on murine hepatic P450 expression has centred on
the regulation of Cypla by polycyclic aromatic hydrocarbons such as TCDD
(2,3,7,8-tetrachlorodibenzo-p-dioxin) and 3-methylcholanthrene (3-MC). Two
genes, Cyp1a1 and Cyp1a2, have been isolated from mouse liver. These are located
on mouse chromosome 9, and are tightly linked to the Mpi-1 locus (Hildebrand et al.
1985). Both are inducible on treatment with polycyclic aromatic hydrocarbons, a
process which is mediated by the Ah receptor (Nebert & Jensen, 1979). The Ah
receptor (Aromatic hydrocarbon responsive) is a cytosolic protein which mediates
Cypla expression by a mechanism similar to that of hormonal induction i.e. the
inducer binds to the cytosolic receptor and the resulting complex is translocated to
the nucleus where it binds chromatin (Tukey et al. 1982) resulting in
transcriptional gene activation (Nebert & Eisen, 1984).
Inheritance of the Ah receptor has been studied in a number of inbred mouse
stains, and has been shown to follow simple Mendelian genetics and to segregate as a
single autosomal dominant trait (Thomas et al. 1972). Two thirds of the mouse
strains studied have a high affinity Ah receptor (Kd=1nM for TCDD binding) and
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show a corresponding induction response when challenged with a suitable ligand. The
remaining one third have a low affinity receptor and therefore require a much
greater dose of TCDD for induction. Less potent inducers such as 3-MC do not cause
induction in non-responsive stains. TCDD administration results in induction of
Cypla expression in both strains, however, demonstrating that genetically non-
responsive mice possess the structural and regulatory genes necessary for inducible
P450 expression (Poland et al. 1974). A later study (Poland et al. 1976)
demonstrated that there was no receptor mutation in non-responsive strains and the
difference in response to polycyclic aromatic hydrocarbons was due to altered ligand
binding affinity. The C57BI/6 mouse is the prototype for the Ah-inducible
phenotype, and the DBA/2 the prototype for the decreased response (Nebert et al.
1982). Inducible Cyp1a1 mRNA expression is correlated with aromatic hydrocarbon
hydroxylase activity, while inducible Cyp1a2 mRNA correlates with acetanilide 4-
hydroxylase activity (Tuteja et al. 1985). Constitutive expression of Cyp1a2 is
higher in mouse liver and requires lower concentrations of inducer than Cyp1a1 to
obtain the induction response, indicating that the inducer-receptor complex binds
with different affinities to the regulatory regions of each gene.
Full-length cDNA clones of Cyp1a1 and Cyp1a2 have been isolated from
hepatic C57BI/6 mRNA (Kimura et al. 1984a,b). Cyp1a1 is 2620 nucleotides in
length, encoding a 521 amino acid protein with a molecular weight of 58,914, while
Cyp1a2 is slightly smaller, with a molecular weight of 58,183. The isozymes are
68 and 73% homologous at nucleotide and protein level respectively. The Cyp1a1
upstream sequence contains a TCDD-inducible enhancer as well as additional
regulatory element which controls constitutive expression (Neuhold et al. 1986).
Comparison of the upstream sequences of these genes reveals a highly conserved
11/12 base pair sequence, which has been proposed as a possible binding site for the
Ah receptor-ligand complex (Gonzalez et al. 1985). Alternatively, or in addition,
this sequence may be involved in the binding of another DNA regulatory element. The
mouse hepatoma cell line, Hepa-1, is Ah receptor-responsive and has proved to be a
useful model for genetic and molecular analysis of the Ah receptor and Cypla gene
expression (Hankinson et al. 1979, 1991).
In the mouse, there is very good correlation between inducible Cypla
expression and polycyclic aromatic hydrocarbon induced carcinogenesis (Kouri et al.
1983). An analogous correlation has been proposed between CYP1A inducibility in
humans and lung cancer incidence in cigarette smokers (Kouri et al. 1982). The
metabolic activation of environmental toxins to reactive oxygenated electrophiles by
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Cypla genes therefore may lead to an increased cancer risk in man.
Constitutive expression of Cyp1a1 is observed during differentiation and is
not dependent on stimulation by a foreign chemical inducer. Following partial
hepatectomy, Cyp1a1 mRNA is increased in C57 (responsive) but not in DBA (non-
responsive) mice, suggesting that the induction process is Ah receptor-dependant
and may involve the binding of an endogenous ligand (Kimura et al. 1987). No
endogenous ligand for the Ah receptor has, however, been isolated (Eisen et al.
1983).
Cycloheximide treatment lead to enhanced transcriptional activation of
several genes involved in cell proliferation, suggesting the presence of such a labile
protein repressor or, alternatively, an enhancer of RNA degradation. The presence of
a labile protein repressor has been proposed for the rat CYP1A1 gene, where
"superinduction" of gene transcription is observed when hepatoma cells are exposed
to dioxin in the presence of cycloheximide (Israel et al. 1985). This superinduction
is only observed in the presence of a functional Ah receptor.
Cyp2a expression in mouse liver is also represented by two genes, Cyp2a4
(55kD) and the 49kD Cyp2a5 (Squires & Negishi, 1988), which are located on
chromosome 7 (Miles et al. 1990). Both genes have a glucocorticoid regulatory
element (GRE) upstream of the transcription initiation site (Lindberg et al. 1989).
The genes exhibit 98% sequence homology at nucleotide level and have only 11 out of
494 amino acid differences. Cyp2a5 is responsible for coumarin hydroxylase
activity, catalysing the conversion of coumarin to its 7-hydroxy derivative
(umbelliferone) (Lang et al. 1985; Lindberg & Negishi,1989). This activity is
highly and specifically inducible by pyrazole (Juvonen et al. 1985) and is also
induced on treatment with the pleiotropic inducer phenobarbital. Cyp2a4, however,
shows no Coh activity, but hydroxylates testosterone at the 15a position (Negishi et
a], 1989). Lindberg & Negishi (1989) compared the catalytic activities of these
genes as a function of their structure by site directed mutagenesis, expressing the
constructs in an appropriate expression vector in Cos-7 cells. Substitution of a
single amino acid at position 209 in Cyp2a4 (Phe->Leu) resulted in an altered
substrate specificity from coumarin to steroid hydroxylation. The nature of the
amino acids at positions 117 and 365 were also shown to be important for catalytic
activity.
Iwasaki et al (1991) expressed a series of mutated Cyp2a P450s in
Saccharomyces cerevisiae in which residue 209 was substituted by a variety of
alternative amino acids. Hydrophobic residues (Phe, Leu, Val) produced P450 in the
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high spin configuration, while substitution of a charged amino acid such as Lys or
Asp produced the low spin form. Asn or Gly in position 209 produced a mixture of
high and low spin forms of the protein. These results demonstrate that the nature of
residue 209 is critical in determining the hydroxylase specificity of the P450 and
therefore its activity towards a wide range of substrates. It has been proposed
(Iwasaki et al. 1991) that residue 209 lies close to the sixth axial ligand on the
distal surface of the heme. This is involved in binding dioxygen and thus plays a
critical role in specifying catalytic activity.
Four P450 proteins were purified from phenobarbital-treated DBA mouse
liver, one of which was the 49kD Cyp2a4 (Honkakoski & Lang, 1989). From NH2-
terminal sequence analysis, however, only one of these proteins, with an apparent
molecular weight of 56.5kD, belonged to the Cyp2b subfamily. Noshiro et al (1 988)
isolated two distinct Cyp2b genes from mouse liver, Cyp2b9 (Mr 56,740) and
Cyp2b10 (Mr 56,856). Both proteins have constitutive testosterone 16a-
hydroxylase activity. Meehan et aj (1988a) reported that the synthetic
glucocorticoid dexamethasone, like phenobarbital, was a potent inducer of Cyp2b
gene expression, and demonstrated that the induction was regulated at the level of
transcription. Dexamethasone also induced P450 levels in the Cyp2c and Cyp3a gene
families. Hypophysectomy resulted in induced levels of these isozymes, implying that
some sort of negative regulator or repressor is secreted by the pituitary, affecting
either the transcription rate of certain P450 genes or the stability of their mRNAs.
In contrast, administration of dexamethasone to the rat did not lead to induced levels
of Cyp2b and Cyp2c proteins.
Cyp2c is present constitutively in mouse liver and is only marginally
inducible by phenobarbital (Waxman et al. 1983; Wolf et al. 1984). The family is
represented by a single gene, located on chromosome 9 (Meehan et al. 1988) which
is tightly linked to the Ah locus. Indeed, Cyp2c proteins have constitutive aromatic
hydrocarbon hydroxylase activity in rats, rabbits and humans and have been shown
to be involved in both the activation and deactivation of polycyclic aromatic
hydrocarbons.
Three Cyp2d genes have been isolated from mouse liver (Wong et al. 1987,
1989; Ichikawa et al. 1989) and are located on chromosome 15 (Gonzalez et al.
1987; Wong et al. 1989). Our experiments demonstrate that Cyp2d protein is
constitutively expressed in mouse liver, and that it does not appear to be regulated to
an appreciable extent by any of the xenobiotics tested. A male specific form, Cyp2d9
(Mr 56,948), responsible for the 16a-hydroxylation of testosterone, was purified
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from mouse liver by Harada et al (1984). Screening a cDNA library with a cDNA
corresponding to this 16a clone revealed the presence of at least 5 highly
homologous genes. Cyp2d10 had the same number of amino acids as Cyp2d9 (504),
but only 92% nucleotide and 85% deduced amino acid homology. Cyp2d11 had an
extra amino acid, but showed 94 and 88% homology respectively. Two further Cyp2d
genes (Cyp2d12 and Cyp2d13) have apparently been characterised but not yet
reported (Wong et al. 1989).
The cDNA encoding the Cyp2e1 protein has recently been isolated from male
Balb/c mouse liver (Freeman et al. 1992). The deduced amino acid sequence codes
for a protein with a molecular weight of 56,781. Cyp2e mRNA and protein were
dramatically decreased on treatment with diethylnitrosamine while pyrazole, a
potent inducer of and substrate for CYP2E1 expression in rats and rabbits, was
ineffective in the mouse, although its administration did lead to increased Cyp2a
expression (Honkakoski et al. 1988). Treatment with acetone (1% (v/v)) lead to an
increase in Cyp2e1 protein expression in both males and females. No corresponding
increase in mRNA levels was observed, suggesting that the induced protein levels
were as a result of increased translation of the mRNA, protein stabilisation or some
contribution from each mechanism. It had previously been demonstrated (Song et al.
1989) demonstrated that acetone induction of CYP2E1 in the rat was the result of
protein stabilisation. Johansson et al (1988) demonstrated that spontaneous and
induced diabetes and starvation induce CYP2E1 in the rat. It has been proposed
(Miller & Yang, 1984) that increased acetone production in these conditions are
responsible, at least in part, for mediating this induction.
Cyp3a expression has not been well characterised, to date, in mouse liver.
Recently, however, a full length Cyp3a cDNA was isolated from dexamethasone
treated ddY mouse liver (Yanagimoto et al. 1992). The deduced amino acid sequence
encodes a 504 amino acid protein with a molecular weght of 57 853. Meehan et al
(1988) reported the regulation of Cyp3a expression by dexamethasone and
hypophysectomy and demonstrated that induction was regulated at the level of
transcription. This is in agreement with the findings of a recent report where
dexamethasone and the antiglucocorticoid pregnenolone 16a-carbonitrile (PCN)
were administered to a primary monolayer culture of rat hepatocytes which had been
transfected with rat liver CYP3A1 (Burger et al. 1992). Induction in this system
was mediated at the level of transcription.
Cyp4a was mapped to mouse chromosome 4 by Kimura et al (1989), and the
cDNA has recently been isolated from clofibrate-treated C57BI/6 mouse liver
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(Henderson et al. manuscript in preparation). CYP4A genes in the rat are induced by
hypolipidaemic compounds such as clofibrate and nafenopin (Reddy & Lalwani,
1983). Administration of these compounds also leads to the induction of the 4co-
hydroxylation of lauric acid and enzymes within the peroxisomal fatty acid (3-
oxidation pathway. These compounds are classified as "peroxisome proliferators",
from the marked proliferation of endoplasmic reticulum and resulting rapid
induction of peroxisome proliferation associated with their administration.
Xenobiotic induction of peroxisome proliferation has received considerable attention
since a relationship was proposed between the induction of hydrogen peroxide
producing peroxisomal enzymes and the development of hepatocellular carcinomas in
rats and mice (Reddy & Lalwani, 1983). Peroxisome proliferators are classified as
"non-genotoxic carcinogens" as they fail to cause DNA damage directly (Warren et
a], 1980). It has been proposed that the increased hydrogen peroxide production
resulting from the administration of these compounds leads to oxidative stress which
leads in turn to DNA damage and possible tumour initiation (Kasai et al. 1989).
Alternatively, or in addition, and similarly to PB and TCPOBOP, peroxisome
proliferators can act as liver tumour promoters (Marsman et al. 1988).
Western blot analysis with rat CYP4A antisera demonstrated the presence of
three Cyp4a isozymes in mouse liver and four in mouse kidney, with molecular
weights of 51, 52, 53 and 55kD. These proteins are developmentally and hormonally
regulated, with considerable variation in regulation observed between individual
isozymes.
3.3 Introduction to TCPOBOP
TCPOBOP, 1,4-bis(2-(3,5 dichloropyridyloxy)benzene) (Figure 3.3.1)
was first isolated as a contaminant in a commercial herbicide, and was reported to be
a potent "phenobarbital-like" inducer of hepatic mono-oxygenase activity in the
mouse, as measured by aminopyrine N-demethylase activity (Poland et al. 1980).
In addition, administration of TCPOBOP lead to an increase in liver weight,
proliferation of the endoplasmic reticulum and induced levels of microsomal epoxide
hydrolase and cytosolic glutathione S-transferase activities. The inductive effect was
long lasting, maintained for up to 20 weeks following a single dose of 3mg/kg of the
compound. Radiolabelling studies with ^H- TCPOBOP demonstrated that the compound
was not metabolised to an appreciable extent within the body, but was stored as the
parent compound, primarily in adipose tissue with a small amount of activity also
detectable in the liver. The presence of such a potent agonist implies the presence of
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a receptor-mediated mechanism of induction.
Previous workers had attempted, without success, to identify a phenobarbital
receptor. Previous "phenobarbital-like" agonists had, however, been structurally
dissimilar (Figure 3.3.1) and lacked potency. Administration of TCPOBOP and
phenobarbital at a range of doses produced parallel dose-response curves, in
agreement with both compounds acting through a common receptor, but having
different binding affinities.
A companion study (Poland et al. 1981) reported that the inductive effects of
TCPOBOP were highly species specific. Although active in the mouse and Syrian
golden hamster, the compound was completely without effect in the rat and guinea
pig, even at substantially higher doses. The effect was not strain dependent, as
several different strains were examined in each species. Surprisingly, the compound
was not metabolised in the non-responsive species, but was stored in adipose tissue
as the parent compound. These workers proposed that the putative "TCPOBOP-
receptor" was either absent from or mutated in the non-responsive species, but as
no receptor had been purified this was purely speculative.
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A number of studies have examined the structure-activity relationship of
TCPOBOP and a series of structurally related analogues. Kende et al (1 985)
synthesised a series of 31 congeners and deduced the following minimum
requirements for activity:
(a) a central 1,4-dioxygenated benzene ring
(b) lateral pyridine rings linked to the central benzene through ether bonds,
although certain other heteroatomic rings had reduced activity
(c) 5,5' substituents of CI, Br or N02 on the lateral rings
X-ray crystallography was performed on TCPOBOP and two structural
analogues, one which showed reduced activity and another which was completely
inactive. These studies demonstrated that the pyridine rings must lie anti to the plane
of the central benzene, with a dihedral angle of 60°. The ether oxygen is sp2 bonded
in conjugation with the heterodipolar bond C(2)-N(1), resulting in restricted
rotation about the ether bonds.
The presence of a defined structure-activity relationship supports a receptor
based induction mechanism, possibly with two similar and complementary binding
sites. As phenobarbital is not structurally related to TCPOBOP, it was proposed that
two molecules of phenobarbital might bind for every molecule of bound TCPOBOP. In
a similar series of experiments, Kelley et al (1985) synthesised a series of 10
analogues and demonstrated that the central benzene could not be replaced with
another ring structure and that para-substitution on the central benzene was
necessary for maximum activity. A similar structure-activity relationship was
observed for a group of 2,4-dichloro substituted polychlorinated biphenyl (PCB)
compounds (Demomme et al. 1983). Interestingly, TCPOBOP administration
(30mg/kg) to pregnant mice lead to transplacental induction of mono-oxygenase
activity (Poland et al. 1980) in a similar manner to that observed on PCB
administration (Demomme et al. 1983). Aniline hydroxylase activity, a marker
substrate for Cyp2e1 was induced only slightly on TCPOBOP treatment, while
coumarin hydroxylase activity was markedly increased (Raunio et al. 1988). Kelley
et al (1990) reported that TCPOBOP did not induce aromatic hydrocarbon
hydroxylase activity in Ah receptor positive strains of mice and, in agreement with
our results, concluded that TCPOBOP effects are not mediated through the Ah
receptor. An alternative mechanism was proposed by Fonne & Meyer (1987), who
suggested that the P450 molecule itself was the TCPOBOP receptor and that TCPOBOP
must bind to the P450 for the induction response to be observed. This was supported
by the finding that rat CYP2B1 did not bind TCPOBOP.
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In addition, Romano et al (1986) reported that TCPOBOP administration
resulted in increased DNA synthesis in rodents and increased microsomal membrane
fluidity in mice. Both TCPOBOP and phenobarbital enhanced the development of
hepatic neoplasia when administered after an initiating carcinogen such as
diethylnitrosamine (DEN). The doses of TCPOBOP required were, however, much
greater than those required for induction of mono-oxygenase activity. Dragani et al
(1985) reported that TCPOBOP stimulated murine hepatocyte proliferation without
causing necrosis or cytotoxicity.
3.4 The effect of TCPOBOP on rodent hepatic cytochrome P450 levels
3.4.1 Xenobiotic induction of hepatic P450 proteins
Initial experiments were carried out to compare the effects of TCPOBOP,
phenobarbital and the synthetic glucocorticoid dexamethasone on murine hepatic
P450 expression. With the exception of Cyp2e1, the levels of protein from all the
cytochrome P450 families and subfamilies examined were significantly increased,
as determined by Western blot analysis, following a single injection of 75pg of
TCPOBOP (Figure 3.4.1.1).
The inductive effect was particularly pronounced for Cypla, Cyp2a, Cyp2b
and Cyp2c proteins. The induction of Cypla proteins by both phenobarbital and
TCPOBOP is particularly interesting, as these isozymes are usually thought of as
polycyclic aromatic hydrocarbon-inducible, mediated through the Ah receptor.
Induction of Cypla by phenobarbital-like compounds has not previously been
reported. Two distinct Cyp2a proteins were induced in mouse liver by TCPOBOP -
the molecular weights of these proteins are consistent with their being Cyp2a4
(55kD, upper band) and Cyp2a5 (49kD, lower band). Interestingly, although Cyp2a
genes contain a functional GRE in their upstream flanking region (Lindberg et al.
1989), no induction was seen with dexamethasone. Phenobarbital and TCPOBOP
treatment did, however, lead to a marked increase in Cyp2a expression. P450s from
the Cyp2c, Cyp3a and Cyp4a have not, to date, been well characterised in the mouse,
but all were induced on treatment with TCPOBOP. Many similarities were observed
with the induction patterns obtained on TCPOBOP and phenobarbital treatment. In
agreement with a previous study (Meehan et al. 1988), dexamethasone, like
TCPOBOP, was a potent inducer of Cyp2b expression. However, in contrast to the
previous report, the levels of Cyp2c and Cyp3a proteins were not significantly
increased by dexamethasone treatment in the experiments reported here. This could
be due to the lower dose of dexamethasone administered (100 vs. 200mg/kg) or the
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mouse strain used (C57BI/6 vs. DBA/2). P450 isozyme expression was also studied
in kidney, lung and testes following treatment with TCPOBOP, but no induction was
observed.
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Male (M) and Female (F) DBA/2 mice were treated with dexamethasone (Dex),
phenobarbital (PB) or a single injection of 3mg/kg TCPOBOP. Liver microsomal
samples (15pg), prepared from pooled tissue from these animals, or suitable
controls, were separated on 9% SDS-PAGE and P450 isozyme content determined by
Western blot analysis using polyclonal antisera to various rat liver P450 proteins.
S = purified rat liver P450 standard
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Previous work (Poland et al. 1981) had demonstrated that TCPOBOP
treatment did not influence hepatic P450 protein levels in the rat. Our experiments
confirmed this finding (Figure 3.4.1.2), and we went on to investigate whether
TCPOBOP treatment lead to increased mRNA expression in the rat, which would
suggest that the lack of elevated protein expression was due to an inter-species
difference in post-transcriptional control (Figure 3.4.3.2).
Figure 3.4.1.2 The effect of TCPOBOP on rat hepatic P450 protein levels
S MFMFMFMF S
CON TC CON TC
MOUSE RAT
Male (M) or Female (F) Wistar rats were treated as controls (CON) or with 3mg/kg
TCPOBOP (TC). Liver microsomal samples (15pg) were prepared from pooled tissue
from these animals, separated on 9% SDS-PAGE and CYP1A and CYP2B isozyme
content determined by Western blot analysis. S = purified rat liver P450 standard
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3.4.2 The effect of TCPOBOP on P450 substrate metabolism
The induction patterns seen on Western blot analysis were confirmed by
determining the rate of metabolism of a series of analagous alkoxy-substituted
resorufin ethers (phenoxazones), which have previously been shown to be marker
substrates for various of the P450 subfamilies (Burke et al. 1985). Figure 3.4.2.1
shows the metabolism of benzyloxyresorufin, a substrate for Cyp2b, by a series of
microsomal samples prepared from mice treated as controls, or with dexamethasone,
phenobarbital or TCPOBOP.
The Cyp2b protein induced is probably that described by Noshiro et al
(1989) as the major phenobarbital-inducible enzyme, Cyp2b-9. The 40-fold
induction of benzyloxyresorufin activity in females and the corresponding 8-fold
increase in males is consistent with increased levels of this protein. This enzyme is
sexually dimorphic in mice, and appears to be induced to a greater extent in females
than in males. This effect was also observed, although less pronounced, on Western
blot analysis (Figure 3.4.1.1). Similarly, the hepatic Cypla protein induced by
TCPOBOP is likely to be Cyp1a2 as the activity towards 7-ethoxyresorufin, a
substrate for Cyp1a1, was only slightly increased on TCPOBOP treatment (Figure
3.4.2.2).
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Figure 3.4.2.1 Benzyloxyresorufin metabolism
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TCPOBOP, although it has a profound inductive effect on murine Cyp4a
gene expression, does not cause peroxisome proliferation (Anna-Karin Sohlenius,
unpublished observations). No increase above control levels in catalase activity or
peroxisomal p-oxidation was detectable in cytosolic or mitochondrial fractions from
TCPOBOP-treated animals. TCPOBOP induction of Cyp4a protein expression is
therefore unlikely to be mediated by the peroxisome proliferator activated receptor
(PPAR)(lssemann & Green, 1990)
97
3.4.3 TCPOBOP effects are mediated at the level of transcription
The effect of TCPOBOP, dexamethasone and phenobarbital on cytochrome
P450 mRNA levels, in most cases, parallelled the changes in protein expression
extremely closely (Figure 3.4.3.1).
Interestingly, and in contrast to the protein analysis, dexamethasone
treatment lead to a marked increase in the levels of Cyp2c and Cyp3a mRNAs. Also,
there appeared to be no correlation between the levels of Cyp4a mRNA and expressed
protein. This may be attributed, in part at least, to the complexity of the gene
families in the mouse and the possibility that the cDNA probe used in the Northern
blot analysis is hybridising specifically to only one mRNA species. There is a
interesting similarity between the ability of TCPOBOP and dexamethasone, but not
phenobarbital to induce a male predominant Cyp4a mRNA.
The conclusion from the Northern blot analysis, therefore, was that the
administration of both TCPOBOP and phenobarbital to mice lead to an increase in the
mRNA levels encoded by genes from almost all the individual P450 gene families.
This indicated that the observed changes in protein expression were due to an
increased rate of transcription - this is agreement with the findings of Hardwick et
a] (1983) who demonstrated that phenobarbital induction of CYP2B1 expression in
the rat occurred by transcriptional activation of the gene.
CY2B1 mRNA levels, the rat equivalent of the major murine TCPOBOP-
inducible form, were relatively unaffected by TCPOBOP treatment, however (Figure
3.4.3.2), demonstrating that the compound has no inductive effect on P450 gene
expression in the rat. This supports the theory that interaction with a species-
specific receptor is necessary for the compound to exert its inductive effect.
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Liver RNA (10pg) from Male (M) and Female (F) DBA/2 mice from pooled tissue from control animals
(Con) or animals treated with dexamethasone (Dex), phenobarbital (PB) or TCPOBOP, was separated on
1% denaturing formaldehyde-agarose gels, transferred overnight to Hybond-N, and hybridised with
cDNA probes representing each of the individual P450 families. Equality of loading was determined by
re-probing each filter with a mouse p-actin cDNA probe.
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Figure 3.4.3.2 Effect of TCPOBOP on rat hepatic cytochrome P450 mRNA levels
Liver RNA (10|ig) from Male (M) and Female (F) Wistar rats from pooled tissue
from control animals (CON) or those treated with 3mg/kg TCPOBOP (TC), was
separated on 1% denaturing formaldehyde-agarose gels, transferred overnight to
Hybond-N, and hybridised with a CYP2B1 cDNA probe. Equality of loading was
determined by re-probing the filter with a mouse (3- actin cDNA probe.
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3.4.4 Long term effects of TCPOBOP on P450 expression
In order to establish the potency of TCPOBOP as a P450 inducer, liver
samples were taken for a period of up to 3 months following a single injection of
3mg/kg of the compound. These experiments (Figure 3.4.4.1) clearly confirmed the
ability of TCPOBOP to induce the expression of P450s from almost all the gene
families studied and demonstrated that the induction was long-lasting. Although, in
some cases, the level of induction at twelve weeks was reduced relative to the level of
protein expression at two weeks, in others only a slight reduction was seen.
In a recent experiment, Cyp2b expression was monitored for 1 year
following a single injection of 3mg/kg (75pg) of TCPOBOP. Protein expression
remained above control level throughout the period of study (Figure 3.4.4.2),
although Cyp2b levels in the male fell more quickly than in the female.
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Liver microsomes (15pg) from pooled tissue from Male (M) and female (F) DBA/2
mice, treated with a single injection of 3mg/kg TCPOBOP or as Controls (Con), were
separated on 9% SDS-PAGE, transferred to nitrocellulose and P450 isozyme content
determined by Western blot analysis using polyclonal antisera to various rat liver
P450 proteins. Samples were prepared 2, 4, 8 and 12 weeks following the
administration of TCPOBOP. S = purified rat liver P450 standard
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Figure 3.4.4.2 Hepatic Cyp2b protein expression 1 year after TCPOBOP
administration
S C 3D 3W 3M 4M 6M 8M 12M S
TCPOBOP—->
Liver microsomes (15pg) from pooled tissue from Male (M) and female (F) DBA/2
mice, treated with a single injection of 3mg/kg TCPOBOP or as Controls (Con), were
separated on 9% SDS-PAGE, transferred to nitrocellulose and P450 isozyme content
determined by Western blot analysis using polyclonal antisera to various rat liver
P450 proteins. Samples were prepared at 3 days, 3 weeks, 3, 4, 6, 8 and 12 months
following the administration of TCPOBOP. S = purified rat liver P450 standard
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Analysis of P450 mRNA levels demonstrated that mRNAs encoding the various
P450 subfamilies were also still elevated 3 months following a single 75pg injection
of TCPOBOP (Figure 3.4.4.3). mRNA levels were observed to decline much more
quickly than the corresponding protein levels, however, (Figure 3.4.4.1),
indicating that the elevated protein expression was due, in part, to some form of
post-translational stabilisation.
The long term effects of TCPOBOP were not only reflected in cytochrome
P450 levels but also in liver size. An approximately two-fold increase in liver
weight was observed 4 days after TCPOBOP treatment. This increase was still
observed 3 months after administration of a single dose of the drug.
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Figure 3.4.4.3 Long term induction of hepatic cytochrome P450 mRNA by TCPOBOP
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Liver RNA (10pg) from pooled tissue from Male (M) and Female (F) DBA/2 mice
from control animals (Con) or those treated with 3mg/kg TCPOBOP, was separated
on 1% denaturing formaldehyde-agarose gels, transferred overnight to Hybond-N,
and hybridised with cDNA probe representative of the individual P450 families.
Mice were sacrificed at 2 weeks, 4 weeks, 8 weeks and 12 weeks following TCPOBOP
administration. Equality of loading was determined by re-probing each filter with a
mouse p-actin cDNA probe.
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3.5 TCPOBOP - a synthetic glucocorticoid?
3.5.1 The effect of TCPOBOP on metallothionein and major urinary protein mRNA
levels
Many similarities were observed between the abilities of TCPOBOP and
dexamethasone to induce murine hepatic P450 expression, including a pronounced
species specificity in their inductive effects. It seemed reasonable, therefore, that
TCPOBOP may exert its inductive effects through the glucocorticoid receptor or
another homologous steroid hormone-like receptor. To test this hypothesis, the
effect of TCPOBOP was determined on the expression of genes which were known to be
dexamethasone-inducible and to contain the glucocorticoid responsive promoter
element (GRE). Two such genes are those encoding the mouse metallothionein lla (Hu
& Davidson, 1990) and the murine major urinary proteins (MUPS) (Knopf et al.
1983). The effect of TCPOBOP on the expression of these genes is shown in Figures
3.5.1.1(a) Short term analysis and 3.5.1.1(b) Long term analysis.
In the short term experiments, TCPOBOP induced metallothionein and MUPS
mRNA levels in females and MUPS gene expression in both males and females.
Interestingly, phenobarbital and dexamethasone also induced metallothionein mRNA
to a greater extent in female tissue. In the long term experiment, although the sex
differences in induction were less marked, the levels of both MUPS and
metallothionein mRNA remained induced 3 months after TCPOBOP administration.
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(a) Short term experiment (b) Long term experiment
Liver RNA (10pg) from pooled tissue from Male (M) and Female (F) DBA/2 mice from control animals
(Con) or those treated with dexamethasone (Dex), phenobarbital (PB) or 3mg/kg TCPOBOP, was
separated on 1% denaturing formaldehyde-agarose gels, transferred overnight to Hybond-N, and
hybridised with cDNA probes for metallothionein I la (MT) or mouse major urinary proteins (MUPS).
Equality of loading was determined by re-probing each filter with a mouse (J-actin cDNA probe.
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3.5.2 The effect of TCPOBOP and phenobarbital on the activation of the MMTV LTR
The above data confirmed that there were similarities in the ability of
TCPOBOP and dexamethasone to influence hepatic gene expression and suggested that
the GRE may mediate induction by TCPOBOP. In order to obtain more direct evidence
of GRE involvement, the MMTV long terminal repeat (LTR) which contains a GRE was
linked to the CAT reporter gene and transfected into the oestrogen-receptor positive
breast cancer cell line ZR-75, with the efficiency of transfection monitored by co-
transfection with the firefly luciferase gene. CAT activity was determined following
exposure to dexamethasone, phenobarbital and TCPOBOP (Figure 3.5.2.1).
CAT activity was highly inducible by dexamethasone, but both phenobarbital
and TCPOBOP were without effect at any of the concentrations tested. In addition,
TCPOBOP did not antagonise the dexamethasone-mediated inducibility of CAT activity
(not shown), indicating that the effects of the two compounds were not regulated by
the same mechanism.
In a further experiment, however, the C3H10T1/2 cell line, which has
constitutive P450 expression (Pottenger & Jefcoate, 1990, 1991) and is
responsive to TCPOBOP (Section 4.6.2), was transfected with a construct
comprising the GRE linked to CAT. In this system, very low levels of TCPOBOP-
inducible CAT activity were detected (Figure 3.5.2.2). These data imply that
although the effects of TCPOBOP do not appear to be mediated directly by the
glucocorticoid receptor, a homologous "steroid hormone-like" receptor may be
involved in regulating the pleiotropic effects of this compound.
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Figure 3.5.2.1 Effect of TCPOBOP and phenobarbital on the activation of the MMTV LTR
CAT activity was measured following transfection of the MMTV-LTR fused to CAT into
ZR-75 cells and subsequent treatment with a range of inducing agents.
M = Mock transfection, -H = transfection without the addition of an inducing agent, G
= R5020, a potent synthetic glucocorticoid, D = dexamethasone, P = phenobarbital ,
T = TCPOBOP.
Phenobarbital and TCPOBOP were administered at at several doses, ranging from
10-6M to 10-9M (6,7,8 and 9 respectively).
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Figure 3.5.2.2 TCPOBOP mediated induction of CAT activity in C3H10T1/2 cells









C3H10T1/2 cells were transfected with a construct comprising either (a) the GRE
fused to the CAT reporter gene (GRE-1) or (b) 2 GRE elements linked in series fused
to CAT (GRE-2). The transfected cells were then treated with vehicle only (CON) or
with dexamethasone (Dex) ot TCPOBOP (TC) at 10" 5M. CAT activity was determined
chromatographically as described in Section 2.7.9 (a). Each sample was analysed in
duplicate.
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3.6 TCPOBOP induction is maintained in hypophysectomised animals
The pituitary has been shown to play a major role in the regulation of certain
cytochrome P450 genes (Skett, 1987; Zaphiropoulos et al. 1989). To determine
whether induction of P450 expression by TCPOBOP was due to direct interaction
with a "receptor-like" protein in hepatocytes or was mediated indirectly by the
pituitary, TCPOBOP, dexamethasone and phenobarbital were administered to
hypophysectomised animals (Figure 3.6.1).
Figure 3.6.1 The effect of hypophysectomy on TCPOBOP induction of hepatic
cytochrome P450 proteins
M F M F
f M F M F^M F M FmM F M F/
CON Dex PB TCPOBOP
Male (M) or Female (F) C57BI/6 mice were hypophysectomised (Hx) or sham-
operated (Sh) before being treated with as Controls (Con) or with dexamethasone
(Dex), phenobarbital (PB) or TCPOBOP. Liver microsomal samples were prepared
from pooled tissues from these animals and were separated (15pg) on SDS-PAGE
using 9% gels. P450 isozyme content was determined by Western blot analysis using
polyclonal rat antisera to the P450 isozymes shown. S = purified rat P450 protein
standard
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Neither hypophysectomy nor the control "sham" operations had any effect on
the ability of any of these compounds to induce P450 levels. Interestingly,
dexamethasone was found to be a potent inducer of both Cyp2c and Cyp3a proteins in
these experiments. This finding is in agreement with Meehan et al (1988), but in
contrast to the effect of administration of this compound to DBA/2 mice described
above. It would appear, therefore that there is a strain difference in the murine
response to dexamethasone administration. It is also interesting to note, in agreement
with Meehan et al. that induction of P450 proteins by phenobarbitai and TCPOBOP
was significantly higher in hypophysectomised animals, implying that some form of
negative regulator or repressor is secreted by the pituitary.
Further evidence that TCPOBOP acts predominantly by exerting a direct effect
on hepatocytes was obtained by demonstrating that TCPOBOP could induce Cyp2b
expression in a primary culture of mouse hepatocytes (section 4.7).
3.7 Discussion
These experiments demonstrate that TCPOBOP is an extremely potent and
pleiotropic modulator of hepatic gene expression in the mouse. The inductive effects
are both tissue and species specific, suggesting a receptor-based mechanism of
induction. The compound shows a marked similarity to phenobarbitai in the
regulation of hepatic cytochrome P450, NADPH cytochrome P450 reductase, epoxide
hydrolase and cytosolic glutathione S-transferase expression and, like
phenobarbitai, is an promoter of DEN-induced carcinogenesis. It has previously been
proposed that phenobarbitai exerts its inductive effects by interaction with a
specific receptor, but no such receptor has, as yet, been isolated. This has been
attributed to the considerable structural variation between "phenobarbital-like"
ligands and their relative lack of potency. TCPOBOP, however, is 650 times more
potent than phenobarbitai in the induction of murine mono-oxygenase activity, and is
therefore an ideal substrate to study the regulation of murine P450 genes.
The induction of Cypla gene expression by polycyclic aromatic hydrocarbons
is regulated by the Ah locus (Nebert & Jensen, 1987). Inbred mice strains are
defined as "responsive" or "non-responsive" depending on the ligand binding
affinity of their Ah receptor protein. TCPOBOP, however, is equally effective in
influencing Cypla expression in both C57BI/6 (responsive) and DBA/2 (non-
responsive) mice, suggesting that its action is not mediated by the Ah receptor.
TCPOBOP influences the expression of many more P450 genes than any
inducer studied previously. Indeed, the levels of all the hepatic isozymes studied,
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with the exception of Cyp2e1, were dramatically increased on treatment with a
single injection of 3mg/kg TCPOBOP. The lack of inducibility of Cyp2e1 can be
explained by the report of Freeman et al (1992), which demonstrated that induction
of Cyp2e1 is regulated by post-translational protein stabilisation, with no
concomitant increase in the levels of mRNA. In contrast, TCPOBOP, like
phenobarbital, exerts its inductive effects at the level of transcription. There may
however be an additional mechanism of P450 induction by both PB and TCPOBOP,
which involves post-translational modification. Aida & Negishi (1991) report a 3-
fold increase in mouse Cyp2a5 (P450Coh) protein which is not associated with
changes in Cyp2a-5 mRNA levels or gene transcription rate. Long term studies of
TCPOBOP induction of P450 expression demonstrate that mRNA levels decrease much
more rapidly than the corresponding protein levels following TCPOBOP
administration, implying that some form of protein stabilisation mechanism exists.
The mechanism of transcriptional regulation of cytochrome P450 genes by
phenobarbital remains to be established, although recent progress has been made in
the identification of a phenobarbital-responsive promoter element which is
conserved between a B.megeterium gene and the rat P450 CYP2B1 gene (He & Fulco,
1991). The presence of this regulatory element has not been demonstrated in the
mouse, however, and if the actions of TCPOBOP and phenobarbital were indeed
regulated by the same mechanism, TCPOBOP would be expected to activate the
phenobarbital-responsive promoter in the rat. The compound is ineffective in
inducing monooxygenase activity in the rat, however, although the presence j_n vivo
of further repressive regulatory elements which could mask or block TCPOBOP-
promoter binding cannot be ruled out. The presence of this phenobarbital-specific
element in CYP2B genes would also not explain the pleiotropic effects of TCPOBOP on
hepatic P450 expression.
The effects of TCPOBOP on hepatic gene expression could be due to direct
action on hepatocytes, or be mediated indirectly by, for example, the pituitary.
Pituitary effects on the regulation of P450 expression have been previously
extensively reported (Skett, 1987; Zaphiropoulos et al. 1989). Hypophysectomy,
however, did not prevent TCPOBOP, phenobarbital or dexamethasone inducing hepatic
cytochrome P450s, indicating that the observed effects of these compounds were
exerted by a direct action on hepatocytes. This was confirmed by the finding that
TCPOBOP and phenobarbital induced Cyp2b expression in mouse hepatocytes in
primary culture.
The similarity between the effects of TCPOBOP and dexamethasone
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administration on murine mono-oxygenase activities suggested that TCPOBOP may
also possess glucocorticoid activity, and that its inductive effects may be mediated by
the glucocorticoid receptor. Indeed, TCPOBOP treatment increased the expression of
several genes which are known to be glucocorticoid responsive and to contain the
glucocorticoid responsive promoter element (GRE). In a series of transfection
experiments, however, TCPOBOP did not activate the GRE to a significant extent or
compete with dexamethasone for receptor binding. Some slight activity was observed
in the C3H10T1/2 cell line, however, suggesting that although TCPOBOP did not bind
the GRE, its effects may be mediated by an analagous member of the steroid hormone
superfamily which has a lower affinity for dexamethasone binding. Chasserot-Golaz
et al (1990) also reported a similarity between the effects of phenobarbital and
dexamethasone in mediating P450 induction, suggesting glucocorticoid receptor
involvement. These workers, however, proposed that phenobarbital treatment
increased the affinity of the GRE for its ligand and also increased the total number of
glucocorticoid receptors available for binding. Whether this effect was as a
consequence of phenobarbital itself being complexed with a specific receptor and thus
no longer competing for GRE binding has not been established.
GRE-like elements have previously been reported in many P450 genes. A
putative "GRE" lies 1.3kb upstream of the transcription initiation site in the rat
CYP2B2 gene (Rangarajan et al. 1987; Jaiswal et al. 1990). This element
(TGTCCT), which shows reasonable homology with the GRE (GGTACANNNTGTTCT) has
been shown to be functional and to confer dexamethasone inducibility on the CAT
reporter gene and is also present in the mouse Cyp2e1, Cyp2b9 and the hamster
CYP2A genes. Hapgood et_aj (1989) demonstrated that the Ah receptor is a sequence-
specific DNA binding protein which is both biochemically and structurally similar to
the steroid hormone receptor superfamily. However, the Ah and the glucocorticoid
receptors do not appear to share any common ligand binding specificity (Poellinger
et al. 1985).
Fonne & Meyer (1989) proposed that the P450 molecule itself could be the
TCPOBOP receptor. This seems inherently unlikely, however, as TCPOBOP
administration leads to such profound effects on many distinct P450 genes. The drug
would therefore have to bind to a very conserved region of P450 sequence. These
conserved regions are found, in general, in regions which are important for catalytic
activity, such as the heme binding site. It seems inconceivable that a drug-receptor
complex could form without an accompanying disruption of heme or dioxygen binding.
Substrate interaction would also be subject to considerable steric hindrance.
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The potency and longevity of the inductive effects observed on TCPOBOP
treatment also support the proposal that these effects are mediated by an
intracellular receptor. The experiments described in this chapter demonstrate that
the administration of a single dose of only 75pg of TCPOBOP to a mouse lead to
increased Cyp2b expression one year after treatment. It is unlikely that metabolic
effects could lead to such profound effects on hepatic gene expression. In addition,
previous studies using radioligands demonstrated that TCPOBOP was stored within
the body, primarily in adipose tissue, as the parent compound. No radiolabeled
metabolites were detectable. Similarly, phenobarbital and not its major
hydroxylated metabolite, p-hydroxy phenobarbital, appears to be the active inducing
agent (Cresteil et al. 1980).
Accumulation of TCPOBOP in adipose tissue may explain the profound
differences in the activities of certain P450 isozymes between male and female mice.
As females in general have a higher body fat content than males, it seems reasonable
that the effective concentration of TCPOBOP is higher in females. In addition,
accumulation of drug in adipose tissue implies that the circulating concentration is
considerably lower than the administered dose and the reported potency is an
underestimate.
Evans (1988) proposed that there exists a large superfamily of genes whose
products are ligand-responsive transcription factors. Steroid hormone receptors and
thyroid hormone receptors form part of this "receptor superfamily", the activity of
which is mediated by a common mechanism. Gene activation is thought to occur by
binding of receptor and ligand and translocation of the resulting receptor-ligand
complex to the nucleus, where it binds chromatin with high affinity. Miyata &
Yahara (1991) demonstrated that he glucocorticoid receptor exists in the cytoplasm
of hormone-free cells as a complex with the 90kD heat shock protein (HSP90).
Glucocorticoids induce dissociation of the HSP90/receptor complex and translocation
of the receptor to the nucleus. The chromatin structure of each cell type is uniquely
organised, and thus different sets of genes may be accessible to the hormone-
receptor complex. Selectivity is further increased by the differential expression of
the different receptors in specific cells and tissues.
Evans also proposed that a single ligand can simultaneously activate distinct
genes, the DNA binding domains of which are similar but not identical. This
mechanism seems plausible for the activation of P450 genes by TCPOBOP, where a
series of genes with distinct but overlapping substrate specificities are
simultaneously induced by the same ligand. Koracek et al (1990) studied the co-
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ordinate induction of rat CYP2A and CYP3A genes by phenobarbital in a Matrigel-
supported hepatocyte culture, and demonstrated that phenobarbital was not equally
effective in influencing the expression of individual P450 genes. These differential
effects could, however, be explained if the putative ligand-receptor complex had a
different affinity for the regulatory region of each gene. If this is the case, it should
prove possible to identify the "TCPOBOP-responsive element" by deletion analysis
of the 5' regions of genes which are highly inducible on TCPOBOP expression.
An alternative approach would be that adopted by Issemann & Green in cloning
the mouse peroxisome proliferator-activated receptor. Having established that
peroxisome proliferators could also act in a manner similar to that of steroid
hormones (Green & Chambon, 1988; Evans, 1988), these workers compared the
amino acid sequences of several nuclear receptors and identified a highly conserved
region within the DNA binding domain. Oligos were constructed based on this
consensus sequence and used to screen a mouse liver cDNA library. Several novel
clones were isolated, one of which encoded a 468 amino acid protein (Mr 52400),
which was shown to be the PPAR. The tissue-dependent expression of this protein
was in agreement with the tissue specific effects of peroxisome proliferators.
Similarly to the Ah receptor, the physiological role of and the endogenous ligand for
the PPAR are, at present, unknown. The effects of peroxisome proliferators on the
peroxisomal (3-oxidation pathway, however, suggests a possible endogenous role for
the receptor in triglyceride and cholesterol homeostasis.
It seems feasible that a similar approach could lead to the isolation of a
"TCPOBOP-responsive " receptor. Several further questions must than be
addressed:
1. It is not clear whether the putative receptor complex interacts directly with DNA
or becomes associated with other transcriptional regulatory proteins
2. Is it necessary for the receptor-ligand complex to remain bound to DNA for the
associated gene(s) to remain active or can a transiently bound receptor initiate
long-term transcriptional activation ? The longevity of the inductive effects could be
explained by a permanent "trickle" of TCPOBOP from adipose tissue to liver. It is
not yet clear whether induction by TCPOBOP can be maintained in the absence of
ligand. Becker et al (1986) demonstrated that hormone binding is necessary for the
transcriptional activation of genes by gucocorticoid hormones. In contrast to these
findings, however, Willman & Beato (1986) reported binding of the hormone
responsive receptor to the MMTV GRE in the absence of a steroid ligand. Further
studies are therefore necessary to determine which mechanism, if any, best
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represents the action of TCPOBOP. The cell line C3H10T1/2 has constitutive
expression of a "Cyp2a-like" protein (Jefcoate et al. 1990, 1991) which is
inducible by TCPOBOP (Section 4.6.2). This may prove to be a suitable model in
which to determine whether induction of P450 gene expresion by TCPOBOP requires
the presence of bound ligand.
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Chapter 4: Cytochrome P450 expression and regulation in
mammalian cell culture
4.1 Introduction and aims
Cell culture has become an invaluable j_n vitro technique for studying the
expression and regulation of many genes. Cell lines have been established from a
variety of species and tissues and have been extensively characterised with respect
to their individual patterns of gene expression. The study of cytochromes P450 in
this model is difficult, however, as the expression of these genes is usually either
lost completely or, at best, significantly altered in established cell lines, often
resulting in the loss of the characteristic P450 induction patterns observed i_n vivo.
The study of cells in primary culture can circumvent this problem to some extent.
As the liver is the primary metabolic site within the body, analysis of hepatic cells
in culture has been widely used to study the expression and regulation of the enzyme
systems involved in drug metabolism.
The aims of this section were twofold: 1) to identify a cell line(s) in which
P450 expression could be regulated by xenobiotics; 2) to compare the effects of
xenobiotic regulation of P450 expression in continuous culture with a primary
culture model and the effects observed i n vivo.
4.2 Primary hepatocyte culture
Hepatocyte culture is thought to be- more physiologically relevant than
isolated microsomes to study P450 regulation j_n vitro, as transport across the cell
membrane and competition between cellular metabolic reactions can still occur
(Begue et al. 1983). Hepatocytes do not proliferate in primary culture however,
and thus all experiments are restricted to the limited life-span of the cells. P450
expression and induction can be maintained in primary hepatocyte cultures under
strictly defined conditions, albeit at a much lower level than observed i n vivo. It has
been demonstrated (Newman & Guzelian, 1982) that hepatocytes require a period of
adaptation to the tissue culture environment before P450 expression is maximised
and, in general, P450 expression declines with increased time in culture. Bissell &
Guzelian (1979) demonstrated that as much as 80% of P450 activity was lost
within 48 hours of establishing hepatocytes as a primary culture.
As human liver samples are difficult to obtain for obvious ethical reasons,
almost all the primary culture models studied to date have used rodent (usually rat)
hepatocytes. Great care must be taken in extrapolating these results to the human
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response, as previous studies have demonstrated that there are significant
differences between P450 activities in adult human and rat liver microsomes
(Kremers et al. 1981). In certain cases, however, human liver samples have been
obtained from patients undergoing kidney transplantation (Begue et al. 1983) or
cholicistectomy (Donato et al. 1990) and hepatocytes isolated by collagenase
perfusion. Human foetal hepatocytes have also been studied (Rollins et al. 1979;
Rane & Tomson, 1980; Guillouzo et al. 1982). Using this model, direct effects of
xenobiotics on hepatic gene expression can be determined, although the physiological
relevance of studying a single cell type in isolation is often limited, and care must be
taken in extrapolating the results of such experiments to the behaviour of a
particular compound in the intact animal, where the regulation of hepatic gene
expression is controlled by many hormonal and metabolic factors. There can be
considerable variation in gene expression in hepatocytes isolated from different rats
and it is therefore important to standardise culture conditions as far as is
practicable between experiments.
For P450 expression to be maintained in cell culture, several factors must
be present: (a) sufficient intracellular heme to be incorporated during protein
synthesis; (b) a suitable membrane lipid environment to allow enzymatic and
catalytic activities to occur; (c) NADPH-cytochrome P450 oxidoreductase and, in
certain cases, cytochrome bg.
Other enzymes involved in drug metabolism, e.g. the glutathione S-
transferases, do not have such strict requirements for activity and their expression
is therefore maintained at close to in vivo levels in cell culture models. As drug
metabolism is often dependent on the interaction of a number of different enzymes, it
is important to determine that all the components of a particular metabolic pathway
are both present and active in the hepatocyte population before metabolism studies
are undertaken. A fine balance between detoxification and activation to a more toxic
form exists in the metabolism of many chemicals, with the actual metabolic route
dependent on the enzyme profile present on xenobiotic challenge. Aflatoxin B1
(Figure 4.2.1) is a good example of such a compound, the metabolism of which is
dependent on both P450 and GST enzymes.
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Figure 4.2.1 The metabolism of Aflatoxin B-|
Redrawn from Coles & Ketterer, 1990
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Bars et al (1989) demonstrated that P450 expression in the rat is not
distributed evenly throughout the hepatocyte population. This heterogeneous
expression is also seen in untreated rodent liver where P450 expression is greater
in centrilobular than in periportal hepatocytes. Induction by phenobarbital, for
example, occurs predominantly in the centrilobular region. Several workers (Bars
et al. 1989; Frey et al. 1984) however, have reported that the isozyme profile
induced by a particular xenobiotic differs in this in vitro system from the intact
liver. For example, the expression of the male-specific CYP2CII isozyme, which is
pituitary-regulated, is lost in cell culture. This has been attributed (Waxman et al.
1990) to lack of the appropriate hormonal factors necessary for expression
although expression was not restored on growth hormone treatment (Guzelian et al.
1988). This was attributed to the necessary episodic patterns of secretion being
absent Ln vitro. In addition, Nemoto et al (1990) reported that in a series of
experiments on mouse hepatocytes, aromatic hydrocarbon hydroxylase activity,
although genetically determined in each strain, could be induced in the hepatocytes of
previously non-responsive strains on treatment with aromatic hydrocarbons when
the cells were transferred to primary culture.
In conclusion, therefore, xenobiotic regulation of P450 expression may be
studied in vitro using this model, but significant differences from the in vivo
metabolism of a particular compound may exist.
4.3 Optimisation of P450 expression in primary culture
Many attempts have been made to improve the levels of P450 expression in
cell culture models and to extend the lifetime of the P450 expressing hepatocytes.
Decad et al (1977) reported P450 expression close to i n vivo levels, measured by
the extent of Aflatoxin B1 metabolism, by the addition of a complex hormone mixture
comprising testosterone, thyroxine, hydrocortisone, estradiol, glucagon, insulin,
linoleic acid and oleic acid to serum-free medium. Each component was found to be
necessary for maximum P450 expression and was added at the lowest effective
concentration. Such complex culture conditions make reproducibility of experiments
extremely difficult, however, as no two hepatocyte cultures are identical and each
has a different hormonal requirement and therefore a different level of P450
expression. Paine (1990) demonstrated that the addition of 0.5mM metyrapone to
the culture medium helped to minimise P450 loss.
The most significant advance in the maintenance of P450 activities in
culture, however, came with the addition of components of the extra-cellular matrix
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to the culture media. Lindblad et al (1991) demonstrated that the in vivo
hepatocellular phenotype, both morphological and functional, was influenced by the
nature of the collagenous substratum on which the cells were grown, with Matrigel
being the most successful at potentiating P450 expression. Matrigel, a reconstituted
basement membrane extracted from the Engelbreth-Holm-Swarm sarcoma
(Kleinman et al. 1982) contains multiple attachment factors including laminin,
type IV collagen and proteoglycan. Cells cultured on this matrix attach but do not
spread and thus maintain their differentiated phenotype. Collagen-type matrices e.g.
Vitrogen, do not maintain P450 expression as well as Matrigel, and other
differentiated functions such as albumin production are also lost (Schuetz et al.
1988). It had previously been proposed (Wiebel et al. 1980) that there is a
correlation between the ability of cultured hepatocytes to synthesise P450 and their
degree of differentiation. Schuetz et al (1988) drew the conclusion from these data
that cells grown on Matrigel are maintained in a more differentiated state.
Co-culturing adult rat hepatocytes with another rat liver epithelial cell type
also potentiated P450 expression and inducibility (Guguen-Guillouzo et al. 1983;
Beaue et al. 1984). Cells were maintained in a differentiated state, as assessed by
their capacity to secrete albumin, for up to several weeks, without the addition of
hormonal supplements or the use of collagenous substrata. Aflatoxin metabolism
by primary hepatocytes, usually undetectable after 48 hours in culture, was still
easily measurable on Day 7 in a co-culture of the hepatocytes with another cell type.
Donato et al (19911 studied a number of epithelial cell lines to determine which was
the most suitable to form functional co-cultures with rat hepatocytes. The candidate
cell line had to have no endogenous drug metabolising activity, be compatible with
the growth requirements of the hepatocytes and be capable of forming a stable
monolayer in the absence of serum. Monkey kidney MS cells proved to the most
successful at maintaining mono-oxygenase activities in co-culture, achieving 50%
of the initial value. These results suggest that both specific cell-cell interactions and
an extra-cellular matrix are needed to prevent rapid phenotypic changes in cultured
hepatocytes. Interestingly, the levels of Phase II enzymes (UDP-glucuronosyl
transferases and glutathione S-transferases) remained constant throughout the
period of study in both pure and mixed cultures.
The mechanisms by which non-parenchymal cells support the expression of
differentiated functions of hepatocytes in co-culture are not fully understood,
although several mechanisms have been proposed. Goulet et al (1988) proposed that
the non-parenchymal cells release soluble factors into the media thus conditioning it
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for hepatocytes, while it has been demonstrated (Clement et al. 1984; Morin &
Normand, 1986; Goulet et al. 1988) that these additional cells synthesise
components of the extra-cellular matrix which are then deposited around the
hepatocytes. This is in agreement with the findings of Guguen-Guillouzo et al
(1983), who report that this production of insoluble extracellular material is the
key function of co-cultures. Wright & Paine (1992) attempted to mimic cell
density, cell-cell interactions and interactions with the extra-cellular matrix by
culturing precision cut liver slices (250pm, 10 cells thick), but these also lost
P450 expression after the first 24 hours in culture. DMSO (2% (v/v)) has been
shown to protect against de-differentiation and loss of cytochrome P450 activity
(Villa et al. 1991) although hepatocyte toxicity can become a problem at this
concentration of solvent. DMSO increases the levels of 8-aminolaevulinic acid
dehydratase, an enzyme necessary for heme biosynthesis. P450 loss has been
associated with shortage of heme due to reduced levels of this enzyme in culture. It
has also been proposed (Bissell & Guzelian, 1975) that loss of functional P450
expression is due to a concomitant rise in the activity of haem oxygenase, although
this does not seem to be a general phenomenon. Paine & Legg (1978) have shown that
high levels of P450 activity can be maintained along with high haem oxygenase
activity in a primary culture of rat hepatocytes.
Immortalised differentiated cell lines have been created from primary
cultures established from tissues from transgenic mice bearing the SV40
temperature-sensitive large T-antigen gene (Yanai et al. 1991). Hepatocytes from
these animals had constitutive CYP1A1 expression which was 3-methylcholanthrene
inducible and stable after 6 months in culture. Similarly, Bayad et al (1991)
created the cell line SVHepB^ from the SV40 transformation of adult rat hepatocytes.
These cells also had a greatly extended lifespan (> 50 subcultures), y-
glutamyltransferase, a marker enzyme in dedifferentiated hepatocytes, was only
present at the limit of detection in these cells, and the hepatospecific tyrosine
aminotransferase was expressed at i n vivo levels.
4.4 Continuous culture
The creation of immortalised cell lines has a number of advantages over
primary cultures. Cells from a much wider range of species and tissues can be
analysed, and a very wide range of human cell lines is available. Reproducibility of
results is much easier to achieve as, in most cases, the profile of gene expression of
a particular cell line remains constant within a defined passage range. It has proved
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possible to establish cell lines from patients with many different stages of disease
and often also from the same patient before and after drug treatment. This is of
obvious importance in the study of enzymes involved in both drug metabolism and
drug resistance. P450 expression in cell lines is low, however, and this has been
attributed, in part at least, to the ability of cell lines to methylate genes which are
not necessary for their survival, thus blocking transcription (Antequara et al.
1990). In many cases, when cell lines retained endogenous P450 expression, it did
not prove possible to modulate the levels of these genes by exposing the cells to
"classical" inducing agents such as phenobarbital and 3-methylcholanthrene.
Although many cell lines have been established from extra-hepatic tissues, P450
expression in vivo in these tissues is low in comparison to liver, and thus becomes
very difficult to detect in the cell culture environment. Again, P450 inducibility
appeared to be related to the degree of differentiation of the cells. Corcos & Weiss
(1988) studied a series of rat cell lines derived from the Reuber H35 hepatoma.
These cells expressed P450s from the CYP1A family in both differentiated and
undifferentiated cells, while phenobarbital-inducible forms were only detectable in
differentiated cells.
P450 expression has been studied in five cell lines during this project.
HepG2 (Knowles et al. 1980) and Hepa-1 (Bernhardt et al. 1973) are human and
mouse hepatoma lines respectively. HepG2 is a highly differentiated human hepatoma
cell line which has retained many of the specialised functions normally lost by
hepatocytes in culture. Active inducible P450 has been reported in this cell line by a
number of groups, but only at 10% of the activity of freshly isolated human
hepatocytes (Dawson et_al, 1985; Grant et al. 1987, 1988). The overall metabolic
profile of these cells is, however, thought to be significantly different from human
liver (Grant et al. 1987,1988), although the levels of NADPH cytochrome c
reductase, UDP- glucuronosyl transferase and glutathione S-transferase proteins
were very similar to i n vivo levels. DMSO and 8-aminolaevulinic acid were again
found to support P450 expression in these cells, but their influence was very
dependent on the media used. Foetal calf serum had a very profound inhibitory
influence on P450 expression (Doostdar et al. 1991).
The mouse hepatoma line, Hepa-1, has constitutive aromatic hydrocarbon
hydroxylase activity which is polycyclic aromatic hydrocarbon inducible, mediated
through the Ah receptor. Israel et a] (1985) demonstrated functional
"superinduction" of CYP1A mRNA in this cell line in the presence of cycloheximide,
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indicating that induction is regulated at the level of transcription. Interestingly, in
agreement with our studies in DBA mice, Karenlampi et al (1989) reported that
this activity is very weakly inducible by phenobarbital, indicating that
phenobarbital can act as a weak ligand for the Ah receptor. This effect was not
observed in the rat.
MCF7 (Soule et al. 1973) and HT29 (Fogh & Trempe, 1975) were chosen as
representative human breast (MCF7) and colon (HT29) tumour cell lines to provide
an j_n vitro comparison with the xenograft tumours described in Chapter 5. P450
expression has previously been reported in both these cell lines. Pasenen et al
(1988) described CYP1A1 expression in human MCF7 cells. Aromatic hydrocarbon
hydroxylase (AHH) activity, characteristic of CYP1A expression, was inducible in
this cell line on treatment with TCDD, although the presence of a functional Ah
receptor could not be detected. MCF7 cells are oestrogen receptor positive.
Interestingly, the subline AL-1, created from MCF7 cells but lacking oestrogen
receptor expression lacked TCDD inducibility. These workers also demonstrated that
there was considerable variation in constitutive P450 expression in a panel of
breast tumour cell lines. This is in agreement with an i n vivo study (Forrester et al.
1990) which described P450 expression in normal and tumour breast tissue. P450
expression in colon cell lines has also been previously described. White et al
(1991) identified CYP1A1, CYP2C9 and CYP2E1 expression in LS174T cells,
although CYP2E1 was only detectable by PCR amplification of mRNA from these cells.
In a previous report, Hammond & Strobel (1990) had measured P450 reductase
activity in the same cell line.
C3H10T1/2 cells, fibroblasts established from C3H mice embryos
(Reznikoff et al. 1973 a,b) have constitutive P450 expression. This line proved to
be the best jm vitro model to study P450 regulation by xenobiotics. The cell line was
created for the study of chemically induced malignant transformation by polycyclic
hydrocarbons i.e. the ability of cells transformed in culture to induce tumours on
inoculation into suitable recipient animals. These cells are unusually stable after
prolonged culture and do not transform spontaneously. On treatment with 5-
azacytidine however, the fibroblasts transform to yield a mixed population of
contractile striated muscle cells, biochemically transformed adipocytes and
chondrocytes, with the proportion of each dependent on the concentration of the
inducing agent (Taylor & Jones, 1979). The wild-type cells exhibit post-confluence
inhibition of cell division, which is abolished on transformation, providing an easily
detectable morphological marker for differentiation. Wild-type cells (Figure 4.4.2)
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grow with a fibroblast-like morphology with long cytoplasmic processes in sparse
cultures. When confluent, they form flat even monolayers and appear epitheloid.
Figure 4.4.2 C3H10T1/2 cell morphology
(A) sub-confluent C3H10T1/2 cells, illustrating characteristic fibroblast
morphology with long cytoplasmic processes
(B) confluent cells
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As polycyclic aromatic hydrocarbons e.g. benzanthracene, benz(a)pyrene
(B(a)P), are metabolised by the P450 system, it seemed reasonable to expect P450
to be present and active in the C3H10T1/2 cell line. Indeed, Gehly et al (1 979)
reported the presence of cytochrome P450, responsible for the metabolism of
B(a)P, in this cell line. Exposure to this compound also resulted in the induction of
AHH activity in these cells. A later report, however, suggested that CYP1A1, the
major PAH-inducible isozyme was not present in the cell line (Pottenger & Jefcoate,
1990). The mouse hepatoma line, Hepa-1, has been shown to express CYP1A1 and to
be regulated by polycyclic aromatic hydrocarbons, and was therefore used for
comparison. It was discovered that a different metabolite profile was produced in
each cell line on exposure to benzanthracene. As both BA and TCDD induce AHH
activity in Hepa-1 cells, but 3-MC, the "classical" inducer does not, Okey et al
(1983) suggested that there may be some inhibitory factor present in this cell line
which prevents 3-MC binding to the Ah receptor. Alternatively, the Ah receptor
itself may be mutated in some way such that binding is no longer possible. Further
attempts to characterise the P450 (McGregor et al. 1991; Pottenger et al. 1990,
1991) strongly suggest that the isozyme expressed in the C3H10T1/2 cells is in
fact a member of the Cyp2a subfamily, with a molecular weight of 55kD. As this
protein is inducible by both BA and TCDD, it may well represent a novel protein. We
have demonstrated that the level of expression of this protein is also inducible on
treatment with TCPOBOP.
4.5 Characterisation of P450 expression in C3H10T1/2 cells
4.5.1 Western blot analysis
Western blot analysis of total cellular protein from C3H10T1/2 cells was
carried out using a panel of antibodies to purified P450 proteins representative of
each gene family (Figure 4.5.1). In agreement with Pottenger et al. the results
demonstrated that Cyp2a protein was present constitutively in this cell line, as
measured by a cross-reacting band at 55kD. This finding is in contrast to the report
of McGregor et al. who reported that the constitutively expressed protein had a
mobility of 48kD. In agreement with McGregor et al. however, very weak cross-
reactivity was also observed using an antibody to CYP1A2, when the sensitive ECL
detection system was used. The mobility of this protein, however, was much greater
than the rat and mouse CYP1A proteins and there was therefore some doubt as to
whether it did in fact represent P450 protein. Two further fibroblast lines (HF and
GCS2) were also analysed for P450 expression (Figure 4.5.1, tracks 1 and 2) to
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determine whether the ability to maintain P450 expression was related to the cell
type studied or extent of differentiation of the cell line, but no expression was
detected with any of the antibodies used.
Figure 4.5.1 Cyp2a expression in fibroblast cell lines
Cyp2a
S 30 30 15 30|ig
GCS HFF C3H10T1/2
Tracks 1 and 2 contain protein from GCS and HFF cells respectively (30pg), both of
which are human fibroblast cell lines. Tracks 3 and 4 contain protein from
C3H10T1/2 cells, loaded at 15 and 30pg per track, respectively. S = purified rat
CYP2A protein (0.8 pmol).
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4.5.2 Immunohistochemical analysis of Cyp2a expression in wild-type C3H10T1/2
cells
Constitutive expression of Cyp2a protein in C3H10T1/2 cells. There is granular
cytoplasmic immunostaining visible in cells grown as a monolayer and fixed in
methanol/acetone (50 : 50)
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4.5.3 Northern blot analysis
Northern blot analysis was carried out on mRNA isolated from C3H10T1/2
cells, using a full-length cDNA probe specific for the CYP2A subfamily (Figure
4.5.3). A single mRNA transcript (1.75kb) was found to cross-hybridise with this
probe. This mRNA species had the same mobility as mouse liver Cyp2a mRNA. Probes
for the other P450 families were not found to cross-hybridise.
Figure 4.5.3 Cyp2a mRNA expression in C3H10T1/2 cells
•» <1-75kb
1 2
Track 1 contains mouse liver RNA (10pg), and track 2 RNA isolated from
C3H10T1/2 cells (20pg). The size of the cross-hybridising transcript (1.75kb)
was determined from a marker track (not shown) containing RNA species with a
range of molecular weights.
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These data strongly suggest that the protein expressed in the C3H10T1/2 cell
line is a member of the Cyp2a subfamily. This protein however, appears to be
distinct from Cyp2a-5, the isozyme responsible for coumarin hydroxylase activity
in the mouse, which has a molecular weight of 48kD and is inducible by pyrazole. A
polyclonal antibody specific for Cyp2a-5 (Lang et al. 1989) did not cross-react
with the P450 expressed in this cell line, and the level of protein expression was
not affected by pyrazole treatment. The precise identity of this expressed protein has
yet to be determined, but it is hoped that reverse transcriptase PCR on the isolated
RNA will lead to sufficient sequence information to determine whether the protein is
indeed a member of the Cyp2a subfamily.
4.6 Xenobiotic regulation of P450 expression in mammalian cell lines
4.6.1 Assessment of cytotoxicity
The first step in the assessment of P450 induction by TCPOBOP, or any of the
other compounds tested, was to determine the inherent cytotoxicity of the test
compound on the candidate cell line, in order that the maximum non-toxic dose of
inducing agent could be administered. This was assessed using the MTT assay.
Experimental conditions were optimised by constructing a growth curve for each cell
line used before drug treatment was begun. It was important to ensure that the cells
were in logarithmic phase at the time of exposure to drug i.e. not so sparse that they
could not tolerate drug treatment, yet not so dense that they would reach confluency
before the end of the assay, thus inhibiting cellular metabolic reactions.
Cells were plated in a microtitre plate at a range of concentrations and
incubated for 4 days, without re-feeding, to mimic the conditions of the MTT assay.
2 Opl of serum-free media was added to each well on Day 2 to represent the addition
of drug. On Day 5, 50pl of MTT was added to each well and the absorbances
corresponding to the formation of blue formazan crystals measured at 540nm and
plotted as a function of cell density. A representative growth curve for the
C3H10T1/2 cell line is shown in Figure 4.6.1.
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Figure 4.6.1 C3H10T1/2 cells growth curve
Cells / well
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The relationship between cell density and OD540 approximated to linearity
over the range of cell densities studied, indicating that the cells were metabolically
active at each concentration. On visual inspection of the plates, however, the cells
plated at higher densities had reached confluency before the end of the assay and were
therefore excluded from further studies. The cell density chosen for each MTT assay
was a function of the growth rate of each individual cell line. Plating densities for
each cell line tested are summarised in Table 4.1.
Table 4.1: Cell plating densities for the MTT assay
Cell line Platina densitv
Hepa-1 2 x 103 cells/well
Hep G2 1 03 cells/well
MCF7 1 03 cells/well
HT29 1 04 cells/well
C3H10T1/2 1 03 cells/well
To assess the toxicity of TCPOBOP, cells were treated with the drug at a range
of concentrations. Stock drug was prepared in DMSO at 10" 3M. This was the
maximum solubility which could be achieved in any of the organic solvents or
solvent combinations tested. When the drug was added to aqueous media, however,
re-crystallisation resulted in the deposition of a fine layer of TCPOBOP crystals on
the cell monolayer. The maximum possible solubility in aqueous media was found to
be 10" 5M, and this concentration was therefore used in all subsequent experiments.
At this concentration, no toxicity was observed to any of the cell lines tested. As an
example, the effect of TCPOBOP on C3H10T1/2 cells is shown in Figure 4.6.2
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Figure 4.6.2 TCPOBOP administration to C3H10T1/2 cells
[drug]
At the highest administered concentrations, only slight toxicity (-90%
survival) was observed, but this slight decrease in cell survival was also noted on
the addition of solvent alone. As the drug began to re-crystallise almost immediately
at this concentration, however, it was not possible to accurately determine the actual
concentration of drug to which the cells were exposed.
When TCPOBOP was administered to cultured liver cells, marked cellular
proliferation was noted, even at low doses of the drug (Figure 4.6.3).
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Figure 4.6.3 TCPOBOP causes cell proliferation in hepatoma cell lines
[drug]
The effect was particularly pronounced in the Hep G2 cell line, and was not
observed in non-liver derived lines. These findings are in agreement with the
proliferative effects of TCPOBOP discussed in Chapters 3 and 6.
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4.6.2 Induction of P450 expression by TCPOBOP
TCPOBOP administration (10" 5M) to C3H10T1/2 cells resulted in induction
of the constitutively expressed "Cyp2a" protein. Hepa-1 cells also expressed a
protein with the same molecular weight and immunological cross-reactivity but this
protein was not inducible by TCPOBOP (Figure 4.6.4). Dexamethasone and
phenobarbital had no effect on Cyp2a expression in these cell lines. Hep G2, MCF7
and HT29 did not have detectable constitutive or inducible Cyp2a expression.
Constitutive Cyp2b expression was not detectable in any of the cell lines, and was not
inducible on treatment with dexamethasone, phenobarbital or TCPOBOP. In contrast
to a previous report (Karenlampi et al. 1991), phenobarbital induction of Cyp1a1
expression in Hepa-1 cells was not observed.
Figure 4.6.4 Cyp2a expression in cell lines - effects of TCPOBOP
Cyp2a
WT 3D 3W WT 3W WT 3W WT 3W
TC TC TC TC TC
C3H10T1/2 MCF-7 HT-29 Hepa-1
Constitutive (WT) Cyp2a expression was determined in four cell lines -
C3H10T1/2, MCF-7, HT-29 and Hepa-1 and following TCPOBOP treatment (10*
5M) for 3 days (3D) asnd 3 weeks (3W)
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4.7 TCPOBOP effects in primary culture
Hepatocytes were isolated from adult male Alderley Park Swiss mice (20-
25g) by in situ perfusion of the liver with collagenase as described by Mitchell et al
(1989). Phenobarbital (PB) dissolved in 0.9% NaCI and TCPOBOP dissolved in
dimethylformamide (DMF) were added to the medium and hepatocytes exposed for 3
days to 2mM PB; 2, 10, or 50mm TCPOBOP or vehicle alone (0.9% NaCI or 0.25%
DMF). Observation under phase contrast microscope showed the presence of few or
numerous crystal needles in the culture medium containing 10 and 50mM TCPOBOP
respectively, indicating the limit of solubility of this compound in CL15 medium.
Phenobarbital was soluble at all the concentrations tested. Western blot analysis
with Cyp2b antisera demonstrated that both PB and TCPOBOP treatment lead to
an increase in the expression of Cyp2b protein. A single band was
detected which had the same mobility as mouse liver Cyp2b protein (Figure 4.7).
Figure 4.7 The effect of PB and TCPOBOP on Cyp2b expression in mouse hepatocytes
in primary culture
Cyp2b
00 2 2 10 10 50 50 0022 IIB1 IIB2
\ i\ /
TCPOBOP (pM) PB (mM) S S
A primary monolayer culture of hepatocytes was established by collagenase
perfusion of the livers of Alderley Park Swiss mice. The cells were treated with
either 2mM phenobarbital (PB), TCPOBOP (2, 10 or 50mM) or vehicle alone
(0.9% NaCI, 0.25% DMF). Cell sonicates were run in duplicate on SDS-PAGE using
a 9% separating gel and Cyp2b isozyme content determined by Western blot analysis.
IIB1 and IIB2 are rat CYP2B1 and CYP2B2 standards.
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4.8 Conclusions
The experiments described in this section illustrate the limitations of cell
culture as a model for studying P450 expression and regulation. Although primary
culture models can often support inducible P450 expression, there are often many
significant differences in the expression and regulation of P450 genes in culture and
in vivo. TCPOBOP, which has been shown to be both a potent and pleiotropic inducer
of murine hepatic P450 expression proved to be relatively ineffective in influencing
P450 expression in cell lines. An exception to this, however, was the cell line
C3H10T1/2, which has constitutive P450 expression and which was inducible on
exposure of the cells to TCPOBOP. This, together with the other experiments
described in this chapter, demonstrated that it was possible to induce only
constitutively expressed P450 proteins in cultured cell lines, suggesting that those
cell lines which did not express P450 constitutively had lost the inherent capacity to
do so. The precise identity of the P450 expressed in C3H10T1/2 cells has yet to be
determined, but our results strongly suggest that it is a member of the Cyp2a
subfamily and may represent a novel protein. Experiments are currently underway
to clone and sequence this gene from reverse transcriptase PCR amplification of RNA
from cells treated with TCPOBOP. GST expression, which has been shown to be
relatively unaffected by the culture environment, was also influenced by TCPOBOP
in this cell line (not shown).
There have been many reports that cells in culture lose their differentiated
phenotype very quickly (Grant et al. 1987), with a concomitant loss of tissue-
specific functions. This is particularly true when a particular cell type is
immortalised as an established cell line. The demonstration by Antequara et al.
(1990) of methylation of CpG islands in genes which are not necessary for cell
survival fits well with the loss of functional P450 expression.
Some valuable information can, however, be gained from these models.
Transfection experiments have been widely used to study in isolation the regulation
of and the range of substrates metabolised by a particular gene. Battula et al (1 987)
were the first to report the vaccinia virus controlled expression of mouse P-|-P45 0
and P3-P450 (Cyp1a-1 and Cyp1a-2). These workers demonstrated that the
transfected clones were translocated to the microsomal membranes, complexed with
heme and adopted a configuration suitable for interaction with NADPH and reductase.
As a result, functional protein was produced. Similar experiments have lead to the
stable expression of a number of P450 genes. Reproducibility between experiments
is good, particularly when a large stock of DNA coding for the gene of interest is
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prepared and used in each successive experiment. Culture conditions (number of
cells plated, media composition, etc.) can be precisely defined and transfection
efficiency monitored by co-transfection with a reporter gene such as luciferase.
Hansen et al (1989) transfected the rat CYP2B1 gene, the major phenobarbital
inducible form, into C3H10T1/2 cells which have no constitutive Cyp2b expression.
The activity of 2-acetyl amino fluorine (2-AAF) which requires metabolic
activation by CYP2B1 was markedly increased in the transfected cells compared to
the wild-type controls. Additionally, Northern blot analysis using the rat CYP2B1
cDNA as a probe, showed cross-reactivity with the transfected cells only.
These studies are of particular importance in the study of human P450 genes.
Aovama et al (1989 a,b) transfected human CYP1A2 into human hepatoma cells (Hep
G2) which had no constitutive expression. This resulted in sufficiently high levels of
expression that the P450 could be quantitated spectrophotometrically. Mouse
Cyp1a2 was similarly expressed and thus comparisons could be made between the
activities of these genes towards a range of substrates. The results obtained
illustrated significant differences in the catalytic activities of orthologous P450s
from different species. Again, the results of these experiments were highly
reproducible - large viral stocks were prepared in each case and stored between
experiments. In similar experiments, other workers (Yamano et al. 1989) have
studied the regulation of NADPH-P450 oxidoreductase.
Although these and similar experiments have proved to be a useful model with
which to determine the j_n vitro function of a particular P450 gene, it is important
to realise that the j_n vivo role may be significantly different, and may be masked
altogether by the activities of many other genes which are constitutively expressed
at higher levels. Gene expression j_n vivo is controlled by a complex network of
hormones and other metabolic factors which it is not possible to mimic in a cell
culture model. In addition, isolated transfection experiments involve the expression
of a single clone isolated from one individual or mouse and thus make no allowance
for any inter-individual variability in the levels of expression or activity of the
transfected gene. Genetic polymorphisms, a relatively common event in the genes
coding for the drug metabolising enzymes, are also unlikely to be detected using this
approach. These experiments have, however, proved invaluable in determining the
role of a particular human P450 gene, without competitive binding or metabolic
modification of the substrate by another P450 isozyme, which is often a
complication in similar studies in animal models.
P450 expression can be maintained much more successfully in primary
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cultures. This is of limited value, however, in the study of human gene expression,
as human liver samples are not easily obtained. When it does become possible to
obtain human tissue, the enzyme profiles within the tissue are often distorted by the
disease state of the patient and it is virtually impossible to obtain true "control"
samples. Primary cultures of rodent hepatocytes have, however, been widely used to
study P450 expression. Long-term induction experiments are, of course, not
possible in this system, as the life span of the cells defines the maximum length of
any experiment. Indeed, both phenobarbital and TCPOBOP induced Cyp2b expression
in mouse hepatocytes demonstrating that, although the action of these compounds may
be influenced Lq vivo by factors such as pituitary hormones, both can exert a direct
effect on hepatic gene expression. Although the considerable variability in gene
expression in primary cultures created from different animals makes
standardisation of experimental conditions difficult, it is a better representation of
the i n vivo situation than that achieved using established cell lines.
In conclusion, therefore, the regulation of P450 genes may be studied to a
limited extent in cultured cells, although significant differences from the j_n vivo
patterns of gene expression are often observed. It is therefore important to validate
the results obtained from a cell culture model, wherever possible, by i n vivo studies
in the intact animal.
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Chapter 5: Regulation of cytochrome P450 expression in human
tumour xenografts
5.1 Introduction
Due in part to the limited availability of tissue for study, it is extremely
difficult to identify the factors which regulate the expression of human cytochrome
P450 genes, particularly in extra-hepatic tissues. As many anti-cancer drugs are
dependent on P450-mediated activation to exert their anti-tumour effects or,
alternatively, are metabolised to a less active form by cytochrome P450, it is
clearly important to identify the factors which control the ]_n vivo expression and
regulation of this ubiquitous class of enzymes in man. The P450 system is thought to
have evolved as an adaptive response to environmental insult and it therefore seems
inherently unlikely that the defence systems, and thus P450 expression, of any two
different organisms e.g. rat and man would be identical. Significant differences in the
expression and regulation of P450 genes between species are indeed observed. It is
therefore difficult to extrapolate the results obtained in one animal model to another.
As discussed in the previous chapter, the use of cells in culture as a model to study
P450 regulation is also of limited value, and it is therefore important to establish an
j_n vivo model where the expression and regulation of human P450 genes can be
assessed.
In this chapter, the development of a model system to address this problem is
described, involving the use of human tumours grown as xenografts in immune
deficient mice. This model has a number of applications:
(a) Constitutive tumour P450 levels can be measured directly - the intra-tumour
level of P450s involved in drug activation is more relevant that the hepatic
concentration in terms of determining local concentrations of active drug
(b) A wide range of tumour types can be analysed
(c) A large number of tumours from the same tissue can be analysed simultaneously,
thus providing information on any inter-individual variation in enzyme expression
5.2 The xenograft model
The xenograft model, where human tumours are implanted sub-cutaneously
in the flanks of immune deficient mice and continue to grow i n situ, has been widely
used to determine the response of human tumours to therapy (Berger et al. 1991). A
number of distinct tumour types and a wide variety of chemotherapy protocols have
been assessed using this model. Inter-individual variations in response can be
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evaluated by establishing a panel of xenograft tumours from the same tissue type,
while the onset of drug resistance can be monitored by assessing the tumours before
and after drug treatment.
Previous studies to evaluate the anti-tumour effects of new drugs or drug
combinations involved the use of transplantable animal tumours such as the Walker
256 rat carcinosarcoma or murine L1210 leukaemia. These tumours, however,
bore only a very vague histological and kinetic resemblance to the behaviour of
human tumours (Mihian et al. 1974; Cobb & Mitchely, 1974; Steel, 1978).
Early studies using human tumour xenografts investigated whether these
tumours retained human characteristics and behaviour after serial passage in mice.
The results were very encouraging and related to a large variety of tumour types.
Berenbaum et_ai (1974) transplanted 116 tumours comprising melanoma, ovarian,
bladder, gastrointestinal, breast and uterine carcinoma into thymectomised,
irradiated and anti-lymphocyte serum-treated mice and obtained established
xenograft tumours from each tumour type. The histological appearance and
characteristics of each tumour were retained in every case examined, as were
differentiated functions such as mucin and keratin production (Shimosata et al.
1976). In addition, the response of these tumours to chemotherapy showed the same
heterogeneity in response as was observed in the donor patients. Selby et al (1 9 80)
carried out a comprehensive study of a panel of xenograft tumours by histology,
histochemistry, electron microscopy, chromosome analysis, immune fluorescence
and measurement of growth rate and mitotic counts, and reported that, in all cases,
the characteristics of the tumour of origin were retained. In addition, the
chemotherapeutic response of a series of patients with bronchial carcinoma was
compared to the response of the same tumours established as xenografts in immune
suppressed mice (Shorthouse et al. 1980). Bronchial carcinoma was chosen as it
demonstrates a comparatively wide spectrum of clinical response to chemotherapy.
Twenty one distinct responses in sixteen individual tumours were very similar.
These workers, however, emphasised that, due to the time required first to establish
the tumour as a xenograft and to carry out subsequent drug testing, the xenograft
model is of limited applicability in predicting appropriate chemotherapy for
individual patients, although it is of great benefit in screening potential new
therapeutic agents. This model has also been used to determine the response of human
tumours to radiotherapy. For example, Rofstad (1992) demonstrated that the
heterogeneous radiation sensitivity of a series of xenograft melanoma tumours were
representative of the original tumour response.
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More recent studies have concentrated on establishing xenograft tumours
representative of a particular disease state, such as malignant mesothelioma
(Chahinian et al. 1991) or cervical carcinoma (Han et al. 1991) and to assess the
response of these tumours to a particular treatment regimen. Nio et al (1991)
described the effects of co-administration of several independently effective
anticancer drugs such as cisplatin and 5-fluorouracil to a number of digestive organ
xenografts. These solid tumours are notoriously difficult to treat as they are often
inherently resistant to chemotherapy. The co-administration of anticancer drugs in
most cases, however, did not lead to an enhanced anti-tumour effect and often lead to
increased side effects. Satta et al (1991) described the establishment of multidrug
resistant gastric and colon xenografts by intra-tumoral injections of adriamycin.
Systemic (intra-peritoneal) injections did not, however, lead to establishment of
the MDR phenotype. In addition, an elegant study (Pearson et al. 1991) demonstrated
the reversal of drug resistance in a MDR-expressing human colon cancer xenograft
by administration of the anti P-glycoprotein monoclonal antibody MRK-16. In a
similar study (Rittmann-Grauer et al. 1992), human melanoma xenografts were
treated with a series of monoclonal antibodies to P-glycoprotein, resulting in the
reversal of resistance to the Vinca alkaloids actinomycin D, vincristine and
vinblastine. This approach, using monoclonal antibodies to chemosensitise
previously drug resistant tumours is particularly attractive. The antibodies used are
highly specific for tumour cells and thus produce fewer side effects than other small
molecule modulators of MDR expression. In addition, this specificity leads to a longer
residence time at the tumour site and a longer serum half-life. Resistance to
adriamycin, however, was not reversed by antibody administration, suggesting that
monoclonal antibody/P-glycoprotein interaction may result in a minor
conformational change which affects the transport of certain drugs but not others.
Adriamycin sensitivity was determined in a series of xenograft tumours of
mixed origin and the response to drug administration correlated with the expression
of MDR, GST n and topoisomerase II, the expression of which has been implicated in
drug resistance (Kim et al. 1992). These workers demonstrated that there was a
significant relationship between the level of Topo II mRNA expression and tumour
sensitivity to adriamycin. In contrast, no relationship was apparent between the
levels of MDR and GST n expression and adriamycin sensitivity. There has been
considerable controversy in recent literature over the level of expression of these
genes within human tumours and their clinical response to chemotherapy (Ball et al.
1990; Moscow et al. 1989; Samuels et al. 1991).
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For a number of reasons, tumours can undergo phenotypic change and hence
have altered drug sensititvities when removed from source. Many tumours are
composed of heterogeneous cell populations, the biological propoerties of which can
vary widely. When challenged by a new enviromment e.g. when grown as a xenograft,
selective pressures may lead to the dominance of one of the subpopulations (Heppner,
1974). Tumour cells are often inherently genetically unstable, and thus extensive
genotypic and phenotypic changes can occur during growth in a new environment. In
addition, drug sensitivity is influenced by cell cycle and the kinetics and distribution
observed j_n situ may not necessarily be reproducible in a xenograft model. To
address this problem, McQueen et al (1991) examined the stability of several
genetic lesions in a series of human colorectal carcinoma xenografts. Cell lines
established from the same source commonly acquired genetic rearrangements during
culture (Brattain et al. 1983; Park et al. 1987). Heamatoxylin and Eosin (H & E)
stained parrafin sections of both primary tumour and xenografts, however, showed
that the original histological pattern for each primary tumour was conserved
through serial passage. In addition, the xenograft tumours had individual but stable
expression of several of the oncosupressor genes thought to be important in the
initiation of colorectal cancer.
In summary, therefore, the xenograft model has been validated in the study of
the response of human tumours to drug treatment. There are no reports, however, of
the mechanisms of drug action in these xenograft tumours. The intra-tumour levels
of expression of drug metabolising enzymes is central to the efficacy of many
administered drugs which require j_n situ bioactivation to exert their anti-tumour
effects. In this chapter, the intra-tumour expression of one of the most important of
these enzyme sysytems, cytochrome P450, is investigated and the modulation of the
levels of expression of these enzymes by the administration of a range of xenobiotic
inducing agents described.
5.3 Characterisation of human P450 expression
Characterisation of human P450 gene expression, particularly in extra-
hepatic tissues, has been greatly hampered by the lack of availability of tissue for
analysis. Many of the hepatic genes which have been isolated have been identified by
screening human hepatic libraries with cDNA or antibody probes to the analagous
gene families in mouse and rat. Although this approach is very useful in determining
the presence (or absence) of a homologous human gene in a particular tissue, it
provides no information about the i n vivo regulation of gene expression. Traditional
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purification procedures are subject to the same limitations. As discussed in Chapter
4, cell culture models have limited applicability to the study of P450 gene
regulation, although recent reports describe primary human hepatocytes cultured on
the basement membrane "Matrigel", in which P450 expression can be modulated by
foreign compounds (Burger et al. 1992). Whether these experiments are
physiologically relevant has yet to be determined. Vaccinia virus mediated
expression of human P450 cDNAs in mammalian cells has, however, proved to be a
convenient and reproducible way to study the function of these genes (Battula et al.
1987; Estabrook et al. 1991). This approach is particularly applicable to the
isolation of low abundance proteins.
There are many similarities, but also some significant differences in the
regulation and substrate inducibility of P450 genes between rodents and man
(Gonzalez, 1990). For example, many of the sex differences observed in the
expression of several P450 genes in the rat are not seen in the corresponding human
genes. In addition, a number of the human P450 genes exhibit a genetic
polymorphism in their expression, which is not seen in the corresponding animal
models. These will be described more fully in Section 5.3.1.
The human P450 genes which have been characterised to date are summarised
in Table 5.1. Current knowledge on the regulation of the individual P450 isozymes is
summarised below:
CYP1A: To date, two members of the CYP1A family have been reported, CYP1A1 and
CYP1A2. Members of the CYP1A subfamily are characterised by their inducibility
following exposure to polycyclic aromatic hydrocarbons (Gonzalez, 1990), mediated
by the inducing agent binding to a cytosolic protein, the "Ah receptor". CYP1A1 has
not, as yet, been purified from human tissues. Screening human tissue libraries
with a cDNA probe to the rodent CYP1A gene, however, yielded a 512 amino acid
protein which, although detectable in lung (McLemore et al. 1990; Omiecinski et al.
1990), lymphocytes (Jaiswal et al. 1985; Song et al. 1985) and placenta (Song et
a], 1985) was undetectable in human liver. The expression of CYP1A1 mRNA in the
lungs of cigarette smokers has been correlated with lung cancer incidence
(McLemore et al. 1990; Antilla et al. 1991). Regulation of human CYP1A1
expression seems to be very closely related to the mechanism of regulation in
rodents, where the presence of two cis-acting DNA elements is required (Fujisawa-
Sehara et al. 1986, 1987, 1988; Yanagida et al. 1990). One of these, the inducible
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enhancer XRE (xenobiotic response element) is located upstream of the gene, while
the other, the BTE (basic transcription element) is found close to the TATA box and
acts as a promoter element.
In contrast, CYP1A2 is highly expressed in human liver. The gene is 68%
homologous (amino acid sequence) to CYP1A1 and has a higher molecular weight.
This is in contrast to the situation in the rodent where CYP1A1 is the larger gene.
Large inter-individual variations have been reported in the expression of CYP1A2
(up to 10-fold), but no genetic polymorphisms have yet been identified in the
expression of this gene which could link the level of expression to cancer
susceptibility. Regulation of CYP1A2 expression has been shown to occur both by
transcriptional activation of the gene and mRNA stabilisation (Pasco et al. 1988).
CYP2A: The CYP2A gene cluster in man is tightly linked to CYP2B on chromosome 19
(Miles et al. 1988). Southern blot analysis of CYP2A revealed the presence of 2/3
genes (Miles et al. 1989). The most fully characterised of the genes, CYP2A6, has
been identified as the human coumarin hydroxylase (Miles et al. 1990, Yamano et al.
1990), the human orthologue of the murine Cyp2a-5 gene (Lindberg & Negishi,
1989). Crespi et al (1990) reported that CYP2A6 was active in the metabolism of
Aflatoxin B1, benzo(a)pyrene, N-nitrosodimethylamine (NDMA) and N-
nitrosodiethylamine (NDEA) to mutagenic and cytotoxic products. CYP2A7, which has
94% amino acid homology with CYP2A6 (Davies et al. 1989) has been less well
characterised. Recently, however, a full-length CYP2A7 clone was isolated from a
human genomic cosmid library with a probe comprising a 0.7kB fragment of human
CYP2A6 cDNA (Ding et al. unpublished observations). A core glucocorticoid-
response sequence was identified in the 5'-flanking region of this gene.
CYP2B: Miles et al (1988) isolated 2 distinct CYP2B clones from a human liver
cDNA library, using a cDNA probe to the rat CYP2B1 gene. On further
characterisation, however, these clones were found to be alternatively spliced
variants of the same gene, designated CYP2B6. These workers reported that therer
was considerable inter-individual variation in the level of expression of both the
functional gene and its alternatively spliced variants. Yamano (1989) isolated a
further CYP2B cDNA clone, CYP2B7, which had only 3 nucleotide and 1 amino acid
differences from CYP2B6.
CYP2C: This gene family is thought to consist of at least 3 genes, CYP2C8, CYP2C9
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and CYP2C10, all of which have been partially sequenced. The genes are thought to
have individual but overlapping substrate specificities. The expression of CYP2C9 is
genetically polymorphic, resulting in certain individuals having reduced ability to
metabolise mephenytoin (see Section 5.3.1). This polymorphism is particularly
prevalent in the Japanese population.
CYP2D: Distlerath et al (19851 isolated a P450 from human liver with an apparent
molecular weight of 51,000 and a high catalytic activity towards debrisoquine and
other drugs involved in the debrisoquine/sparteine polymorphism (see Section
5.3.1). This was presumably the same protein described by Gonzalez et al (1988) as
CYP2D6, the human debrisoquine 4-hydroxylase. This enzyme is involved in the
metabolism of many clinically important drugs, such as propranolol and
dextromethorphan (Eichelbaum & Gross, 1990; Meyer et al. 1990). Kimura et al
(1989) identified two further genes, CYP2D7 and CYP2D8, but both had mutations
resulating in their inactivation.
CYP2E: The CYP2E family in humans is represented by a single gene (Song et al.
1986) which encodes a 493 amino acid protein. CYP2E metabolises and is induced by
ethanol administration, catalysing the oxidation of ethanol to acetaldehyde. It is also
inducible by a range of other substrates such as N-nitrosodimethylamine (NDMA),
aniline and acetone. NDMA, which occurs as an environmental pollutant as well as in
food, drink and cigarette smoke, is a potent rodent carcinogen which has also been
implicated in human carcinogenesis. Again, variable levels of CYP2E1 mRNA and
protein have been reported in a panel of human livers.
CYP2F: A cDNA encoding CYP2F1 and an alternatively spliced variant were isolated
from a human lung library by screening with a cDNA probe to human CYP2C9
(Nhamburo et al. 1990). The gene has been localised to human chromosome 19.
Little is known at present about the regulation of this gene family.
CYP3A: At least three CYP3A proteins have been identified in adult human liver,
CYP3A3, CYP3A4 and CYP3A5. CYP3A4 is usually expressed at the highest level and
there is considerable inter-individual variation in the expression of CYP3A3. A
further CYP3A protein, CYP3A7 has recently been isolated from human foetal liver
(Kitamura et al. 1992). The CYP3A7 cDNA was shown to be highly homologous to the
cDNA for CYP3A4, isolated from an adult human liver cDNA library. Rifampicin,
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barbiturates and glucocorticoids are all potent inducers of CYP3A gene expression.
CYP4A: Human CYP4A gene expression has been relatively poorly characterised to
date. A recent report, however, described the isolation of a partial CYP4A clone from
screening a human genomic cDNA library with a full-length rat cDNA probe (Hood et
a], manuscript in preparation). Partial sequencing of this clone demonstrated that it
had 85% nucleotide homology with the rat form, but that homology was confined to
the heme binding region.
Table 5.1 Classification of human P450 genes








































Adapted from Wolf, 1990
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The examples of regulating agents are illustrative only, and are by no means
comprehensive. Individual members of a gene family or subfamily can be regulated
differently and not all members within a gene family respond to the same inducing
agents.
5.3.1 Genetic polymorphisms in human P450 expression
Genetic differences in the expression of carcinogen metabolising enzymes has
long been thought to account, in part at least, for individual susceptibility to cancers
attributable to environmental carcinogens. Several human P450 genes exhibit
genetic polymorphisms in their expression which severely compromises the ability
of certain individuals to metabolise a wide range of drugs.
Spurr et al (1987) demonstrated a polymorphism in the 3' flanking region
of the CYP1A1 gene with the restriction endonuclease Msp1. Attempts have been made
to link this polymorphism to susceptibility to lung cancer (Kawajira et al. 1991),
but the results are equivocal and must be considered in terms of individual tumour
types. Similarly, there is a polymorphism in the 5' flanking region of the CYP2E1
gene with Rsa1 (Watanabe et al. 1990). DNase 1 footprint analysis and gel
retardation assays demonstrated that the polymorphic region interacts with a
transcription factor, probably HNF-1, which leads to differential transcriptional
regulation of the gene.
The best characterised P450 polymorphism, which affects between 5 and
10% of the Caucasian population, is that found in the human CYP2D6 debrisoquine
hydroxylase gene. Affected individuals (poor metabolisers, PMs) have a
compromised ability to metabolise a range of therapeutic drugs including
debrisoquine, propranolol and dextromethorphan, leading to unpleasant side effects
and, in extreme cases, death (Mahgoub et al. 1977). Three gene inactivating
mutations have been identified in the CYP2D6 gene (Gonzalez et al. 1988; Gough et
a], 1990): (a) a G-A transition at the intron 3/exon 4 junction; (b) deletion of the
entire CYP2D6 gene and (c) a base pair deletion in Exon 5. A DNA-based assay has
recently been developed (Gough et al. 1990) to unequivocally identify these defects
and thus identify individuals with the poor metaboliser phenotype.
The polymorphic expression of CYP2D6 has been linked to the incidence of a
number of cancers including lung and bladder cancer, leukaemia and melanoma,
although the small number of samples analysed and limitations in the analytical
methods used have made the results of many of these studies difficult to interpret.
Wolf et al (1992) have recently studied a very large population of cancer patients
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and reported that although there appeared to be no link between the polymorphic
expression of CYP2D6 and lung cancer, a statistically significant increase in the
proportion of poor metabolisers was seen in leukaemia, bladder cancer and melanoma
patients. These results imply either a direct involvement of CYP2D6 in carcinogen
detoxification or linkage of this gene to another "cancer-causing" gene on human
chromosome 22.
The pathogenesis of Parkinson's disease may also be influenced by the
polymorphic expression of CYP2D6. A recent study (Smith et al. 1992)
demonstrated that individuals with the poor metaboliser phenotype were 2.54 times
more likely to develop the disease compared to a control population. I n vitro studies
(Fonne-Pfister et al. 1987) have shown that MPTP (1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine) can be metabolised by CYP2D6. This compound, a
contaminant of synthetic meperidine narcotics, can induce Parkinsonism when
oxidatively metabolised by the mitochondrial monoamine oxidase to its active form
MPP+, the 1-methyl-4-phenyl pyridinium ion (Calne et al. 1983). This ion is
selectively toxic to the substantia nigra. MPP+ can also bind to and be metabolised by
CYP2D6, the expression of which has been identified in this region of the brain
(Nisnik et al. 1990).
Other genetic polymorphisms which have been less well characterised exist
in the CYP3A4 gene (Nakamura et al. 1985) which is responsible for the
metabolism of nifedipine and in CYP2C9, which leads to a compromised ability to
metabolise mephenytoin (Kupfer & Preseig, 1984). This polymorphism is
particularly pronounced in the Japanese population . The expression of CYP2C10,
which metabolises tolbutamide, is also genetically polymorphic. The genetic basis for
these polymorphisms has not yet been characterised.
5.4 P450 expression and carcinogenesis in human breast and colon
tissue
Colorectal cancer remains one of the most common malignancies in Western
countries, and is the second commonest cause of cancer deaths in the world. The
disease primarily affects the elderly, and incidence has been correlated with diet,
smoking and alcohol consumption (Kikendall et al. 1989; Whittemore et al. 1990).
Cytochrome P450-mediated metabolism of the carcinogen dimethylhydrazine has
also been shown to increase with age (Newaz et al. 1983) and activation of this
compound has been implicated in the aetiology of colonic cancer. Although certain
dietary components are thought to reduce the risk of developing colon cancer, other
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dietary factors as well as cigarette smoke and alcohol can be metabolised to toxic
products by the P450 enzymes expressed in the colon.
Colonic carcinoma is extremely difficult to treat with chemotherapy, as many
tumours are inherently drug resistant on presentation. A number of possible
mechanisms have been proposed for this resistance, including:
(a) High levels of expression of P-glycoprotein in colon tumours. This protein, the
product of the MDR1 gene, functions as an energy dependent efflux pump which
excludes a wide range of structurally dissimilar drugs from the cell. Recent studies
have demonstrated that in mouse liver, TCPOBOP administration can suppress MDR
expression (Russell et al. manuscript in preparation). Whether this leads to
increased drug accumulation and whether the same effect can be observed in human
tumour tissue is currently being investigated.
(d) Down regulation of P450 expression. A number of drugs e.g. cyclophosphamide
and the novel morpholino-doxorubicin anthracyclines require P450-mediated
activation before exerting their anti-tumour effects, and are therefore of limited
effectiveness in treating many poorly vascularised tumours where the expression of
P450 is low or absent. Inducing the intra-tumour levels of these enzymes by
compounds such as TCPOBOP may therefore lead to greater drug efficacy.
There have been several reports in recent literature of cytochrome P450
expression in human colon, but there are many inconsistencies between the findings
of different research groups. This can, however, be partly attributed to inter-
individual variation in the expression of these enzymes. Stralka & Strobel (1989)
studied P450 activity and distribution in normal (i.e non-tumour) human colon
mucosa. Activity was assessed by the rate of metabolism of the potent colon-specific
carcinogen 1,2-dimethylhydrazine (DMH), the toxicity of which is mediated by the
methyldiazonium ion. The involvement of P450 enzymes, particularly CYP2E1, in
the metabolism of this chemical was demonstrated by antibody inhibition studies. The
ability to metabolise DMH increases with age and carcinogen activation is therefore
greater in old people. This is in agreement with the incidence of colon cancer which
also increases with age. Peters et al (19891 reported that, in the rat, P450 content
decreased from duodenum to ileum i.e. from proximal to distal small intestine. In the
human, however, more than 50% of large bowel cancers are diagnosed in the distal
section, suggesting either that the distribution of P450 enzymes is significantly
different in human tissues or, alternatively, that P450 mediated carcinogen
activation is not an important risk factor in colon cancer.
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A number of studies have used animal models, usually rat, to study P450
expression in the colon. As constitutive expression was found to be very low,
however, many animals were pre-treated with an inducing agent before their P450
content was determined, making it difficult to relate the results of these studies to
true constitutive expression. Rosenburg (1991a) investigated P450 expression in
rats treated with phenobarbital and (3-naphthoflavone. Constitutive CYP1A1
expression was detectable in the colon and was inducible by p-NF, while CYP2B1 was
detectable in the small intestine but not the colon. Stralka & Strobel (1991) detected
CYP2B1, CYP2A1 and P450 reductase protein in rat colon, while de Waziers et al
(1991) reported that CYP3A4 was the only detectable form in both normal colonic
mucosa and colorectal carcinoma, although the level of expression in the tumour was
greatly reduced compared to normal tissue. GST n was, however, significantly
increased in tumour tissue, resulting in an altered enzyme balance and therefore
response to drug treatment. As constitutive expression in these tissues has been
shown to be dependent on diet and is inducible by many dietary components, however,
it is of limited relevance to make direct comparisons between the level of P450
expression in human colon and levels of expression in rodent models. Rosenberg
(1991b) reported that P450 expression could be affected by components of the
animal bedding, while Vana et al (1991) reported induction of CYP1A1, 1A2, 2B1,
2B2 and 2E1 by broccoli in rat liver and colon. Although these effects being the
indirect result of a pesticide contaminant has not been ruled out, the active inducing
agents are thought to be indoles and flavones e.g. 1-methoxy-indole-3-carbaldehyde.
In addition, benzanthracene was reported to induce the expression of CYP1A1 and
CYP1A2 in the colon carcinoma cell line LS174T (White et al. 1991). In the same
study, trace amounts of CYP2C9 and CYP2E1 were also detectable, but only by
reverse transcriptase polymerase chain reaction amplification of cellular mRNA.
The experiments described in this chapter were designed to investigate the
level of expression of individual cytochrome P450 isozymes in a panel of human
colon tumours, and describe the regulation of P450 expression by a number of
xenobiotic modulators in a human xenograft colonic tumour.
In a detailed study of P450 and GST expression in a panel of normal and
tumour breast tissues, Forrester et al (1990) demonstrated that P450 expression
was very low, with a single P450 isozyme from the CYP2C family the only detectable
form on Western blot analysis. This protein had a different mobility from the human
hepatic CYP2C isozyme, but was apparently identical to the form expressed in an
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ovarian tumour. Immunohistochemical analysis demonstrated that the expression of
this protein was very heterogeneous, although strong uniform staining was observed
for CYP3A. This isozyme had not been detectable by Western blotting, although these
experiments were performed before the advent of the more sensitive ECL detection
system. Recent studies have demonstrated that an enzyme within the CYP3A family is
responsible for the metabolism of the anti-oestrogen Tamoxifen in human liver
microsomes (Jalacot et al. 1991). Whether the same isozyme is active within breast
tumour tissue remains to be established. Murray et al (19911 reported the
heterogeneous expression of CYP1A protein in a panel of human breast tumours.
Again, however, this was not confirmed by Western blot analysis. The expression of
CYP1A protein in the breast carcinoma cell line MCF7, although low, has been
correlated with reduced oestrogen receptor status, decreased drug accumulation and
overexpression of P-glycoprotein (Vickers, 1989).
Variation in the levels of these proteins, whether by an environmental
pollutant or therapeutic drug, alters the cellular response to a toxic challenge.
Using a human breast tumour grown as a xenograft as a model, the expression of
human tumour P450 proteins has been investigated, before and after xenobiotic
administration. Modulation of the intra-tumour levels of certain of these isozymes
may be of benefit in tumour targetting anti-cancer drugs which require P450
mediated activation.
5.5 P450 expression in human colorectal mucosa
The expression of individual cytochrome P450 isozymes and P450 reductase
was investigated by immunohistochemical analysis in normal and neoplastic colon
tissue from a panel of 20 patients. Tumour P450 levels were confirmed in 5 cases
by Western blotting.
5.5.1 Immunohistochemical analysis
Both normal and tumour tissues had low, but detectable, levels of P450
expression. There was considerable variation in staining intensity between
individual cases, although no consistent differences were observed between normal
and neoplastic tissue. In addition, there appeared to be no correlation between the
site of origin of the tumour and the intensity of P450 staining. Figure 5.5.1 shows
the distribution of CYP4A, which was strongly expressed in enterochromaffin cells
in normal mucosa and also focally within neoplastic tissue. Distal colon and rectal
mucosa, which have the highest incidence of neoplasia, contain more
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enterochromaffin cells and therefore a greater local concentration of CYP4A
expression. CYP4A has an important endogenous role in ecosanoid metabolism and
prostaglandin production (Capdevila et al. 1981), suggesting a possible autocrine
function for these cells. The presence of CYP4A positive cells in some tumours is
consistent with the reported appearance of cells with neuroendocrine differentiation
in certain colorectal cancers. Expression of CYP3A, which has also been implicated
in carcinogenesis, was found in vascular smooth muscle, but also weakly at the
surface in colonic mucosal epithelium. Cytochrome P450 reductase was detected in
both normal and neoplastic tissue.
5.5.2 Western blot analysis
Western blot analysis confirmed the results obtained by
immunohistochemical staining and highlighted the considerable inter-individual
variation between cases. P450 expression was, in general, very low and was only
detectable using the sensitive ECL detection system. The expression of P450
isozymes from all of the individual gene families with the exception of CYP2C was,
however, detectable (Figure 5.5.2). P450 reductase was present in each of the
tumour samples analysed.
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Immunohistochemiscal analysis (A) demonstrated that CYP4A protein
expression was restricted to the neuroendocrine cells of colonic crypts. CYP4A
positive cells were more numerous in the distal colon (i.e. left side) in keeping with
the known distribution of neuroendocrine cells in the gastrointestinal tract. Colonic
carcinomas also contained occaissonal CYP4A positive cells (B).
Normal colon (left) showed very weak expression of CYP3A (C). In some
cases, as shown here (right and lower), malignant epithelium in the adenocarcinoma
demonstrated increased, but still weak, expression of the gene product.
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The level of expression of individual P450 isozymes and of NADPH-cytochrome
P450 reductase was determined by Western blotting in a panel of six human colon
tumours. 40pg of microsomal protein was loaded per track. HL = human liver
microsomes; S-| andS2 are purified P450 proteins
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5.6 Xenobiotic regulation of P450 expression
5.6.1 Western blot analysis
A variety of compounds, known to induce P450s from a range of gene families
or subfamilies in animal models, was administered to mice bearing either human
breast or colon tumours as xenografts. The effectiveness of the induction protocol
was confirmed by demonstrating that the predicted changes in murine hepatic
cytochrome P450 gene expression had occurred.
Control untreated xenograft samples had extremely low P450 content.
However, a protein which reacted with the antibody to CYP2A1 was identified by
Western blot analysis (Figure 5.6.1). This protein had a different mobility to
recombinant human CYP2A6, which has been associated with hepatic coumarin
hydroxylase activity (Miles et al. 1990; Yamano et al. 1990). Very low constitutive
levels of proteins reacting with antibodies to CYP2B1 and CYP2C6 were detected in
the colon tumour using the highly sensitive ECL detection system (Figure 5.6.2).
The relative mobility of the protein detected with the CYP2B1 antibody (54.5kD)
was different from human hepatic CYP2B6 (51.0kD) while the mobility of the
protein detected with anti CYP2C6 was the same as human hepatic CYP2C9
(54.5kD).
Tumour cytochrome P450 content was significantly altered by the
administration of several of the P450-inducing agents tested (Figure 5.6.1). 3-
Methylcholanthrene (3-MC) and (3-naphthoflavone ((3- N F) are both well
characterised inducers of P450 proteins in the CYP1A and CYP2A gene families
(Guengerich, 1987). Both of these compounds could induce the level of a CYP1A
protein, probably CYP1A1, within both the colon and breast tumour tissues. The
level of a protein reacting with the CYP2A1 antibody (Figure 5.6.1, lower band) was
also increased 2-3 fold and approximately 5-fold in the breast and colon samples
respectively, by both 3-MC and p-NF. A further protein with a higher apparent
molecular weight (55.5kD, upper band) was also very slightly induced by these
compounds in the breast, but not the colon tissue. Interestingly, in further
experiments using ECL as the detection system, 3-MC also caused slight induction
(2-3 fold) in the level of the protein reacting with the antibody to CYP2B1 (Figure
5.6.2).
TCPOBOP and dexamethasone are potent "phenobarbital-like" inducing agents
in the mouse, but have virtually no effect on the expression of the major
phenobarbital-inducible isozymes in the rat (Poland et al. 1980; Meehan et al.
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1988, Chapter 3). The ability of these two compounds to induce human tumour P450
levels was therefore compared to the effects of phenobarbital. TCPOBOP, at a dose of
3mg/kg was a potent modulator of human P450 expression, inducing proteins in the
CYP1A, CYP2A, CYP2B, CYP2C, CYP3A and CYP4A gene families. In breast tissue, the
constitutively expressed CYP2A form (lower band) and that slightly induced by 3-
MC (upper band) were both significantly induced. In colon tissue, only the 51.5kD
protein (lower band) was induced. Proteins reacting with antisera to CYP2B1 were
markedly increased on TCPOBOP treatment in both the breast and colon tissues, with
the induction of CYP2B in the colon being particularly pronounced. This induced
protein had the same mobility as the constitutively expressed form and appears to be
distinct from CYP2B6. Whether this protein is CYP2B7 or a novel cytochrome P450
isozyme is currently being investigated. Proteins reacting with the CYP2C6 and
CYP3A1 antibodies were also induced in the xenograft tissue by TCPOBOP. The
mobilities of these induced proteins were identical to CYP2C9 and CYP3A5
respectively. TCPOBOP administration also lead to a profound increase in the
expression of a protein reacting with the antibody to CYP4A1. This induction was
particularly pronounced in the breast tumour, but was also observed in the colon
samples.
In a similar manner to TCPOBOP, dexamethasone also induced proteins in the
CYP2B gene family in both the breast and colon tumours (Figure 5.6.1).
Interestingly, this compound also caused a profound induction of the protein reacting
with the CYP4A antibody in colon but not in breast tissue. Relative to TCPOBOP and
dexamethasone, phenobarbital was much less effective as an inducing agent in the
xenograft tumours, but did cause some increase in the levels of CYP2A and CYP2B
proteins in both tumours and CYP4A in the breast xenograft. Clofibric acid had very
little effect on tumour P450 expression but did appear to induce the protein reacting
with the CYP2A antibody (lower band). Surprisingly, this compound did not induce
proteins reacting with the antibody to CYP4A1.
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Human colon (A) or breast (B) tumours were grown as xenografts in immune deficient mice to a
diameter of 1cm. Animals were then treated intra-peritoneally with a variety of compounds, as
described in Materials and Methods. Microsomal fractions were prepared from the tumour samples and
analysed for cytochrome P450 content by Western blotting using the antibodies shown. 15pg of
microsomal protein was loaded per track. C = Control, MC = 3-methylcholanthrene, NF = |3-
naphthoflavone, CI = clofibric acid, T = TCPOBOP, D = dexamethasone, PB = phenobartital, S = purified
rat P450 standard. The relative mobility of recombinant human P450s are shown in the right hand
track.
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HL C MC TC1 TC2 TC3 TC4 S
TUMOUR
P450 content was determined by Western blotting in a human colon tumour grown as
a xenograft. Animals were treated intra-peritoneally with vehicle only (Con), 3MC
(100mg/kg, 3 injections) or a single injection of TCPOBOP (1mg/kg (TC1) ,
3mg/kg (TC2), 10mg/kg (TC3) or 15mg/kg (TC4)). HL = human liver
microsomes, S = purifie
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5.6.2 Localisation of the induced proteins
A potential problem in the use of tumour xenografts to study human gene
regulation is the possibility that the observed changes in gene expression are due to
infiltration of the tumour with cells of the host and that the enzymes studied are, in
fact, murine. Immunohistochemical studies with P450 polyclonal antisera
unequivocally demonstrated that the induced proteins were localised within
malignant human epithelial cells rather than mouse derived tissues (Figure 5.6.3<.
Staining of P450 proteins was often found to be heterogeneous, with some areas of
tumour staining strongly, while others were weak or even negative. Good agreement
was obtained between the levels of protein detected on Western blot analysis and
immunohistochemical staining.
Figure 5.6.3 Immunohistochemical localisation of the induced proteins
P450 expression in xenograft colon (A) and breast (B) tumours was
determined using antibodies against rat (i) CYP1A2 (reactive with both CYP1A1 and
CYP1A2) (ii) CYP2B1 and (iii) CYP4A1 proteins. Control tumours showed low or
negative expression except for breast which expressed CYP2B at low levels and colon
which demonstrated focal reactivity for all three antibodies. Induction of CYP4A was
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(B) Breast tumour
Control After TCPOBOP treatment
(iii) CYP4A
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5.6.3 Evidence that TCPOBOP induces CYP2B protein expression by transcriptional
activation of the gene
1. Northern blot analysis
CYP2B mRNA levels were determined in the human colon xenograft by
Northern blot analysis using a cDNA probe for human CYP2B6 (Figure 5.6.3.1). Two
major bands of 3.0kb and 1.65kb respectively were detected in both the human liver
mRNA and the xenograft samples. Cyp2b mRNA isolated from the liver of the host
mouse had a much smaller transcript size (1.5kb), and was clearly distinguishable
from the mRNA species identified in the tumour tissue. It is interesting to note that
the predominant mRNA species induced in the tumour tissue is the 3.0kb transcript,
while that in the liver runs at 1.65kb. This supports the possibility that the major
inducible P450 isozyme within the tumour is distinct from CYP2B6, but is from the
same gene family. Alternatively, the differences in the relative abundance of the
mRNA transcripts may be due to alternative splicing of the mRNA as reported by
Miles et al. (1988).
CYP2B mRNA from both the liver of the host mouse and the associated
xenograft tumour was highly induced on xenobiotic treatment. In the liver, induction
by TCPOBOP was far greater than that observed on 3-methylcholanthrene treatment.
Within the tumour tissue, however, mRNA levels for both the 3-methylcholanthrene
and TCPOBOP treated groups were equally induced.
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Figure 5.6.3.1 Northern blot analysis of CYP2B mRNA levels in a human colonic
tumour xenograft
Northern blot analysis of CYP2B mRNA levels in the xenograft colon tumour was
performed as described in Materials and Methods. Animals were treated intra-
peritoneally with either vehicle alone, or with 3-MC or TCPOBOP. HL = human liver
RNA, C = control xenograft, or tumours from MC = 3-methylcholanthrene
(100mg/kg x 3), TC-j = TCPOBOP (3mg/kg) or TC2 = TCPOBOP (15mg/kg) treated
animals
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2. In situ hybridisation for mRNA
The induction of a CYP2B protein within the xenograft tumours was
confirmed by m situ hybridisation for mRNA using an oligonucleotide probe derived
from the human CYP2B6 cDNA sequence (Fig 5.6.3.2). This oligonucleotide has 6
mismatches with mouse Cyp2b9 (see Section 2.10), and would therefore not be
expected to hybridise to Cyp2b mRNA. These studies confirmed the localisation of
P450 mRNA to the human breast and colon tumour cells and, in agreement with the
Northern blot analysis, indicated that the observed induction of CYP2B protein had
occurred at the level of transcription.
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Figure 5.6.3.2 in situ hybridisation for mRNA in colon and breast tumours using a
probe to CYP2B6
in situ hybridisation was performed using oligonucleotide probes derived from Exon
2 of the human CYP2B6 gene. (A) Breast xenograft from control animals using the
antisense oligonucleotide probe showing little significant labelling; (B) TCPOBOP-
treated breast xenograft using antisense probe showing widespread, but
heterogeneous cytoplasmic reactivity; (C) TCPOBOP-treated colon xenograft using a
sense probe, showing no specific binding; (D) TCPOBOP treated colon xenograft using
antisense probe showing strong, fairly homogeneous cytoplasmic reactivity
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5.6.6 Does TCPOBOP administration have a synergistic effect on the anti-tumour
effect of cyclophosphamide?
Cyclophosphamide is metabolised to its active form by CYP2B proteins (see
Section 1.5.3). As the intra-tumour levels of these proteins can be modulated by
TCPOBOP administration, it seemed reasonable to investigate whether inducing the
intra-tumour CYP2B levels would lead to greater metabolism of cyclophosphamide
within the tumour and thus greater efficacy. TCPOBOP and cyclophosphamide were
therefore administered singly and in combination to mice bearing breast and colon
tumours as xenografts and the tumour surface areas monitored on a weekly basis.
Cyclophosphamide administration lead to marked tumour regression in the breast
model, but was without any significant effect in the colon tumour. In addition,
TCPOBOP appeared to have potent anti-tumour effects in its own right (Figure
5.6.6). Some enhanced anti-tumour activity was indeed observed when the
compounds were administered in combination. Experiments to investigate the
possible anti-tumour effects of TCPOBOP and to determine whether the effect, if
observed, is dose-dependant, are currently being carried out.
Although these experiments are preliminary, it seems that co-administration
of TCPOBOP and cyclophosphamide did indeed lead to enhanced tumour kill. The
synergistic effect was particularly pronounced for the colon tumour which did not
respond to cyclophosphamide administered alone. This is in agreement with the low
and heterogeneous expression of CYP2B enzymes, responsible for the metabolic
activation of cyclophosphamide, observed in a panel of human colon tumours (Section
5.5.2). Whether this is simply a function of the inherent anti-tumour effects of
TCPOBOP has yet to be determined. If further experiments validate these results,
however, this would represent an extremely powerful strategy to increast the intra-
tumour levels of active drug, leading in turn to a selective increase in cell kill.
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Figure 5.6.6 (A) Breast tumour
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time (weeks after TCPOBOP administration)
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5.6.8 Xenobiotic regulation of P450 expression in a xenograft tumour derived from
the cell line Hepa 1.
Hepa 1 cells have constitutive P450 expression, but this was not inducible
by any of the xenobiotics tested when the cells were grown in culture (Section
4.6.2). To investigate whether this lack of inducibility was a function of the limited
ability of cells in culture to maintain regulable P450 expression, Hepa 1 cells were
established as a solid tumour which was grown as a xenograft in nude mice. These
mice were treated intra-peritoneally with phenobarbital, 3-MC and TCPOBOP. As
illustrated in Figure 5.6.8, the level of intra-tumour P450 expression was
influenced by xenobiotic administration. Although 3-MC and phenobarbital were
a
effective inducing agents^ in both liver and tumour in this model, TCPOBOP
administration lead to induced levels of P450 protein only in the liver of the host
mouse.
If the effects of TCPOBOP are indeed receptor mediated, it seems plausible
that the expression of this receptor was lost when the Hepa-1 cells were grown in
continuous culture and thus the tumour established from this cell line remained
non-responsive to TCPOBOP administration i n vivo. Neither of the other xenograft
tumours had previously been grown as cell lines.
This experiment, although preliminary, demonstrated that cell lines grown
in culture can be established as solid tumour xenografts and shows that the intra-
tumour levels of drug metabolising enzymes can be modulated by xenobiotic
administration. This is potentially of great benefit for future experiments in which
stably transfected cell lines expressing a particular gene of interest will be created
and established as transgenic tumours and thus their in vivo metabolic profiles
determined.
*of Cypla and Cyp2b expression respectively,
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Figure 5.6.8 Xenobiotic modulation of P450 levels in a xenograft tumour created
from the cell line Hepa-1
CYP1A
CYP2B
CYP2A — — 0 —
S SC C PB MC TC C PB MC TC HL S
LIVER TUMOUR
Mice bearing solid tumour xenografts established from the cell line Hepa-1 were
treated as controls (C) or with phenobarbital (PB), 3-methylcholanthrene (3-MC)
or TCPOBOP (TC). HL = human liver microsomes, S = purified rat P450 proteins,
SC = stock control i.e. liver from a non-tumour bearing mouse
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5.7 Discussion
In this chapter, a model is described which can be applied to study how
environmental and hormonal factors regulate the expression of human cytochrome
P45G genes. The strength of this model is that it circumvents the previously
intractable problem that the expression and induction of cytochrome P450
expression in cell lines is lost, possibly due to methylation of the cytochrome P450
genes (Antequara et al. 1990). It also allows the effects of humoral or metabolic
factors such as hormones and lymphokines which can not be easily studied in in vitro
systems to be evaluated.
Although the influence of the mouse host on P450 expression cannot be ruled
out, immunohistochemical analysis clearly demonstrated that the observed changes
in gene expression occurred within human tumour tissues and therefore reflected the
responsiveness of human cells to the administered agents. Both the tumour tissues
studied maintained their human phenotype throughout these experiments and
remained characteristic of the tumour of origin.
The data presented in this chapter demonstrated that human breast and colon
tumours constitutively express low levels of certain cytochrome P450 isozymes.
This is agreement with previous findings which demonstrate that P450 expression is
detectable in tumour biopsy samples from these tissues (Senler et al. 1985;
Forrester et al. 1990; Murray et al. 1991). The constitutive expression of a
protein in the CYP2A gene family in both the breast and colon tumours is interesting
in view of the recent report of the isolation of a CYP2A protein from mouse liver
tumours (Maurice et al. 1991). In addition, there was considerable inter-individual
variation in the level of expression of many of the P450 isozymes detected within a
panel of human colon tumour samples, implying that the the constitutive levels of
these proteins may be inducible.
Indeed, these experiments demonstrated that cytochrome P450 levels in
human colon and breast tumour tissues can be profoundly influenced by
environmental agents. The patterns of gene regulation observed were often consistent
with what is known about hepatic P450 regulation in rats and mice. In certain case,
however, e.g. 3-MC induction of CYP2B expression, significant differences from the
rodent model were observed. These data imply that human breast and colon tissues
have the capacity to express P450s from many of the gene families involved in
foreign compound metabolism. Many of the proteins identified in the xenograft
tissues had different mobilities on SDS-PAGE from the human hepatic P450s and
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may therefore represent novel enzymes. This is currently being investigated.
Of particular interest in these studies was the capacity of dexamethasone and
TCPOBOP to induce human tumour P450 expression. The marked species specificity
in the capacity of these compounds to induce P450 expression raised the question of
whether they would also be active in man. Both compounds however, especially
TCPOBOP, had marked effects on the expression of many human cytochrome P450
isozymes, particularly in the induction of CYP2B and CYP4A proteins.
Immunohistochemistry and i_Q situ hybridisation studies demonstrated that the
induction of CYP2B occurred within human tissue and indicated that it was the result
of transcriptional activation of the gene. These studies also illustrated the marked
heterogeneity in both the constitutive expression and inductive response of many of
the P450 isozymes observed to several of the inducing agents tested.
It is conceivable that the species-specific effects of TCPOBOP are due to
effects on another tissue such as the pituitary and that this compound may still be
inactive in man. This is unlikely to be the case however, as we have previously
shown that TCPOBOP-mediated P450 induction in the liver is due to direct action on
hepatocytes (Section 4.7). Species differences in the metabolism of TCPOBOP to the
active inducer could also explain the specificity of this compound. However, this also
seems unlikely as TCPOBOP is an inert compound, and there is no evidence that
metabolism is required before it exerts its inductive effects (Poland et al. 1980).
The immunohistochemical data unequivocally confirmed that TCPOBOP has the
capacity to alter human gene expression.
TCPOBOP and dexamethasone administration also had a profound effect on the
expression of CYP4A proteins in the human breast tumour. The metabolic
consequences of CYP4A induction in this tissue have not yet been determined, but
CYP4A proteins have been shown to have an important endogenous role in fatty acid
metabolism and prostaglandin and leukotriene biosynthesis (Capdevila et al. 1981).
These enzymes are also important mediators of peroxisome proliferation (Reddy &
Lalwani, 1983). There are currently no reports of CYP4A expression in either colon
or breast tissue.
Mechanisms of regulation of human P450s in extra-hepatic tissues, by
agents other than polycyclic aromatic hydrocarbons (McLemore et al. 1990; Vang et
al, 1991; Stralka & Strobel, 1991), are essentially unknown. Although animal
models have previously shown that colon tissue will respond to compounds such as
phenobarbital (Degawa et al. 1991; Hammond & Strobel, 1990), the particular
P450 isozymes affected are poorly characterised. A similar situation exists for
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rodent mammary tissues. It also remains to be established how closely P450
regulation within tumour tissues reflects that of the normal tissue of origin. It has
been demonstrated, however, that tumour cell lines, as well as rat hepatic
preneoplastic lesions, retain many of the transcription factors required for P450
induction (Degawa et al. 1991). In this regard, the cell line Hepa 1, which did not
respond to a range of xenobiotics in culture, became responsive when the cells were
grown as a solid tumour xenograft. The only exception to this was TCPOBOP which, in
contrast to the previous results, had no effect on P450 expression in this tumour.
These studies imply that the expression of a specific receptor or transcription factor
is necessary for TCPOBOP-mediated P450 induction, and that expression is lost or
down regulated when cells are grown in continuous culture. The xenograft tumours
which were used in all the other experiments described in this chapter had been
established directly from the primary tumour.
The technique of establishing cell lines as solid tumour xenografts is
potentially very powerful. Cell lines can be readily transfected with DNA coding for a
particular P450 gene and used to determine the substrate specificity of a particular
isozyme. Establishing this transgenic cell line as a solid tumour xenograft provides
an in vivo model to study the regulation of a particular gene by a range of
xenobiotics. This system can be extended to include genes with precisely engineered
mutations, such as those which lead to polymorphisms in the expression of the P450
protein.
These studies have a variety of implications. Individuality in the expression
of tumour P450 levels may relate to the responsiveness of patients to
chemotherapeutic agents which require P450-mediated activation to exert their
anti-tumour effects. If the P450 expression within the tumour is very
heterogeneous, some cells will be able to activate the anti-tumour drug more
effectively than others. Cells with low P450 expression and thus reduced activating
capacity will proliferate to a greater extent than those which can activate the pro¬
drug and are, in turn, killed. In addition, heterogeneous expression of the enzymes
involved in the onset of drug resistance can lead to the clonal expansion of a
proliferating cell population and tumour progression. Establishing a number of
xenograft lines from different tumours of the same tissue type should provide
information on any inter-individual variation in constitutive P450 expression or
heterogeneity in response to induction.
The ability to modulate tumour P450 levels raises the possibility that the
efficacy of chemotherapeutic agents which require P450-mediated activation in
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order to exert their anti-tumour effects could be increased by prior or concomitant
administration of compounds such as TCPOBOP. Of particular interest in this regard
are cyclophosphamide, Tamoxifen and the novel morpholinodoxorubicin derivatives.
These compounds require j_n situ bioactivation by specific cytochrome P450
isozymes which are inducible within the human tumours by TCPOBOP (Powis &
Prough, 1987; Jalacot et al. 1991; Mani & Kupfer, 1991; Lewis et al. 1992). The
anti-oestrogenic compound Tamoxifen is widely used clinically in the treatment of
breast cancer. This drug is metabolised j_n vivo by enzymes from the CYP3A family,
the expression of which has been shown to be regulable within the breast tumour by
TCPOBOP. These enzymes have also been shown to bioactivate the
morpholinodoxorubicins, a new class of anti-cancer drugs which are derived from
adriamycin, but do not have the same cardiotoxic side effects (Acton et al. 1984).
Cyclophosphamide is activated by CYP2B which is maximally increased within the
tumour cells by TCPOBOP. Although optimisation of the experimental protocols is
clearly necessary to maximise the effect, the experiments described in Section 5.6.6
suggest that the efficacy of cyclophosphamide administration was indeed increased by
concomitant administration of compounds such as TCPOBOP.
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Chapter 6 : Summary of results and future prospects
In this thesis, the regulation of cytochrome P450 gene expression by a
number of foreign compounds has been described. In particular, the effects of
TCPOBOP (1,4 bis 2(3,5-dichloropyridyloxy)benzene) on P450 gene expression
has been evaluated in a number of model systems. The major findings from this work
are summarised below.
6.1 Xenobiotic regulation of murine hepatic P450 expression
Murine hepatic P450 expression was markedly increased by the intra¬
peritoneal administration of several xenobiotic inducing agents - the synthetic
glucocorticoid dexamethasone, phenobarbital and the "phenobarbital-like" inducer,
TCPOBOP. There were many similarities in the regulation of individual P450
isozymes by each of the administered compounds. The most profound and pleiotropic
inductive effects were, however, observed with TCPOBOP.
TCPOBOP, first isolated as a pesticide contaminant, exhibited a marked
species specificity in its inductive effects. Although a potent inducer of
monooxygenase activity in mice and Syrian golden hamsters, the compound was
without effect in rats and guinea pigs, thus implying that induction by TCPOBOP may
be receptor mediated.
The administration of TCPOBOP, at a dose much less than that required for
induction by any of the other inducing agents tested, lead to increased expression of
proteins within each of the P450 subfamilies, with the exception of Cyp2e. The
highest levels of induction were observed for Cyp2b, the major "phenobarbital-
inducible" form. Induction appeared to be regulated at the level of transcription, as
the corresponding P450 mRNA levels were also significantly increased. The lack of
Cyp2e induction is in agreement with the report of Freeman et al (1991), which
demonstrated that induction of murine Cyp2e protein expression by compounds such
as ethanol and acetone was not accompanied by an increase in the corresponding
mRNA, indicating that the increased protein expression was due to post-translational
modification.
The inductive effects of TCPOBOP were confined to the liver - analysis of
P450 protein expression in lung, kidney and testes showed no induction following
TCPOBOP administration. This further supports the proposal that the effects of
TCPOBOP are mediated by a tissue and species specific receptor. It has been proposed
that the effects of phenobarbital are exerted through a receptor-mediated
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mechanism, although, to date, such a receptor has not been isolated. In addition, the
effects of dexamethasone have been shown to be mediated, in part at least, through a
cytosolic glucocorticoid-responsive receptor.
Analysis of the long term effects of TCPOBOP administration demonstrated
that the induction of P450 gene expression was long lasting. Twelve weeks following
a single injection of the compound, P450 protein expression as still significantly
elevated above control levels. The corresponding mRNA levels, although elevated,
were observed to fall much more quickly, however, indicating that although
induction was regulated at the level of transcription, some form of post-
translational protein stabilisation was also involved in the expression of these genes.
The mRNA levels in male mice fell much more quickly than in the corresponding
females. This effect was also observed, although less markedly, in the expression of
P450 proteins following acute treatment with TCPOBOP. In agreement with this, a
longer term study of hepatic P450 protein expression demonstrated that Cyp2b, the
major phenobarbital and TCPOBOP-inducible isozyme, remained above control levels
for up to one year following treatment in female mice, while the level of expression
in males declined more rapidly. A possible explanation for this is the relatively
higher proportion of adipose tissue in female mice compared to males. As
radiolabelling studies with TCPOBOP have shown that the compound is stored
primarily in adipose tissue, it may be that the stored concentration of active drug is
higher in females. Alternatively, if TCPOBOP action is indeed receptor mediated,
there may be a different affinity of the drug for the receptor in male and female
mice. Alternatively, the decrease in protein expression in male mice may represent
selective loss of the TCPOBOP-responsive receptor.
There are several similarities between the inductive effects of TCPOBOP and
the synthetic glucocorticoid dexamethasone with respect to their effects on P450
expression. Experiments were therefore performed to investigate whether the
effects of TCPOBOP were mediated through a steroid hormone-like receptor,
analagous to the glucocorticoid receptor. The GRE containing MMTV LTR linked to the
CAT reporter gene was transfected into the hormone-responsive cell line ZR-75, but
no increase in CAT activity was detectable when the cells were exposed to either
phenobarbital or TCPOBOP. A similar experiment, carried out using the cell line
C3H10T1/2 which had been shown to be TCPOBOP-responsive, however, resulted in
the generation of acetylated reaction products on TCPOBOP treatment. Although the
effect of glucocorticoids such as dexamethasone were much more pronounced than
TCPOBOP, the possibility that TCPOBOP acts through a response element similar to
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the GRE is worthy of further investigation.
Pituitary hormones do not play a significant role in the regulation of gene
expression by TCPOBOP. Induction of P450 proteins by dexamethasone,
phenobarbital and TCPOBOP was maintained in hypophysectomised animals. Indeed, a
slight increase in hepatic P450 expression was observed following hypophysectomy,
implying that some form of repressor may be secreted by the pituitary.
In addition to the profound effects on hepatic gene expression observed on
TCPOBOP administration, a marked increase in liver size was also observed.
Preliminary immunohistochemical studies indicate that the increase is due to
hyperplasia, illustrated by increased expression of proliferating cell nuclear
antigen and increased bromodeoxyuridine uptake in TCPOBOP-treated liver. In
agreement with the increase in microsomal monooxygenase activity, hyperplasia was
confined to the liver.
6.2 Cytochrome P450 expression and regulation in mammalian cell
culture
The experiments described in Chapter 4 illustrate the limitations of
attempting to study P450 regulation in cultured cell lines. The three human cell
lines studied - the hepatoma HepG2, breast carcinoma MCF7 and colon carcinoma
HT29, all lacked constitutive P450 expression and did not respond to TCPOBOP
administration. Although this raised the possibility that human cells were not
responsive to this compound, possibly due to a lack of a functional "TCPOBOP-
receptor", later experiments in human tumours grown as xenografts demonstrated
that this was not the case. Indeed, TCPOBOP administration had a profound effect on
the expression of P450 proteins in both breast and colon tumour tissues. Antequara
et al (1990), however, demonstrated that many cells in continuous culture down-
regulate the expression of genes which are not necessary for their survival. This
mechanism is thought likely to account for the loss of functional P450 expression in
these cell lines.
Interestingly, although P450 expression was not inducible in the human cell
lines on TCPOBOP treatment, in agreement with similar studies in mouse liver,
administration of TCPOBOP to the human hepatoma cell line HepG2 lead to marked
cellular proliferation. This phenomenon was also observed in the murine hepatoma
call line Hepa-1. In agreement with the i n vivo studies, therefore, the proliferative
effects of TCPOBOP appear to be liver specific. Another important observation was
the low apparent cytotoxicity of TCPOBOP to any of the cell lines tested. This again
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was in agreement with i_n vivo studies in the mouse, which demonstrated profound
induction of hepatic P450 gene expression without any detectable associated systemic
toxicity.
In contrast to the human cell lines, the expression of one P450 isozyme was
maintained in both the mouse cell lines studied. Hepa-1 cells, a mouse hepatoma cell
line, had constitutive expression of a protein which cross-reacted with Cyp2a
antisera, as did the mouse embryo fibroblast cell line C3H10T1/2. While Hepa-1
cells did not respond to TCPOBOP treatment, the levels of Cyp2a protein in
C3H10T1/2 cells were markedly increased on exposure to this compound. Although
the expression of further P450 isozymes was not detectable in wild-type or
TCPOBOP-treated cells, the increased level of Cyp2a expression demonstrated that
the C3H10T1/2 cell line represents a possible model for studying the regulation of
P450 gene expression by TCPOBOP.
The "Cyp2a" protein in this cell line has not yet been identified, although it
has been demonstrated that it is distinct from Cyp2a-5, the murine coumarin
hydroxylase. Previous reports suggested that the expressed P450 was active in the
metabolism of some, but not all, polycyclic aromatic hydrocarbons. Whether this
activity is due to very low levels of a protein which cross-reacted with the Cypla
antibody has yet to be determined. In addition, mRNA prepared from C3H10T1/2
cells hybridised with a cDNA probe for Cyp2a, and had the same mobility as mRNA
isolated from mouse liver. Per amplification of the cDNA generated from reverse
transcription of mRNA isolated from C3H10T1/2 cells should yield the cDNA for the
expressed "Cyp2a" protein. Sequence analysis will then confirm whether the
protein is indeed a member of the Cyp2a subfamily, and will show whether it is, in
fact, a novel gene. If a Cypla protein is indeed present at very low concentrations,
the Cypla cDNA should also be isolable using this procedure. As the regulation of the
expressed protein appears to be significantly different from Cyp1a1, this may also
represent a novel protein.
C3H10T1/2 cells have previously been used in transfection experiments,
where the cDNA encoding a P450 gene which is not constitutively expressed is
inserted into the genome in order that, for example, its substrate specificity may be
determined. As the cell line has also been shown to be TCPOBOP-responsive,
transfection of deletion mutants of highly TCPOBOP-inducible genes such as Cyp2b9
or the human CYP2B6 linked to a reporter gene such as CAT, may lead to the
identification of a TCPOBOP-responsive promoter region which is common to or
similar among all responsive P450 genes. Such experiments involving transfection
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of the MMTV-LTR into suitable recipient cell lines have already been performed in
order to determine whether the effects of TCPOBOP were mediated by the GRE.
Mouse hepatocytes in primary culture proved to be the most sensitive in
vitro model in which to study the regulation of P450 genes. In agreement with the
effects observed in vivo, treatment of a primary hepatocyte culture with either
phenobarbital or TCPOBOP lead to a significant increase in the expression of Cyp2b
protein. This data unequivocally demonstrated that TCPOBOP can act directly on the
liver to regulate P450 gene expression and, while the effects of metabolic factors in
mediating this induction cannot be ruled out, further regulatory mechanisms are
clearly not essential for regulable P450 expression.
6.3 Regulation of cytochrome P450 expression in human tumour
xenografts
Establishing human tumours as xenografts in immune deficient mice has
proved to be an extremely useful model in which to study the i_n vivo regulation of
human P450 genes. Intra-peritoneal treatment of tumour bearing mice with a range
of xenobiotic agents, known from animal studies to be powerful modulators of P450
gene expression, lead to a marked induction of the intra-tumour levels of several
distinct P450 isozymes. The patterns of induction observed in the liver of the host
mouse were as expected from previous animal studies, but there were several
significant differences in the regulation of gene expression in the human tumour
tissues. Most notable of these was the marked induction of CYP2B expression, both
mRNA and protein, by the polycyclic aromatic hydrocarbon 3-methylcholanthrene,
which had previously been considered as an Ah receptor mediated specific agonist for
the CYP1A subfamily. In addition, clofibric acid, a potent modulator of hepatic CYP4A
gene expression in rodent models, did not induce intra-tumour levels of CYP4A
protein, although it did lead to increased expression of CYP2B protein.
TCPOBOP exhibited a marked species specificity in its inductive effects - it
was a potent inducer of monooxygenase activity in the mouse, but was completely
ineffective in the rat. Administration of TCPOBOP to mice bearing either human
breast or colon tumours as xenografts lead to marked induction of the intra-tumour
levels of expression of CYP1A, CYP2A, CYP2B, CYP2C, CYP3A and CYP4A proteins.
In agreement with the effects of this compound in mouse liver, CYP2B was the major
TCPOBOP-inducible isozyme. That the induction occurred specifically in human
tumour tissue rather than in the surrounding mouse stromal cells was demonstrated
by immunohistochemical analysis. In all cases, the staining intensities observed in
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control and TCPOBOP-treated tissues mirrored the patterns of induction obtained on
Western blot analysis.
For several P450 isozymes, the mobility of the proteins detected within the
human tumours differed from the mobility of the proteins expressed in human liver
microsomes. It seems likely, therefore, that these tumour P450s may represent
novel proteins.
Northern blot analysis of mRNA prepared from the xenograft tumours
demonstrated that induction was regulated at the level of transcription. Using a cDNA
probe specific for CYP2B6, induction of intra-tumour mRNA was observed on
administration of both TCPOBOP and 3-methylcholanthrene. This was in agreement
with the induction of CYP2B proteins by 3-methylcholanthrene observed on Western
blot analysis and implies that either 3-MC can induce P450 expression by a
mechanism which does not involve the Ah receptor or, alternatively, that the Ah
receptor-ligand complex can also bind to the upstream region of the CYP2B6 gene. It
was also interesting to note that that the mRNA transcript sizes recognised in mouse
liver and in the human tumours by the CYP2B6 cDNA were significantly different
and that, in addition, the tumour mRNA had the same mobility as mRNA isolated from
human liver. s
To further confirm that the observed induction was indeed occurring at the
level of transcription and was specific to the human tumour tissues, i_n situ
hybridisation for mRNA was performed on both the breast and colon tumours using
oligonucleotide probes to a region of the human CYP2B6 gene which would not be
expected to cross-hybridise with the murine Cyp2b genes. Marked induction of
human CYP2B6 mRNA was again observed in the TCPOBOP-treated tumours.
The anti-tumour agent cyclophosphamide is metabolised j_n vivo to its active
form by CYP2B enzyme(s). It seemed reasonable to propose, therefore, that
increasing the expression of CYP2B protein within a tumour would lead to greater
metabolic activation of cyclophosphamide and hence greater drug efficacy. A
preliminary experiment where cyclophosphamide was administered following
TCPOBOP treatment indicated that this may indeed be the case, and demonstrated that
TCPOBOP itself may have an anti-tumour effect. Later experiments, however,
administering TCPOBOP alone, did not lead to such marked tumour regression.
A solid tumour xenograft was also established from the cell line Hepa-1.
These cells, although responsive to 3-MC, did not respond to phenobarbital or
TCPOBOP in culture, but were responsive to both 3-MC and phenobarbital when
these agents were administered i_n vivo. TCPOBOP was, however, without effect in
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influencing P450 expression in the Hepa-1 tumour. This lends further support to
the theory that the effects of TCPOBOP are indeed receptor dependent, and suggests
that the expression of such a receptor is lost when cells are established in continuous
culture as cell lines. Neither the breast or colon tumours used in the previous
induction experiments had been passaged in tissue culture before establishment as
solid tumour xenografts.
6.4 Future prospects
The experiments described in this thesis illustrate the potency of TCPOBOP as
a species-specific inducer of monooxygenase activity.
Using the mouse as a model system, TCPOBOP was shown to be a potent and
pleiotropic inducer of hepatic monooxygenase activity. Administration of TCPOBOP to
a primary culture of mouse hepatocytes demonstrated that the inductive effects of
this compound could be reproduced without the need for any external metabolic
factors such as pituitary hormones. Experiments where P450 induction was also
maintained when TCPOBOP was administered to hypophysectomised animals
confirmed this finding.
There were many similarities in the ability of TCPOBOP, phenobarbital and
the synthetic glucocorticoid dexamethasone to influence hepatic P450 expression. It
had previously been proposed that both phenobarbital and dexamethasone exerted
their inductive effects through a receptor-mediated mechanism, in a similar manner
to the Ah receptor-mediated induction of CYP1A gene expression by polycyclic
aromatic hydrocarbons. Much of the data presented in this thesis supports the
possibility the regulation of P450 gene expression by TCPOBOP is also receptor
mediated. Experiments were therefore performed to determine whether TCPOBOP
could, like dexamethasone, activate the GRE, the glucocorticoid responsive promoter
element which is present in the upstream region of many P450 genes. Although
TCPOBOP was much less active than dexamethasone in activating the GRE, activity
which was significantly higher than control levels was achieved. Therefore, although
TCPOBOP does not appear to bind the GRE directly, it seems feasible that an analagous
steroid hormone-like receptor may mediate the effects of this compound. To test this
hypothesis, it will be necessary to create a series of constructs comprising deletion
mutants of a highly TCPOBOP-inducible gene such as CYP2B6 linked to the CAT
reporter gene. These constructs will then be transfected into a cell line which
responds to TCPOBOP administration such as C3H10T1/2. Administration of
TCPOBOP to the cells containing the full length gene should lead to the activation of
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the CAT reporter gene. Analysis of the various deletion mutants should reveal regions
of the gene which are necessary for TCPOBOP activity. In order to determine the in
vivo effects of xenobiotic modulators on P450 gene expression, it will be necessary
to establish the cell lines containing the transfected genes of interest as solid tumour
xenografts, as described for the Hepa-1 cell line in Chapter 5. These "transgenic
tumours" can then be challenged with a range of xenobiotic modulators and their
effects on gene expression i n vivo determined.
Establishing human tumours as xenografts has proved to be an extremely
powerful model for studying the regulation of human P450 genes. TCPOBOP was
shown to be a potent and pleiotropic inducer of human P450 gene expression in
human tumour tissues. To date, a breast tumour and a colon tumour have been
studied, and TCPOBOP was equally active in influencing P450 expression in each
model. Further experiments are planned, extending the studies to include a greater
number of tumours and different tumour types. Xenobiotic regulation of the
expression of Phase II drug metabolising enzymes such as the glutathione S-
transferases and UDP-glucuronosyl transferases has also been studied in this model
- TCPOBOP was equally effective at influencing the intra-tumour levels of
expression of these proteins.
The precise identity of the P450 proteins induced within the tumours by
TCPOBOP, or any of the other xenobiotic inducing agents studied has yet to be
determined. In particular, it will be of great interest to determine which, if any, of
these isozymes are the same proteins as those expressed in human liver, and which
represent novel enzymes. As several of the proteins expressed within the xenograft
tumours have different mobilities on SDS-PAGE from those expressed in human
liver, it seems likely that they may indeed represent novel isozymes.
In order to unequivocally identify these expressed proteins, it will be
necessary to isolate and sequence the corresponding cDNAs. A relatively
straightforward approach to this is to reverse transcribe mRNA isolated from the
treated tumours and amplify the resulting cDNA by the polymerase chain reaction.
Each of the tumours studied appeared to have very low, but detectable, constitutive
expression of certain of the P450 isozymes. The cDNAs encoding these proteins
should also be isolable using this approach.
Once any novel genes have been isolated, it will be necessary to determine
their substrate specificity. An initial j_n vitro approach involves transfecting the
cDNA of the gene of interest into a suitable recipient cell line which can then be
challenged with a number of candidate drugs. Compounds identified as substrates for
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the particular gene of interest may then be administered to tumour-bearing mice in
order to determine whether the effects on P450 gene expression observed in vitro
are similar i n vivo. C3H10T1/2 cells have been shown to support functional P450
expression and are responsive to TCPOBOP. As such, this is an ideal cell line in
which to perform the transfection experiments.
The administration of TCPOBOP to experimental animals has been shown to
cause hyperplasia in the liver. The xenograft model can also be used in the study of
cell proliferation, both in the liver of the host mouse and also in the associated
tumour tissues. Several of the inducing agents which induced intra-tumour P450
expression also had profound effects on the expression of genes such as p53 and pcna
which are involved in cell cycle control. This represents an important area for
further study.
Many anti-tumour drugs which are commonly used in cancer treatment,
including cyclophosphamide and tamoxifen, are inactive as administered and are
metabolised i n vivo to their active forms by one or more P450 isozymes. Modulation
of the intra-tumour levels of these enzymes is therefore potentially of clinical
significance. If the tumour does not express P450, or the levels of expression are
very low, the pro-drug will be metabolised in the liver and the anti-tumour effects
will be dependent on transport of active drug to the tumour site. In this situation,
hepatic metabolism often leads to the conjugation and/or excretion of the majority of
the administered drug before it can be transported to the site of the tumour. If,
however, the levels of the P450 isozyme which is active in the metabolism of the
pro-drug can be significantly increased by prior or concomitant administration of an
inducing agent such as TCPOBOP, then the pro-drug may undergo activation i n situ
leading to greater efficacy resulting in enhanced tumour kill. In addition,
administration TCPOBOP should also lead to highly induced levels of human hepatic
P450s. Thus, the concentration of circulating active drug will be higher and more
will be transported to the tumour site. As many anti-tumour drugs are highly
cytotoxic as administered, it may also be possible to reduce the amount of drug
administered if the conversion to active metabolites is increased. It may also be
possible to specifically target the tumour cells by, for example, conjugating the
anti-tumour drug to a monoclonal antibody raised against a human tumour-specific
antigen. This has the added benefit of increased binding specificity of the drug to the
tumour cells, leading to a longer residence time of the drug at the tumour and, thus,
greater efficacy.
Many tumours are either inherently drug resistant on presentation or
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acquire resistance during chemotherapy. Several mechanisms have been proposed to
account for this phenomenon. One of these, the overexpression of P-glycoprotein, an
energy dependent efflux pump which is the product of the MDR gene leads to the
exclusion of active drug from the cell. Previous work in this laboratory has
demonstrated that TCPOBOP administration leads to a marked reduction in MDR
expression in mouse liver. This fits well with the report of Romano et al (1 986)
that TCPOBOP administration leads to increased membrane fluidity. The xenograft
model is ideally suited to determining whether the same mechanism of regulation is
present in human tumour tissues. If so, administration of xenobiotic modulators such
as TCPOBOP may result in the reversal of multidrug resistance and the
resensitisation of tumours to therapy. Another mechanism which has been proposed
to account for cellular resistance is the low expression or complete lack of
expression within tumours of drug metabolising enzymes such as cytochrome P450
which are responsible for drug activation. This is particularly true for many
tumours which are poorly vascularised. It may be possible, therefore, to sensitise or
re-sensitise these tumours to chemotherapy by raising intra-tumour P450 levels
by the administration of exogenous inducing agents. The administration of TCPOBOP
as such an inducing agent is particularly attractive - this compound is a highly
potent modulator of P450 gene expression in human tumour tissues at an
administered dose which is significantly lower than the doses required for induction
for any of the other inducing agents tested. In addition, studies in experimental
animals and in a cell culture model indicated that the compound has very low
associated cytotoxicity and the inductive effects are persistent.
A pilot experiment where cyclophosphamide and TCPOBOP were administered
in combination to mice bearing human breast and colon tumours as xenografts
indicated that enhanced cyclophosphamide activation may indeed have occurred. A
much more sophisticated series of experiments is obviously required in order to
fully investigate this strategy. For example, it will be necessary to measure the
concentration of active drug with and without prior TCPOBOP administration, and to
investigate the optimum doses and dosing schedules for each compound. It will also be
necessary to develop a more rigourous strategy for assessing tumour kill.
Histopathological examination of many of the xenograft tumours revealed a high
degree of necrosis. Hence, although there may be no observed decrease in tumour
volume on drug treatment, the number of viable cells within the tumour may be
significantly reduced.
In addition, it will be necessary to determine whether the levels of P450
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protein within the xenograft tumours, as assessed by Western blotting and
immunohistochemistry, represents catalytically active enzyme. Although it did not
prove possible to quantitiate P450 substrate metabolism in frozen xenograft tumour
samples, functional P450 was identified spectrophotometrically. In addition,
NADPH-cytochrome P450 reductase was readily measurable in the tumour samples,
demonstrating that reductase concentration was not rate limiting. Analysis of fresh
(i.e. not frozen) tissue samples should allow measurement of substrate metabolism
by the P450 isozymes expressed within the xenograft tumours which will, in turn,
yield valuable information about the nature of the expressed proteins.
In summary, therefore, the xenograft model provides an opportunity to study
the j_n vivo regulation of gene expression in human tumours, not only by xenobiotic
modulators, but by endogenous factors such as hormones and lymphokines.
Preliminary experiments have been performed which suggest that lymphokine
administration can alter constitutive P450 expression in the xenograft tumours and,
in addition, can alter the response of these tissues to administered xenobiotics.
Although these effects have not yet been fully characterised, it is already apparent
that infection and inflammation can have major metabolic consequences, not only in
altering the response of patients to drugs which are metabolised by cytochrome
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Blood Transfusion Service, Law Hospital, Carluke, Lanarkshire,
ML8 5ES
anti-mouse HRP, anti-rabbit HRP
Sigma Chemical Co., Ltd., Fancy Road, Poole, Dorset
ethidium bromide, agarose, lysozyme, MOPS, methylene blue, L-glutamine,
dithiothreitol, diethylpyrocarbonate, bovine serum albumin, p-mercaptoethanol,
Coomassie brilliant blue R, TEMED, 4-chloro-1-naphthol, sucrose,
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